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INTRODUCCIÓN: La resistencia a los tratamientos oncológicos es un factor 
importante que limita la eficacia de los mismos; siendo posiblemente el problema 
clínico más significativo en el tratamiento del paciente oncológico. Pueden definirse 
dos tipos diferentes de resistencia a la quimioterapia: (i), la resistencia intrínseca, que 
se da en pacientes con tumores refractarios ya en el momento del diagnóstico, y (ii) la 
resistencia adquirida, que ocurre como consecuencia de los tratamientos de 
quimioterapia. Además, durante el proceso de adquisición de quimioresistencia el 
tumor puede hacerse resistente a diferentes fármacos, resistencia cruzada, lo que en 
última instancia conduce al fracaso del tratamiento. Los mecanimos de resistencia son 
complejos y de afectación multifactorial. Muchos agentes quimioterapéuticos destruyen 
las células tumorales. Así, la desregulación de los genes implicados en la activación o 
ejecución de dichos mecanismos puede asociarse con procesos de resistencia a la 
quimioterapia. Desregulación que puede darse por diferentes mecanismos, entre los 
que se encuentran los mecanimos epigenéticos. Estos mecanismos pueden 
desregular genes de forma individual por la hipermetilación del ácido 
desoxirribonucleico (ADN) de su promotor y/o global por la hipometilación. Mientras 
que la hipermetilación conlleva el silenciamiento de genes (ej. supresores tumorales), 
la hipometilación global produce la activación de aquellos genes que se requieren para 
las diferentes etapas del proceso de transformación neoplásica. Aunque parezcan 
mecanismos contradictorios, los dos tienen lugar en las células transformadas y les 
confieren ventajas selectivas.  
 
OBJETIVOS GENERALES: 
1. Comprobar si hay cambios en el perfil de metilación del ADN de los promotores 
de genes asociados con la adquisición de resistencia a la quimioterapia. 
Estudios que realizaremos en cáncer colorectal y en tumores germinales 
testiculares.   
2. Evaluar si los cambios en los patrones de metilación juegan un papel en los 
procesos de adquisición de resistencia a dacarbazina y a agentes platinados, 
como el oxaliplatino y el cisplatino. 
3. Evaluar el valor pronóstico y/o predictivo de respuesta a la quimioterapia de los 
nuevos potenciales marcadores identificados.  
 
MATERIALES Y MÉTODOS: El gen estudiado en el primer artículo, O6-methylguanine 
DNA methyltransferase (MGMT), un gen de reparación del ADN, ha sido seleccionado 
en base a previos datos publicados por nuestro grupo. En el segundo estudio, 
analizamos el perfil diferencial de metilación de promotores de genes en un modelo in 
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vitro de resistencia adquirida al oxaliplatino. Así lo analizaremos en la línea celular de 
cáncer de colon (LoVo-S) y su línea derivada, diez veces más resistente al oxaliplatino 
(LoVo-R). El análisis será realizado empleando el array de metilación Human DNA 
Methylation 27K IlIumina cuyas sondas, distribuidas estratégicamente por todo el 
genoma, permiten detectar cuantitativamente el estado de metilación de 27.000 
dinucleótidos citosina/guanina (CpG), distribuidos en 14.495 genes. Los genes 
candidatos fueron posteriormente validados por secuenciación genómica del ADN 
modificado por tratamiento con bisulfito, seleccionando  el gen protein kinase C delta 
binding protein (SRBC), un gen supresor tumoral para estudios in vitro y en muestras 
de pacientes. En los tumores primarios de pacientes, el estado de metilación del 
promotor de los genes MGMT y SRBC ha sido analizado mediante una reacción en 
cadena de la polimerasa, especifica de metilación (MSP). El impacto clínico de la 
metilación de estos dos genes en pacientes con cáncer colorectal metastásico se 
evalujó por curvas de Kaplan-Meier, donde se estudio la posible correlación entre 
metilación y tasa de respuesta al tratamiento, tiempo a la progresión y supervivencia 
libre de progresión. Siguiendo la misma metodología, también investigamos el impacto 
clínico de la metilación del gen MGMT en pacientes con cáncer testicular de células 
germinales. Este gen fue seleccionado a partir de estudios epigenéticos diferenciales 
de modelos tumorales generados por implantación ortotópica de tumores primários en 
ratones atímicos (concocidos como patient-derived xenografts u orthoxenografts) y de 
su evaluación in vivo en modelos de resitencia adquirida al cisplatino. De forma 
adicional mediante estudios de hibridación genómica comparada (CGH) de los mismos 
modelos tumorales, seleccionamos un conjunto de genes diferencialmente alterados 
entre tumores sensibles y resistentes al cisplatino. Así, entre estos está incluido el gen 
glucosyl ceramide synthethase (GCS), habiendo sido profundizado en este trabajo su 
importancia en la adquisición de resistencia. 
 
RESULTADOS: Estudio 1: Se incluyeron 68 pacientes con cáncer colorectal 
metastásico y se evaluó la metilación del promotor del gen MGMT. Dos pacientes (2%) 
alcanzaron una respuesta parcial y ocho (12%) consiguieron la estabilización de la 
enfermedad. La tasa de control de enfermedad (respuesta parcial + enfermedad 
estable) se asoció significativamente con la metilación del promotor del gen MGMT.  
 
Estudio 2: Identificamos que la resistencia adquirida al oxaliplatino en líneas celulares 
humanas de cáncer colorectal se asocia con la inactivación del gen SRBC por 
hipermetilación de su promotor. En las dos cohortes independientes de pacientes con 
cáncer colorectal metastásico analizadas (Serie 1: n=131; y Serie 2: n= 58), el 
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promotor del gen SRBC se encontraba metilado en un 30% de los tumores primarios. 
La hipermetilación se asoció con una supervivencia libre de progresión menor, siendo 
especialmente importante en los casos tratados con oxaliplatino para los que no 
estaba indicada la cirugía de las metástasis (p=0,01 y p=0,045 para ambas cohortes 
respectivamente). 
 
Estudio 3: Mediante estudios comparativos en xenografts ortotópicos de tumores 
germinales tersticulares (no seminomas) sensibles vs. resistentes al cisplatino 
generados en ratones atímicos hemos identificado un grupo de genes potencialmente 
asociados con la adquisición de resistencia a esa droga. Así hemos identificado: GCS, 
ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 (ATP6V1G1), alpha-1-
microglobulin/bikunin precursor (AMBP), polymerase (DNA directed), epsilon 3, 
accessory subunit (POLE3), pregnancy-associated plasma protein A, pappalysin 1 
(PAPPA) y solute carrier family 31 (copper transporter), member 1 and 2 (CTR1/2). 
Estudios funcionales en líneas celulares humanas de cáncer testicular demuestran la 
importancia del gen GCS en los procesos de adquisición de resistencia al cisplatino. 
Además identificamos al agente químico DL-treo-PDMP, un inhibidor específico de la 
enzima GCS, como un re-sensibilizador de los tumores no seminoma refractarios al 
cisplatino. Siendo un ejemplo de reposicionamiento de un fármaco utilizado para otras 
enfermedades o drug repositioning.  
 
Estudio 4: Identificamos la hipermetilación del gen MGMT asociado con la resistencia 
al cisplatino en xenografts de tumores germinales testiculares del tipo no seminoma. 
Asociación que se confirmó en estudios en líneas celulares. La relevancia clínica fue 
establecida analizando el estado de metilación del MGMT en una serie clínica de 
pacientes con tumores germinales testiculares metastásicos (n=72). Serie que incluye 
casos refractarios a la quimioterapia. La metilación del promotor del gen MGMT se 
asoció con una supervivencia global (p=0,025). Estudios preclínicos en nuestros 
modelos de xenografts demuestran que la inactivación farmacológica del enzima 
MGMT con el inhibidor Oxigeno (O)6- benzilguanina en los tumores resistentes 
resensibilzaba estos tumores nuevamente al cisplatino. Adicionalmente la adición de 
temozolomida mejoraba la respuesta. Nuestra aproximación dá las bases para el 
desarrollo de un ensayo clínico que permita evaluar la utilidad terapeútica de la 
temozolamida en casos refractarios al cisplatino en pacientes con inactivación por 
metilación del gen MGMT. 
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Discusión: El proceso de resistencia a los tratamientos de quimioterapia, ya sea 
endógena o adquirida, es complejo y multifactorial, involucrando tanto eventos 
genéticos y/o epigenéticos. La mayoría de estudios se han centrado en la genética, 
siendo menos los estudios que han investigado la contribución de la epigenética. La 
hipermetilación del promotor de MGMT es uno de los ejemplos mejor conocidos, 
siendo un biomarcador de respuesta al tratamiento con temozolomida en gliomas. 
Para otros tipos tumorales, como el cáncer de colon y los tumores germinales 
testiculares, son pocos los estudios desde este punto de vista, no habiéndose 
identificado biomarcadores epigenéticos de una forma tan clara. En esta tesis 
profundizamos en el aspecto epigenético de la quimioresistencia en estos tumores, 
identificando dos nuevos biomarcadores.  
 
En cáncer colorectal, que representa la segunda causa más común de muerte por 
cáncer, encontramos que la hipermetilación del gen MGMT predice sensibilidad a la 
dacarbazina. Nuestras observaciones apoyan la hipótesis de que tumores colorectales 
metastásicos defectuosos en los mecanismos de reparación del ADN, son más 
susceptibles a este tipo de agentes quimioterapéuticos. Hecho análogo a lo descrito en 
gliomas, en relación a la temozolomida, un análogo de la dacarbazina. Los tumores 
que expresan MGMT tienen un sistema específico para la reparación de aductos de 
O6-metilo, el daño principal provocado por este tipio de agentes quimicos. Los tumores 
con inactivación/no expresión del gen presentan una mayor probabilidad de respuesta. 
Aunque la tasa de respuesta global en este estudio fue  baja, 2%, no nos podemos 
olvidar que son pacientes para los cuales no existe alternativa terapéutica. Este es una 
posible opción terapeútica para el subgrupo de tumores seleccionados en base al 
biomarcador, debido a que los tumores que respondieran a la dacarbazina fueron los 
que presentaban hipermetilación del promotor del gen MGMT. Además, la baja 
respuesta observada podría estar condicionada por el hecho de que los pacientes del 
estudio habían sido previamente tratados con varias líneas de quimioterapia, y 
posiblemente tuvieran comprometida la capacidad hepática, necesaria para activar la 
dacarbazina. En este sentido, el uso de la temozolomida, un agente alquilante análogo 
y que se activa de forma higado- independiente, podría ser una buena opción 
terapeúitca para el desarrollo de un nuevo ensayo clínico, estratificando en base del 
biomarcador. 
 
En un segundo estudio identificamos la metilación del promotor del gen SRBC en 
tumores colorectales asociada con la quimoresistencia al oxaliplatino, uno de los 
fármacos claves del tratamiento de este tipo de cáncer, tanto en adyuvancia como en 
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el cáncer avanzado. Este gen ha sido previamente descrito como un supresor tumoral. 
In vitro las células humanas de colon de cancer resistentes al oxaliplatino tambien 
presentavan hipermetilación del promotor de SRBC, así como su expresión 
disminuida. En estudios en series de pacientes con cáncer colorectal avanzado, 
estadio IV, la metilación predijo una supervivencia libre de progresión más corta. 
Nuestros datos basados en el análisis de series tumorales y en estudios in vitro 
sugieren que la metilación del promotor del gen SRBC sería más importante en la 
adquisición de resistencia al oxaliplatino, que en la resistencia propiamente intrínseca. 
Desde un punto de vista funcional el papel  de SRBC con respecto a la sensibilidad al 
oxaliplatino puede justificarse por su interacción con la proteína breast cancer 1, early 
onset (BRCA1), elemento clave de la maquinaria de reparación del ADN. Esta proteína 
ejerce un papel importante en la reparación del ADN de cadena doble, por lo que su 
deficiencia puede poner en peligro la capacidad de las células cancerosas en reparar 
los daños producidos en el ADN tras la quimioterapia. El platino, y por analogía sus 
derivados como el carboplatino y el oxaliplatino ejercen su acción tras unirse al surco 
mayor del ADN. El papel de la proteína SRBC, en este complejo mecanismo es 
desconocido. SRBC, ha sido identificada también interaccionando con caveolin 1, 
caveolae protein (CAV1), hecho que podría afectar el tráfico vesicular, y por tanto el 
transporte y procesamiento intracelular del fármaco.  
 
Aunque los tumors germinales testiculares son muy sensibles a las terapias basadas 
en el cisplatino (85%), incluyendo los pacientes metastásicos, todavía existe un 
porcentaje de pacientes jovenes con enfermedad diseminada (15%) que no se curan y 
fallecen a consecuencia de la enfermedad. Con nuestro trabajo basado en la 
generación de los únicos modelos u orthoxenografts que existen actualmente para el 
estudio de esta enfermedad hemos identificado dos genes que potencialmente se 
pueden regular farmacológicamente, con el fin de revertir la resistencia al cisplatino: 
GCS y MGMT. GCS es una proteína importante en la síntesis de glucosilceramidas, lo 
que permite a una célula escapar de la muerte inducida por ceramidas. Estudios 
publicados relacionan la alta expresión de esta proteína con el incremento de la 
resistencia celular a la doxorrubicina y a la daunorrubicina. Con nuestra investigación  
relacionamos también su elevada expresión con la aparición de resistencia al 
cisplatino en tumors testiculares tipo no seminoma. Respecto al gen MGMT, lo 
encontramos hipermetilado en los tumores no seminoma, sensibles al cisplatino. 
Ambas proteínas, GCS y MGMT posean inhibidores farmacológicos que se han 
propuesto o se están utilizando en el tratamiento de otras enfermedades/tumores. Los 
inhibidores de la síntesis de los glicoesfingolípidos han surgido como un nuevo 
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enfoque para el tratamiento de enfermedades metabólicas como Gaucher, Niemam-
Pick y la diabetes. Siendo el enzima clave de esta vía la GCS, existen ya inhibidores 
que están o bien en uso clínico o en diferentes fases de desarrollo, incluyendo 
Migustat, DL-treo-PDMP, EXEL-0346, etc. Nuestros resultados preclínicos demuestran 
que DL-treo-PDMP podría ser un importante candidato al desarrollo de un ensayo 
clínico con el objetivo de intentar resensibilizar al cispaltino pacientes con tumores 
testiculares de células germinales refractarios. Otra opción terapeútica sería la 
selección de pacientes refractarios  con hipermetilación/inactivación del gen MGMT, o 
su bloqueo farmacológico con los inhibidores tipo el O6-benzylguanina, seguidos del 
tratamiento con temozolomida más cisplatino. Tanto la O6-benzylguanina como la 
temozolomida han sido ya utilizados en diferentes fases de la clínica. Ambas en 
ensayos clínicos fase I y fase II. La temozolamida también en la clínica para el 
tratamiento de melanoma y glioma. Así, ambos tratamientos propuestos para el cáncer 
de testículo refractario se basarían en estrategias de reposicionamiento de fármacos o 
drug repositioning.  
 
CONCLUSIÓNES: 
1. Existen cambios en el perfil de metilación de los promotores de genes, en los 
modelos estudiados de quimioresistencia a la dacarbazina, oxaliplatino y cisplatino. 
 
2. El estado de metilación de los promotores de los genes MGMT y SRBC influye en 
la quimosensibilidad de los tumores, a diferentes agentes antineoplásicos. 
2.1. La metilación del promotor del gen SRBC se asocia con la adquisición de 
resistencia al oxaliplatino en cáncer colorectal avanzado. 
2.2. La hipermetilación del gen MGMT se asocia con sensibilidad a la dacarbazina 
en pacientes con cáncer colorectal metastásico; y al cisplatino en tumores 
germinales testiculares metástasico tipo no seminoma.  
 
3. El  estado de metilación del promotor del gen SRBC es un buen candidato a 
biomarcador predictivo de resistencia al oxaliplatino, en pacientes con cáncer 
colorectal metastásico, para los cuales no es indicada la resección de las 
metástasis. Por otra parte la metilación del promotor del gen MGMT podría ser 
utilizada como biomarcador predictivo de respuesta a la dacarbazina también en 
cáncer colorectal metastasico y al cisplatino, en cáncer testicular de células 
germinales. 
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4. Los estudios realizados en base a las líneas celulares y a los orthoxenografts de 
tumores germinales testiculares identifica dos genes (GCS y MGMT) como base 
para el desarrollo de nuevas aproximaciones terapéuticas resensibilizantes al 
tratameinto con cisplatino. 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
  
 

 
 
 
 
 
 
 
 
 
 
 
GENERAL INTRODUCTION
 

  
                                                                                            GENERAL INTRODUCTION 
15

1. Cancer 
Cancer is a disturbance of one or more cellular activities that are crucial for the 
development and the maintenance of multicellular organisms, namely: growth, 
differentiation, programmed cell death, and tissue integrity. It is a malignant disease 
because frequently cancer cells invade into neighboring tissues and survive in this 
ectopic site. These cells that invade beyond the constraints of the normal tissue, from 
which they originate, enter into the circulation from where they can reach distant 
organs and eventually form secondary tumors, called metastases [1].  
 
To perform a cancer diagnosis several parameters need to be taken in consideration; 
the site of the tumor, the histological type of the cancer, its grade of differentiation and 
its extent of growth and invasion. Attention is also paid to the host cell reaction 
evidenced by the stroma, blood vessels and leukocytes. Because cancers are known 
to metastasize, clinically it is mandatory to search for secondary tumors in the lymph 
nodes and in distant organs [1]. 
 
Qualitative and quantitative criteria are used to stage and grade cancers for therapeutic 
and prognostic purposes. Staging of tumors is done following the volume of the primary 
tumor and its depth of invasion (T stage), the number of lymph nodes with invasion (N 
stage) and the presence of distant metastases (M stage)-TNM system [2].  
 
The above mentioned biological and clinical observations indicate that cancer is a 
disease caused by the accumulation of modified cells, disturbing differentiation and in 
most cases, causing loss of structure and function of the tissue and organ, leading to 
cancer cell invasion and cancer cell survival in an ectopic environment [3]. 
 
In order to get cell and tissue alterations a series of genetic and epigenetic changes 
occur in cancer cells (Figure 1). These genomic alterations occur in oncogenes and in 
tumor suppressor genes. In oncogenes, one allele is activated leading to gain of 
function, while in tumor suppressor genes, both alleles need to be inactivated leading 
to loss of function. Activation mechanisms of oncogenes implicate mutation, gene 
amplification, and promoter activation. Mechanisms of tumor suppressor genes 
inactivation are exemplified by loss of heterozygosity plus silencing of the second allele 
genetically, through mutation; or epigenetically, through deoxyribonucleic acid (DNA) 
methylation [4].  
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These molecular alterations arise mainly as a consequence of individual’s exposure to 
carcinogenic events that can be external factors (e.g. tobacco, infectious organisms, 
chemicals and radiation) or internal (e.g. inherited mutations, hormones, immune 
conditions and mutations that occur from metabolism). These causal factors may act 
together, or in sequence to initiate or promote the development of cancer [5]. 
 
1.1. Colorectal Cancer 
Worldwide, every year, more than 1 million of individuals will develop colorectal cancer. 
In the developed world the disease-specific mortality rate is nearly 33% [6]. Most of the 
tumors are sporadic (Figure 2A); fewer than 5% are hereditary, being Familiar 
Adenomatous Polyposis (FAP) and Hereditary Nonpolyposis Colorectal Cancer 
(HNPCC) the two recognized inherited forms (Figure 2B) [7]. The risk factors for 
developing colorectal cancer include a family history of this type of cancer, 
development of polyps, inflammatory bowel disease (e.g., ulcerative colitis), obesity, 
tobacco and alcohol abuse, high stress, and factors associated with the Western diet 
[8]. 
 
Colorectal cancer development is a multistep process and the vast majority of tumors 
are adenocarcinomas, which arise from preexisting adenomatous polyps that develop 
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in the normal colonic mucosa. This adenoma-carcinoma sequence is well 
characterized, and several molecular events that underlie the initiation and progression 
of colon cancer have been identified (Figure 2)[9, 10]. Traditionally colorectal cancer is 
explained by two pathways: 
 
i. The gatekeeper is responsible for about 85% of sporadic colorectal cancer and 
FAP syndrome. Mutation of the tumor suppressor gene adenomatous polyposis 
coli (APC) is one of the key steps in this pathway. This alteration interferes in 
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the regulation of cell proliferation via -catenin. Many other tumor suppressor 
genes (eg. deleted in colorectal carcinoma and tumor protein p53 (TP53)) and 
oncogenes (eg. kirsten rat sarcoma viral oncogene homolog (KRAS) and v-myc 
avian myelocytomatosis viral oncogene homolog) are also involved [11]. These 
types of tumors have a molecular profile characterized by specific chromosomal 
amplifications and transformations, aneuploidy, and loss of heterozygosity [12]. 
 
ii. The caretaker pathway is responsible for 15% of sporadic colorectal cancer and 
the hereditary HNPCC syndrome. It is characterized by mutations or epigenetic 
changes of genes that maintain genetic stability like mismatch repair (MMR) 
genes (eg. mutL homolog 1 (MLH1) and mutS homolog 2). The aberrant 
function of these genes, results in microsatellite instability (MSI) phenotype. 
MSI is characterized by somatic alterations in the size of simple repeat 
microsatellite nucleotide sequences, common throughout the genome. As a 
consequence, genes containing simple repeat sequences, such as transforming 
growth factor beta receptor II, epidermal growth factor receptor (EGFR), or 
BCL2-associated X (BAX) [13], are often mutated in these tumors [12]. 
Colorectal malignancies demonstrating MSI have a very heterogeneous 
histological appearance and better prognosis [14].  
 
In fact the two pathways might not be completely separated and additional pathways 
could exist. For example, the serrated, flat and depressed colorectal neoplasms cases 
[15, 16]. Loss of imprinting and histone acetylation, as well as modifier genes, such as 
prostaglandin-endoperoxide synthase 2 and peroxisome proliferator-activated receptor 
gamma, also seem to be involved in the genesis of colorectal cancer [17]. 
 
If colorectal cancer diagnosis is made early when the disease is localized on the bowel 
mucosa, generally it is curable with over 90% probability of survival at 5 years [18]. 
However, a majority of the cases will eventually develop liver metastases, being this 
organ the most common metastasic target (50-60% of cases) [19]. Close to one third of 
patients have liver metastases either at the time of diagnosis (synchronous cases) or 
during the disease course (metachronous cases). Patients with metastasic colorectal 
cancer (stage IV), present a 5-year survival rate of 8% [20]. 
 
1.2. Testicular Germ Cell Cancer 
Testicular cancers, 95% of which are type II germ cell tumors, are the most common 
solid malignancies affecting males between 15 and 35 years, although it accounts for 
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only 2% of all cancers in men [21]. In addition, the worldwide incidence of these tumors 
has more than doubled in the past 40 years [22]. West and North Europe present the 
higher incidence rates in contrast to Asia and Africa. In Spain every year, 400-500 new 
cases are diagnosed [23]. 
 
Germ cell tumors arise from embryonic germ cells that fail to properly differentiate and 
instead, undergo malignant transformation [24]. This type of cancer occur in testis, but 
also in ovary and occasionally in extra-gonadal primary sites [25]. As we can see in 
Table I, they can be divided in five singular types, with different localization, phenotype 
and origin [24, 25]. Although testicular germ cell tumors are represented in three types 
of germ cell tumors (I, II and II), since we focus our posterior studies in testicular germ 
cell type II tumors (seminoma and non-seminoma tumors), from now on we will use 
testicular germ cell tumors, to refer only them. 
 
Seminomas are well circumscribed solid tumors that appear in patients between 30-40 
years old and correspond to 40% of the testicular germ cell tumors [26]. Non-
seminomas tumors appear in patients between 20 and 30 years, representing 50% of 
type II of testicular germ cell tumors. This last type of tumors presents different cell 
types, being classified in several sub-types like: embryonic cell carcinoma, 
choriocarcinoma, yolk sac tumor, and teratoma. Teratomas are considered to be either 
mature or immature, depending on whether adult-type differential cell types or partial 
somatic differentiation, similar to that present in the fetus are found [25].  
 
Testicular germ cell tumors that present one predominant histological pattern are rare 
and normally a mixture of multiple histological types is represented [26]. As we can see 
in Figure 3 this can be due to the capability of pre-germinal cells to be reprogrammed 
[27]. 
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For treatment purposes, two broad categories are recognized: pure seminomas and all 
others, which together are termed non-seminoma. When both elements are present in 
a tumor, treatment is made as if it was a non-seminoma tumor, since this type is more 
aggressive [26]. 
Most of the testicular germ cell tumors are sporadic, although familiar clustering has 
been observed ( 2%), particularly among siblings [28]. Several risk factors have been 
identified, including: positive testicular germ cell tumor family history [29], 
cryptorchidism or testicular dysgenesis [30], Klinefelter syndrome, the presence of a 
contralateral tumor [31] or testicular intraepithelial neoplasia and infertility [25, 32]. 
 
At molecular level little is known about these tumors but many of them have complex 
karyotypes, with hipo or hyper-triploid index [33]. The most common chromosomal 
abnormalities identified are an ishochromosome of the short arm of chromosome 12 in 
90% of cases [34] and the amplification of chromosome 17q in 70% [35]. Other genetic 
alterations that have been described are a deletion of 1.6 mega bases (designated 
gr/gr) in chromosome Y [36], a point mutation in V-kit Hardy-Zuckerman 4 feline 
Table I: The five types of germ cell tumor 
Type Anatomical 
site 
Phenotype Age
 
Originating cell 
I 
Testis/ ovary/ sacral 
region/ 
retroperitoneum/ 
mediastinum/ neck/ 
midline brain/ other 
rare sites 
(Immature) 
teratoma/yolk-sac 
tumor 
Neonates and 
children 
Early PGC/ 
gonocyte 
II 
Testis 
Seminoma 
/non-seminoma 
>15 years 
(median age 35 
and 25 years) 
PGC/ 
gnonocyte 
Ovary Dysgerminoma/non-seminoma >4 years 
PGC/ 
gnonocyte 
Dysgenetic gonad Dysgerminoma/non-seminoma Congenital 
PGC/ 
gnonocyte 
Anterior mediastinum 
(thymus) 
Seminoma/non-
seminoma Adolescents 
PGC/ 
gnonocyte 
Midline brain/(pineal 
gland/hypothalamus 
Germinoma/non-
seminoma 
Children 
(median age 13 
years) 
PGC/ 
gonocyte 
III Testis Spermatocytic seminoma >50 years Spermatogonium/spermatocyte 
IV Ovary Dermoid cyst Children/adults Oogonia/oocyte 
V Placenta/ 
uterus Hydatidiform mole Fertile period Empty ovum/spermatozoa 
PGS: Primordial Germ Cell 
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sarcoma viral oncogene homolog (KIT) [37], hipomethylation of LINE1 
retrotransposable element 1 [38], over-expression of micro RNA-371-3 [39] and the 
familiar segregation for genes found in the locus Xq27 [40]. Other factors related with 
the increased risk of appearance of testicular germ cell tumors are reduced levels of 
androgen hormone during teenage period [41], pre-birth hypertension or infections with 
Epstein-Bar or cytomegalovirus [42, 43] or even the environment [44]. 
 
Tumors markers like -fetoprotein (AFP), beta subunit human chorionic gonadotropin 
(-hCG) and lactate dehydrogenase (LDH) have an established role in the 
management of testicular cancer. AFP is the major serum protein of the fetus. It is not 
found in adults, with exception for some hepatic disorders or in young males with a 
malignant teratoma. -hCG is a placental hormone. Its detection in males implies the 
presence of testicular germ cell tumors that presents throphoblastic elements. LDH is 
an enzyme that is expressed in cardiac and skeletal muscle as well as in other organs, 
although it is often found in testicular germ cell tumors [45]. 
 
2. Cancer Treatment  
Therapeutic procedures for cancer patients still remain largely empirical. Treatment 
depends upon a variety of individual factors, which may include the specific 
pathological and molecular characteristics of the tumor, its location, extent of disease 
and the health status of the patient. The ultimate objective is to destroy all cancer cells 
whilst inflicting minimal damage on the normal tissue. This can be achieved in a 
number of ways, either directly or indirectly by depriving cancer cells of signals needed 
for cellular proliferation or by stimulation of the immune response [46]. 
 
There are several types of treatment, which may be used alone or in combination, 
either simultaneously or sequentially: surgical removal (resection), radiation exposure 
(radiotherapy) and use of antineoplasic agents. Cancer resection is the first choice, 
being most of times curative for patients with tumors in early stage. The use of 
antineoplasic agents involves molecules of different origin, mainly chemical drugs 
(chemotherapy) and biological agents (e.g. antibodies, small molecules, 
immunotherapy and gene therapy) [46]. Treatment with antineoplasic agents and/or 
radiotherapy can be applied after tumor resection, in order to kill some possible 
remaining cells (adjuvant or postoperative regimen) or as a first approach, in order to 
reduce tumor size with the intent of after proceed to its resection (neoadjuvant 
regimen). After neoadjuvant setting there are some patients that still not fill the surgery 
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criteria. In order to try an improvement of its quality of life it is applied the palliative 
treatment [47]. 
The concepts: response rate, overall survival, progression free survival, and time to 
progression, will be now introduced, since they will be crucial in the next points. They 
will be explained in the chemotherapy treatment context [47].  
 
Response Rate is the percentage of patients whose tumor shrinks or disappears when 
they are under a treatment.  
 
Overall Survival is the percentage of patients who are still alive after a certain period 
of time, since their cancer diagnosis. The overall survival is often stated as a five-year 
survival rate, which is the percentage of people in a study or treatment group that lives 
five years after their diagnosis. It can be also called survival rate. 
 
Progression Free Survival is the time-span from diagnosis until tumor progression 
takes place. In a clinical trial, measuring the progression free survival or time to 
progression is one way to see how well a new treatment works. 
 
Time to Progression is the length of time in which the disease is present but it does 
not get worse. 
 
Because of tumors heterogeneity (site of origin, stage, and other molecular 
characteristics) and different adaptation of tumor cells to therapy with antineoplasic 
agents, evaluation of successful regimens and improvement of the rate response to 
treatment are complicated and sometimes deceptive. Reduction or stabilization of 
tumor mass, decline of symptoms, and decrease levels of specific tumor biomarkers in 
serum, rather than 5-year overall survival, represent the main goals in treating and 
monitoring patients outcome to different treatment regimens [48]. 
 
2.1. Chemotherapy 
Chemotherapy can be defined as the treatment of cancer with chemical drugs. The first 
example of its use in clinical practice involved the treatment of a malignant lymphoma 
with nitrogen mustard [49]. Medical intervention in cancer continues to rely heavily on 
chemotherapy, being used in all clinical settings – from adjuvant treatment to palliation. 
 
The excessively active growth-signaling pathways in cancer cells makes them 
susceptible to a wide range of drugs which target growth-signaling molecules and/or 
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processes involved in cellular replication and gene expression. However, these 
processes also happen in normal cells, particular in the bone marrow constituents and 
those of the intestinal lining, being the drugs effect in cancer cells preferential but not 
exclusive, which results in the undesired side-effects. The relatively wide spectrum of 
activity of cytotoxic drugs makes them a rather harsh and non-specific form of 
treatment that can only be tolerated for short periods. Indeed the effects of the 
treatment may sometimes cause more distress than the disease. These side-effects 
include dry flaky skin, loss of hair, nausea and vomiting, changes in taste and appetite, 
blood clotting problems, fatigue, depressed immune system and possible sterility. Most 
side-effects subside after the treatment is over, but sometimes there is permanent 
damage to the kidneys, heart, lungs or reproductive system. In general, however 
benefits outweigh the disadvantages, chemotherapy is the commonest form of cancer 
therapy [46]. 
 
Chemotherapy drugs can be divided into three major groups on the basis of their mode 
and site of action: genotoxic agents; antimetabolites and mitotic spindle inhibitors 
(Figure 4) [46, 50].  
 
Genotoxic agents either bind to DNA or indirectly damage it by affecting enzymes 
involved in replication, which leads to cell death induction. This class of drugs may be 
subdivided into three different groups. 1) Alkylating agents modify DNA bases leading 
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to mutations and bases cross-linking, interfering with replication and transcription (e.g. 
dacarbazine, temozolomide); 2) intercalating agents, chemicals that bind to DNA, 
interfering with polymerase activity during replication/transcription (e.g. cisplatin and 
oxaliplatin) and 3) enzyme inhibitors, agents that block replication by inhibiting 
enzymes, such as topoisomerases (e.g. etoposide and irinotecan) [46]. 
 
Antimetabolites include: 1) folate antagonists or antifolates are inhibitors of the 
folates, co-enzymes required for methylation and necessary for the formation of 
purines (e.g. methotrexate and pemetrexed); 2) pyrimidine antagonists block pyrimidine 
nucleotide formation or cause premature termination by themselves being incorporated 
into newly synthesized DNA (e.g. 5-fluororacil (5-FU) and gemcitabine); and 3) purine 
antagonists inhibit adenine and guanine synthesis (e.g. 6-mercaptopurine and 6-
thioguanine) [46]. 
 
Mitotic spindle inhibitors disrupt mitosis by affecting the formation/function of spindle 
microtubule fibers required for chromosome alignment. They prevent the 
polymerization of tubulin monomers and act in a cell cycle-dependent manner. They 
also affect normal cells but to a much lesser extent, due to the lower frequency of cell 
division (e.g. plant-derived vinca alkaloids and taxanes) [46]. 
 
Since the projects that came out from this thesis are related with specific genotoxic 
agents, like dacarbazine, temozolomide, oxaliplatin and cisplatin, these drugs will be 
described in a more detail. 
2.1.1. Dacarbazine 
Dacarbazine is a synthetic analog of a naturally occurring purine precursor (Figure 
5A). After intravenous administration this drug is enzymatically activated in the liver. 
The mechanism of action is not well understood, but appears to exert cytotoxic effects 
via its action as an alkylating agent (e.g. DNA damage). Other theories include DNA 
synthesis inhibition by its action as a purine analog. As with other alkylating agents, 
cells in all phases of the cell cycle are susceptible to dacarbazine. It is the most active 
agent used in metastatic melanoma and can be also combined with doxorubicin and 
other agents in the treatment of different sarcomas and Hodgkin’s disease [51, 52]. 
 
2.1.2. Temozolomide 
Temozolomide is a cytotoxic pro-drug and an imidazotetrazinone derivate of 
dacarbazine that, when hydrolyzed, inhibits DNA replication by methylation or 
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alkylation of nucleotide bases (Figure 5B). O6 position from guanine base is the 
preferred target for temozolomide action (70% of adducts) [53]. Clinical response to 
temozolomide is closely linked to the activity of MGMT, a DNA repair protein that 
removes O6-alkylguanine adducts from DNA [54]. Both in vitro and in vivo preclinical 
studies have shown that temozolomide is active against a variety of tumor types. Of 
particular interest is its clinical efficacy in patients with malignant glioma or malignant 
melanoma and its ability to enhance health related quality life [55, 56].  
 
2.1.3. Cisplatin  
Cisplatin (Figure 5C) is a platinum analog that has demonstrated efficacy against 
several tumor types. It is highly effective in the treatment of testicular and ovarian 
cancers and is also employed for treating bladder, cervical, head and neck, 
esophageal, and small cell lung cancer [57]. However tumors such as colorectal cancer 
have intrinsic resistance to it, while others develop resistance after initial treatment [58]. 
 
Once cisplatin has been intravenously administrated to a patient, it is rapidly diffused 
into the tissues and highly bond to plasma proteins [59]. The mechanism by which it 
crosses the cellular membrane is still unclear. At first, it was believed that cisplatin 
entered the cell by passive diffusion [60]. However several transporters, including the 
sodium+, potassium- adenylpyrophosphatase, ATP monophosphatase, triphosphatase, 
SV40 T-antigen, adenosine 5'-triphosphatase, ATP hydrolase, complex V 
(mitochondrial electron transport), (Calcium2+ + Magnesium2+)-ATPase, HCO3-
ATPase, adenosine triphosphatase (ATPase) and members of solute carrier 
transporters (CTR1 and CTR2) have been implicated in facilitating the entry of this 
compound into the cells [61, 62]. The organic cationic transporters, solute carrier family 
22 proteins had also been shown to participate in cisplatin influx [63]. Thus, cisplatin 
can enter cells by passive or facilitated diffusion and by active transport. 
 
The biochemical mechanism of cisplatin cytotoxicity involves its binding to DNA but 
also to non-DNA targets (e.g. proteins and ribonucleic acid (RNA)) with subsequent 
induction of cell death through apoptosis, necrosis or both. The damage induced upon 
cisplatin binding to genomic DNA may interfere with normal transcription and/or DNA 
replication mechanism [60]. Genomic DNA adducts are more frequent in guanine 
residues, especially the ones located in the major groove of the double helix, since they 
are the most accessible and reactive nucleophilic sites for platinum compounds (mono-
adducts). Beside this it can be produced other types of DNA adducts like: intra- and 
inter-strand cross-links and protein-DNA cross-link [64]. Cisplatin DNA-adducts are 
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usually repaired by nucleotide excision repair, MMR and DNA-dependent protein 
kinase pathways [65]. 
 
Besides lesions in genomic DNA, it is also known that cisplatin forms a high amount of 
adducts with mitochondrial DNA. So it should not be ruled out the possibility that 
mitochondrial DNA may also be an important pharmacological target for cisplatin [66]. 
Hence, of interest is the observation that only 5% of covalently bond cell associated 
cisplatin is found in DNA fraction, whereas 75-85% of the drug binds to protein and 
other cellular constituents. The resulting inactive forms, involving small thiol molecules 
such as glutathione, cysteine or methionine, then participate in cisplatin detoxication 
[67]. What concerns to cisplatin efflux, the adenosine tri-phosphate (ATP) dependent 
glutathione-conjugated efflux pump and copper (Cu) transporters like ATPase, Cu++ 
transporting (ATP7) A and ATP7B have been implicated [63]. 
 
2.1.4. Oxaliplatin 
It has been used as an anticancer medication since 1999, together with 5-FU, for the 
treatment of colorectal cancer [68]. This chemical drug is a third generation platinum 
compound, which acts similarly to cisplatin, but it has activity in cisplatin-refractory 
tumor types [69]. The difference with its analog is the possession of a bulky 
diaminocyclohexane moiety and the presence of an oxaliplatin leaving group (Figure 
5D). Due to this fact, oxaliplatin and cisplatin adducts have biological properties slightly 
different, not showing full cross-resistance and being the first drug more efficient in the 
DNA synthesis inhibition. Differences also have been described in intracellular 
cascades induced by DNA damage [70]. Different from cisplatin, oxaliplatin-DNA 
adducts are not able to activate MMR system and, for this reason, this drug is effective 
in MMR deficient tumors, such as colorectal cancer. Oxaliplatin DNA-adducts are 
mainly repaired by nucleotide excision repair system [69]. 
 
Passive diffusion is believed to be the main mechanism in oxaliplatin cellular uptake 
[70]. Once inside the cell, a variety of mechanisms of action are triggered. Induction of 
DNA lesions, like it happens with cisplatin, seems to be the main cytotoxic effect, 
leading to cell cycle arrest and cell death [71]. However other mechanisms were 
described. For example the synthesis of messenger RNA is blocked by platinum-DNA 
adducts which either bind to transcription factors or inhibit RNA polymerase [72]. 
Furthermore oxaliplatin seems to induce immunogenic signals on the surface of cancer 
cells before apoptosis, triggering interferon gamma production and interaction with toll-
like receptor 4 on the dendritic cells, resulting in the immunogenic death of cancer cells 
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[73]. Oxaliplatin-adducts have been also detected in proteins and other 
macromolecules (e.g. RNA and glutathione) [70]. 
 
2.2. Antineoplasic Agents in Metastasic Colorectal Cancer Therapy 
In general, antineoplasic agents based therapy given to colorectal stage IV patients, 
metastasic patients, pretends an increase in survival and a life quality improvement 
[74]. There are some patients with metastasis that can go under surgery (Figure 6), 
and others that cannot, depending this on metastases number, size, and/or sites of 
involvement [19, 75]. Surgery of liver metastasis for which the margins of the removed 
tissue are free from cancer cells, is related with 30-40% of overall survival at 5 years. 
Important refer that 15% of liver metastasis that cannot be removed at diagnosis time, 
can be removed after neoadjuvant therapy [76].  
 
Over thirthy five years, the only agent available to treat metastasic colorectal cancer 
was 5-FU, followed by 5-FU regimens in combination with leucovorin in the 1990s [77]. 
However, in the last decade, three cytotoxic agents (irinotecan, oxaliplatin, and 
capecitabine) and two biologic agents (bevacizumab and cetuximab) have been 
approved for treatment of metastasic colorectal cancer [77].  
 
Irinotecan was initially introduced as therapy for metastasic colorectal cancer refractory 
patients to 5-FU+leucovorin, being implemented as a second line treatment [78]. 
Clinical trials using irinotecan+5-FU+leucovorin (FOLFIRI) showed an improvement of 
response rate, median overall survival and progression free survival. Thus this 
combination replaced 5-FU+leucovorin as the standard therapy for metastasic 
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colorectal cancer [79]. Lately, the same results were observed when oxaliplatin was 
combined with 5-FU+leucovorin (FOLFOX). Because of this, FOLFOX also became a 
standard of care in metastasic colorectal cancer [79]. Clinical studies comparing the 
application order of the chemotherapy schemes (FOLFIRI+FOLFOX or 
FOLFOX+FOLFIRI) in first and second line treatment did not show significant benefit 
differences [75]. Actually they are being used without any specific order. 
 
On the other hand, triple combination of 5-FU+leucovorin, oxaliplatin, and irinotecan, 
(FOLFOXIRI) was also compared with FOLFIRI in the first-line setting. Although 
FOLFOXIRI conferred significant benefit in progression free survival, overall survival 
and response rate, it was more toxic [80]. Given this fact and the lack of consensus on 
its superiority over standard therapy, this regimen is sparingly used in practice. 
 
In 2005 capecitabine, an oral fluoropirimidine, analogue of 5-FU, was introduced in 
metastasic colorectal cancer treatment. New capecitabine based scheme seemed to 
be as effective as the ones based in 5-FU, previously described [81]. 
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Other agents beside chemotherapeutic drugs were developed for the treatment of 
metastasic colorectal cancer. The synergic role of the biological agents plus the 
traditional chemotherapy is actually accepted, being they used in addition. They are 
biological agents like, cetuximab, panitumumab and bevacizumab. 
 
Cetuximab and panitumumab are monoclonal antibodies that block epidermal growth 
factor (EGF) binding site, inactivating EGFR [18]. EGFR is a trans-membrane receptor 
that belongs to a family of four related proteins (v-erb-b2 avian erythroblastic leukemia 
viral oncogene homolog (ERBB) 2, ERBB3, and ERBB4). After ligand activation, EGFR 
receptor forms a dimer that signals within the cell by autophosphorylation, through 
tyrosine kinase activity. This triggers a series of intracellular pathways that may result 
in cell proliferation, block of apoptosis, invasion and/or angiogenesis [82].These 
biological agents have shown clinical activity, either alone or in combination with 
irinotecan, in pre-treated metastasic colorectal cancer patients, generating interest for 
their use in first-line [83]. Although based in results from different clinical trials the use 
of anti-EGFR agents for metastasic colorectal cancer treatment should be limited to 
those patients with KRAS wild type [84, 85]. Moreover, it should be remembered that, 
also in this case, other mechanisms of escape, such as v-raf murine sarcoma viral 
oncogene homolog B (BRAF) gene mutations, or deregulation of the 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3A)/ 
phosphatase and tensin homolog / v-akt murine thymoma viral oncogene homolog 1 
(AKT) pathway, may bypass the EGFR inhibition by these agents [86, 87]. The 
combination of these agents with 5-FU plus irinotecan have been proven to be effective 
at first-line and second-line of metastasic colorectal cancer treatment, contrary to the 
observed in oxaliplatin-based combinations [88] . 
 
Bevacizumab is a humanized monoclonal antibody that binds to and sequesters 
vascular epidermal growth factor avoiding it binding with its receptor and consequent 
inactivation [18]. It has been approved in United States and Europe for the first-line 
treatment of patients with metastasic colorectal cancer [89]. The vascular epidermal 
growth factor receptor pathway plays a crucial role in tumor angiogenesis, and its 
blockage has been intensely pursued as a therapeutic target. Although the absence of 
benefit as a single-agent, it has been evaluated it effect also in combination with the 
standard chemotherapy regimens mentioned above [90]. The first trial showing a 
benefit for the use of bevacizumab in first-line of treatment was the comparison of 
5FU+leucovorin+bevacizumab versus 5FU+leucovorin+placebo. The first combination 
led to an improvement in overall survival and in progression free survival [91]. Further, 
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bevacizumab was approved to be combined with standard schedules established for 
metastasic colorectal cancer treatment. 
 
At the present time, to patients with metastasic colorectal cancer is typically 
administered a first-line chemotherapy regimen that is continued until documented 
disease progression. At progression, treatment is switched to a regimen with 
demonstrated activity in the refractory disease setting. This pattern of treatment until 
progression and then switching to non-crossresistant therapies continues until the 
patient has received all five active classes of agents. At that point, patients may be 
referred for Phase I clinical trials or provided with symptom-directed care [75]. It has 
been shown that patients that received different lines of treatment, in which there is a 
variability of drugs compounds, present an increase survival [92].  
 
2.3. Metastatasic Non-seminoma Testicular Germ Cell Cancer Therapy  
Nowadays, management of testicular germinal cell tumors is tailored using a universal 
applicable schema that was drawn up by the International Germ Cell Cancer 
Collaborative Group (IGCCCG) [93]. Non-seminoma patients based on this schema are 
divided into good, intermediate and poor prognosis. In the context of non-seminoma, 
AFP, -hCG, and LDH levels are reliable markers of tumor burden, prognosis, and 
response to treatment [94, 95]. 
 
For 70-75% of non-seminoma patients that at diagnostic time present a clinical early 
stage disease, orchidectomy (resection) alone is curative [96]. Thirty percent of non-
seminoma patients have already metastases at diagnosis. In this type of cancer the 
pattern of metastases is not predictable although the most common sites are 
retroperitoneal lymph nodes, mediastinal and supraclavicular nodes, lungs, brain and 
bone [97]. 
 
Cisplatin based combination chemotherapy, introduced in the 1978 has revolutionized 
the management of metastasic germinal cell tumors exceeding the cure rates the 80%. 
No patient with germ cell cancer, no matter how ill at diagnosis, should be considered 
beyond prospect of cure. Standard therapy for non-seminoma, including the metastasic 
cases, combines cisplatin with etoposide and bleomycin (BEP regimen) [98]. During 
chemotherapy, serum markers are checked regularly and should fall to normal levels 
as disease responds. When negative, surgery is an option to remove residual lesions 
[99]. While first chemotherapy treatment is curative for many, up to 50% in poor 
prognosis category will progress or relapse [99]. 
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In contrast to initial therapy, second line treatment for non-seminoma is less well 
defined and presently there is not a well-established standard therapy. Nevertheless, 
treatment is still curative in approximately a third of the cases. Decision depends on 
different parameters such as the nature of the initial treatment and the subsequent 
response, the localization, and the time since treatment [96, 99]. Salvage conventional 
chemotherapy including ifosfamide, in combination with vinblastine or specially 
paclitaxel [100] associated with surgery of postchemotherapy residual masses when 
they are present is the most used strategy [101]. Moreover twenty to forty percent of 
patients who relapse after adjuvant treatment will achieve long-term survival with the 
use of platinum-containing standard-dose or high-dose salvage chemotherapy with 
autologous stem cell support [102, 103] (Figure 7). Patients who progress during or 
after salvage chemotherapy exhibit an extremely poor prognosis and long-term survival 
is achieved in less than 5% of patients [104, 105]. The identification of new active 
drugs remains a priority in these patients.  
 
Like in many cancer types, target therapy has also been used in non-seminoma 
treatment. Sunitinib, an inhibitor of multiple receptor tyrosine kinases, was the first 
targeted substance to be tested in the treatment of cisplatin resistant non-seminoma, 
although the results were disappointing [106]. 
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2.4. Chemoresistance 
Although chemotherapy drugs often effectively suppress tumor growth in cancer 
patients, a significant proportion of tumors either do not respond (intrinsic or primary 
resistance), or later develop resistance to these chemotherapeutics, after primary 
therapy (acquired or secondary resistance) [107]. This leads to tumor progression, 
disease dissemination and ultimately patient mortality, which remains a major 
challenge for successful cancer treatments [48]. Therefore the identification and 
characterization of cellular genes responsible for chemotherapeutic drug resistance is 
critical for successful prognosis and treatment of cancer. 
 
2.4.1. Potential Mechanisms of Chemoresistance 
The problem of drug resistance is complex and some mechanisms were suggested as 
responsible for its appearance. Resistance can be due to different processes including 
alterations in the drug uptake, drug inactivation, alteration of the target molecules, 
enhanced DNA repair, replicative bypass, altered checkpoints, proliferative signals, and 
reduced cell death response (Figure 8) [107]. 
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2.4.1.1. Drug Uptake  
Access of drugs to their intended site of action is a problem that is encountered and 
must be regarded as a form of resistance. The central portion of large tumors tends to 
have a poor blood supply and drugs will have limited access to this area. Therefore, 
chemotherapy is more effective for smaller tumors and becomes less effective as the 
tumor becomes larger. Treatment of brain tumors also faces problems posed by the 
blood-brain barrier. This is a dynamic network of vessels, which restrict movement of 
molecules into the central nervous system. Many drugs are ineffective because they 
cannot pass through this barrier. Others, which may initially have been able to 
penetrate inside, may later be blocked due to the dynamic nature of this resistance 
[108]. 
 
Other problem that can arise is the ineffective drug delivery to the cellular environment. 
Here resistance is achieved by hindering transport into, or by over-activation of 
transport efflux in the cell [107]. Alterations in transporter and metabolic enzymes are 
associated with differences in drug absorption, distribution, metabolism and excretion, 
and are considered to be the major determinants of inter-individual variability. For 
example, decreased uptake/increased efflux of cisplatin leads to lower intracellular 
concentrations of drug. Most in vitro models of acquired resistance to cisplatin exhibit a 
2- and 4-fold decrease in platinium accumulation [109]. Recent reports describe that 
cisplatin resistant tumors over-express some members of the efflux family ABC-
ATPase transporters, as ATP-binding cassette, sub-family C (CFTR/MRP), member 1 
[110]. The members of this family have been associated with resistance to drugs of 
different origin, as oxaliplatin or temozolomide, leading also to multidrug resistance 
phenotype. 
 
2.4.1.2. Drug Inactivation  
Drug metabolism circumvents the cytotoxic nature of a drug typically by reducing 
availability of free drug to interact with its target. One way is the enhancement of 
hepatic drug elimination, with the decrease of drug concentration in the plasma. 
Another physiological response is the over-expression of drug metabolizing enzymes 
or carrier molecules. For example 5-FU is catabolised and inactivated by the cytosolic 
enzyme dihydropyrimidine dehydrogenase [111]. Over-expression of this protein both 
in vitro and in vivo is linked to 5-FU resistance [112]. Another example is the over-
expression of glucoronidation enzymes UDP glucoronosyltransferase in irinotecan 
resistance [113]. Other mechanisms, as ubiquitinization, also contribute to inactivation 
of drugs by forming conjugates that are excreted [114]. 
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By contrast, under-expression of drug-metabolizing enzymes can also reduce drug 
efficacy in situations where an administered inactive pro-drug has to undergo catalytic 
conversion to an active form. For instance, carboxilesterase lack of activity in the liver 
to convert irinotecan and capecitabine in their active metabolites has been related to 
resistance to these drugs [115, 116]. 
 
Platinium drugs such cisplatin and oxaliplatin are able to form conjugates with the 
antioxidant glutathione synthetase, resulting in the inactivation of these drugs [117]. 
This conjugated form is a substrate for ABC transporter proteins, thus, it is shuttled out 
of the cell [118]. Increased levels of glutathione synthetase have been identified in 
cancer cells resistant to platinum drugs [119]. Glutathione synthetase conjugation is 
catalysed by glutathione S-transferase kappa 1 enzyme family, with increased 
expression of the glutathione S-transferase pi 1 subgroup correlated with resistance to 
cisplatin in ovarian cancer cells and tumors [120]. Furthermore, repression of 
glutathione synthetase has reversed cisplatin resistance in breast cancer cells [121]. 
 
2.4.1.3. Altered Targets 
Mutated drug targets or their over-expression can impact the efficacy of a drug. For 
example, the expression levels of thymidylate synthetase, the primary target molecule 
of 5-FU, regulates chemosensitivity to this drug [122]. It has been described some 
polymorphisms in the correspondent gene: two in the promoter region related to over-
expression of this protein and one 6 base pair deletion in 3’untranslated region, related 
with messenger RNA stabilization. All of them have been associated with resistance to 
5-FU [123, 124]. In another instance, decreased topoisomerase I or II activity due to 
reduced protein or mutations in the correspondent gene confers resistance to 
irinotecan or doxorubicin respectively [125, 126]. Topoisomerases are enzymes that 
regulate the overwinding or underwinding of DNA, for example during replication or 
transcription. 
 
2.4.1.4. Enhanced DNA repair and Replicative bypass 
Many chemotherapeutic regimes attempt to induce massive DNA damage, either 
directly (e.g. dacarbazine) or indirectly (e.g. doxorubicin). If plentiful enough, this 
damage should induce cell death. However, in some instances, the over-expression of 
DNA repair genes can efficiently reverse any acquired damage. For example, platinum 
agents result in bulky DNA adducts and are predominantly repaired by the nucleotide 
excision repair pathway [127]. Although this pathway involves multiple different genes, 
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over-expression of some few rate-limiting players (e.g. excision repair cross-
complementing rodent repair deficiency, complementation group 1 and xeroderma 
pigmentosum, complementation group A) is sufficient to induce platinum resistance. 
These genes are involved in the excision of the damaged strand and its over-
expression is correlated with cisplatin resistance in clinical samples of numerous tumor 
types [128, 129]. 
 
Interestingly, cases of resistance are also reported in repair system deficient cells, like 
for some platinum drugs. Drug tolerance can be achieved without the need for DNA 
repair. For example in order for platinated DNA to be replicated, DNA polymerase must 
skip the platinum adduct, which is most commonly an intrastrand lesion. The classic 
DNA replication polymerases –, , and  – cannot bypass the lesion; however, several 
polymerases have been shown to bypass intrastrand crosslinks by translesion 
synthesis –namely, , , 	, and 
. Over-expression of DNA polymerase  has been 
shown to lead to cisplatin resistance, while down-regulation using anti-sense RNA 
leads to sensitivity. Polymerase 	 has been shown in MMR deficient cells to play a role 
in DNA tolerance and bypass of lesions. The MMR system is critical for the 
maintenance of genomic stability as it scans newly synthesized DNA, excising single-
base mismatches and insertion-deletion loops. The loss of MMR was linked to DNA 
methylation and MSI phenomena [130]. Cisplatin resistance has been attributed to 
defects in the MMR system arising from hypermethylation of the MLH1 promoter [131]. 
Fascinatingly, cell lines which have been shown to be resistant to cisplatin due to MMR 
defects remain sensitive to oxaliplatin [132]. This observation has been attributed to the 
structural differences between the cisplatin DNA-adduct and the bulky oxaliplatin DNA-
adduct, which are not recognized by the MMR system [133]. Furthermore, the loss of 
MMR coincided with increased translesion synthesis, suggesting the replicative bypass 
as a plausible mechanism which allows these cells to evade death [134]. 
 
2.4.1.5. Altered Checkpoints 
To ensure that genetic integrity is maintained between generations, cells employ an 
elaborate system of checks and balances termed cell cycle checkpoints. In a normal 
system, cells induce apoptosis over proliferation. The master switch between DNA 
damage detection, cell cycle arrest and apoptosis is the TP53 protein [135]. Indeed, its 
importance is illustrated by the observation that TP53 is mutated in up to 50% of 
cancers [136]. However, it appears that TP53 gene mutations do not correlate with 
expression in 30-40% of cases [137]. Conflicting reports also exist about its role in drug 
resistance. For example, opposing outcomes (sensitizing and desensitizing) have been 
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reported on the effect of TP53 mutations in cisplatin [138, 139] and 5-FU in vitro and in 
vivo studies [140, 141]. From a molecular perspective it is also difficult to deduce the 
effects of TP53 on resistance. On one hand a lack of TP53 may prevent a cell from 
inducing apoptosis while on the other hand; wild type or increased expression may 
increase the amount of time for DNA repair during cell cycle arrest. Either way, both 
result in a resistant phenotype. Interestingly, doxorubicin seems to have a more 
predictable outcome. Its sensitivity is dependent upon a wild type TP53 function with 
mutated and null TP53 leading to resistance [142].  
 
2.4.1.6. Proliferative and Survival Signals 
Cancer cells have developed various methods by which they can proliferate regardless 
of their environment. One method includes over-expression of protein kinases, like 
EGFR family proteins. Binding of growth factors such as EGF or tumor growth factor , 
results in the activation of downstream pro-survival and proliferative pathways, such as 
PIK3CA/AKT, mitogen-activated protein kinase 3 and 1, signal transducer and activator 
of transcription 3 (STAT·3) and STAT5B pathways [143]. Over-expression of EGFR 
and ERBB2 in glioblastomas has been shown to increase resistance to chemotherapy 
in vitro and poor prognosis in the clinical set [144, 145]. Published results show that 
targeting the protein kinase receptors can improve the effectiveness of commonly used 
chemotherapies [146]. As mentioned before, actually in the clinical, some treatment 
schedules already include besides chemotherapy, antibodies that inactivate these 
receptors. For example, the combination of trastuzumab (ERBB2 inhibitor) with 
chemotherapy in previously untreated patients has been shown to prolong time to 
progression, increase response rate and significantly improve survival in comparison 
with chemotherapy alone [147].  
 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NF-kB) is a pro-
inflammatory transcription factor which its aberrant activation has been proposed as an 
important cause of chemoresistance, through the activation of anti-apoptotic genes 
[148]. Different studies have reported an association between NF-kB inhibition and 
oxaliplatin activity [149, 150]. The pharmacological inhibition of NF-kB using specific 
inhibitors such as BAY 11-7082 or SC-514, sensitized human prostate cancer cells; 
parthenolyde, a natural inhibitor, could markedly enhance sensitivity of human lung 
cancer cells; quinacrine, an antimalarial drug, sensitizes human colon carcinoma cells 
and genistein, a natural isoflavonoid, sensitized resistant pancreatic cancer cells all to 
oxaliplatin [149, 151-153]. High levels of this protein were also detectable in multidrug 
resistant cells. The mechanism of this resistance was attributed to the activation of the 
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CCAAT enhancer binding protein family of transcription factors and induction of ATP-
binding cassette, sub-family B (MDR/TAP), member 1 gene expression [154]. What 
concerns the clinical stage, NF-kB serum level have been found elevated in cancer 
patients. Its relation with chemotherapy resistance comes from a study that described 
an NF-kB autocrine production in breast cancer cells that could promote resistance to 
chemotherapy, in contrast to cells that did not express it [155].  
 
Besides, extracellular factors from the microenvironment were also linked to 
chemoresistance. Correlating chemosensitivity and stroma secreted proteins, in 
different tumors and different culture systems, it was found that elevated levels of 
acidic and basic fibroblast growth factors induced a broad-spectrum chemoresistance 
(paclitaxel, doxorubicin and mitomicin). Whereas, the known inhibitor of fibroblast 
growth factors suramin, was able to produce the reversion of this phenomenon [156, 
157].  
 
2.4.1.7. Failure of Cell Death Pathways 
2.4.1.7.1. Apoptosis 
Apoptosis is the death of a cell through a purposeful, mechanistic dismantling of the 
cellular machinery. To trigger apoptosis it is believed that cellular damage has to pass 
a certain threshold level. The malfunction of genes responsible for recognizing cellular 
damage can develop insensitive certain types of cancers to specific chemotherapeutic 
drugs. Upstream factors involved in the cellular response to damage mediate the 
induction of a network that transmits both pro- and anti-apoptotic signals. So, any 
interference that induces anti-apoptotic signal transduction, or abrogates pro-apoptotic 
pathways including transcriptional and translational response can be also a potential 
mechanism of drug resistance [158]. 
  
One apoptotic pathway, named intrinsic pathway, is regulated by mitochondrias, which 
are affected early in the apoptotic process and are known to act as central coordinators 
of cell death [159]. Several factors can induce mitochondrial-mediated apoptosis, 
including chemotherapy, ultra violet light, DNA damage, reactive oxygen species and 
growth factor withdrawal. Important players of this pathway are the B-cell 
CLL/lymphoma 2 (BCL-2) family of proteins. This family includes both pro-apoptotic 
(BCL2-associated agonist of cell death, BCL2-antagonist/killer 1 and BAX) and anti-
apoptotic members (BCL-2, BCL2-like 1 (BCL-XL) and myeloid cell leukemia sequence 
1). Not surprisingly, there is a good correlation between the expression levels of the 
BCL-2 family of proteins and the response to a wide range of chemotherapeutic 
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agents. Specifically, down regulation of the anti-apoptotic members BCL2 and BCL-XL 
increase sensitivity to oxaliplatin, while loss of pro-apoptotic BAX decreases it [160]. In 
the clinical setting, several studies have shown that high BCL-2 expression correlates 
with a poor response to chemotherapy [161, 162]. What concerns to BAX, some clinical 
studies show a correlation between expression and response to chemotherapy, 
although other studies have not found a correlation [163, 164]. 
 
The extrinsic pathway is regulated by cell surface death receptors of TNF-receptor 
family, such as Fas cell surface death receptor [13], tumor necrosis factor receptor 
superfamily (TNFSF10), member 10a and member 10b. Further, activation of proximal 
caspases in these patways leads to activation of downstream effector caspases, most 
importantly caspase 3 and 7. These executioner caspases cleave celular substrates to 
bring about morphological and biochemical changes that characterize apoptosis, 
including chromatin condensation and nuclear fragmentation, membrane blebbing, and 
cell shrinkage. In vitro studies have shown that targeting death receptors with 
recombinant death ligands or agonistic antibodies can induce apoptosis and/or 
enhance chemotherapy-induced apoptosis. In a clinical study from colorectal cancer 
patients, 5-FU treatment led to FAS over-expression, suggesting that this protein is an 
important mediator of response to chemotherapy. Apoptosis mediated by both FAS and 
TNFSF10a/TNFSF10b can also be inhibited by cytoplasmatic factors like CASP8 and 
FADD-like apoptosis regulator (C-FLIP). Inhibition of this protein dramatically sensitizes 
a panel of colon cancer cell lines to 5-FU, oxaliplatin, and capecitabine, suggesting an 
important role of C-FLIP in regulating colon cancer cell chemosensitivity. Interestingly 
C-FLIP has been found to be over-expressed in a high percentage of colonic and 
gastric carcinomas. Despite, it potencial as a predictive response biomarker was not 
studied. Survivin is other player in the inhibition of apoptosis. Over-expression of this 
protein has been shown to inhibit chemotherapy-induced apoptosis in vitro. Clinically, 
low levels of survivin have been correlated with better response to chemotherapy and 
improved prognosis in a range of cancers, suggesting that it may be a useful clinical 
marker [165, 166].  
 
In somatic cells, the ends of chromosome (telomeres) shorten in each cell division. 
However, in tumor cells, telomere length is maintained, mainly thought activation of the 
reverse transcriptase enzyme telomerase. It has been reported that in cervical cancer 
cells sensitive to low doses of cisplatin may die through apoptosis as a consequence of 
cisplatin binding to telomerases and subsequent telomere loss. Therefore a putative 
                                                                                            GENERAL INTRODUCTION 
39

resistance mechanism to cisplatin might be related to telomerase hyperactivation and 
inability of the tumor cell to engage apoptosis [167].  
 
2.4.1.7.2. Necrosis 
Necrosis is considered a passive event in which the cell is irreversibly damaged by an 
environmental insult, leading to cell death. Several authors have reported the activation 
of the necrotic pathway in cells treated with oxaliplatin, especially in those harboring 
TP53 mutations [168]. One protein related to this, is the glycogen synthase 3  the 
inactivation of which induces cell death by caspase-independent necrototic process 
[169]. Its activation has been reported in colon carcinomas resistant to oxaliplatin. DNA 
damage induced by alkylating agents and ligation of death receptors, among others, 
were also described to be related with regulation of necrosis [170]. Oxaliplatin 
effectiveness was also associated with the production of oxygen reactive species, 
which in turn is a contributor to the execution of necrosis [171]. In addition, resistance 
to necrosis is also possible in cells over-treated with alkylating agents. 
 
2.4.1.7.3. Autophagy 
Autophagy is a critical catabolic process required for maintaining cellular homeostasis 
in health and pathological situations. It is typically observed in response to cellular 
stress, hypoxia, DNA damage or endoplasmic reticulum stress. Autophagy is activated 
in many tumors and its inhibition can lead to either increased cell death or increased 
survival, depending on several factors [171]. Its role in promoting chemoresistance or 
chemosensitivity is controversial. For instance, reducible high mobility group box 1 
induces Beclin1 dependent autophagy and promotes tumor resistance to oxaliplatin 
[172]. In the same way down-regulation of autophagy related 5 proteins, enhanced 
sensitivity to oxaliplatin [173, 174].Other authors have reported that oxaliplatin 
treatment activates autophagy in hepatocellular carcinomas, and in cell lines and 
xenografts models of colon cancer, contributing to the tolerance of this drug by 
modulating oxygen reactive species generation, and as a consequence to 
chemoresistance. Contradictory examples are also described. Autophagy induction 
trought RAD001 (a potent activator of autophagy) in papillary thyroid cancer [175] or 
throught inhibition of oncomiR-21 in myeloid leukemia [176], enhanced the therapeutic 
response to cytotoxic chemotherapy.  
 
2.4.1.7.4. Senescence 
Cellular senescence can be induced through a multitude of internal/external pressures 
and in ideal situations acts as a selfprotecting mechanism [177]. It is a growth-arrest 
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program that prevents unlimited cell proliferation being linked to tumour suppression. 
However, if senescence is bypassed, cells can become immortalized and potentially 
undergo a malignant transformation [178]. Although there is little information about the 
conection between senescence and chemoresistance, researchers have already 
described that cancer cell lines can undergo senescence, when exposed to drugs like 
cisplatin, oxaliplatin or doxorubicin [179-181]. The same was reported in some in vivo 
cancer models [182] and also in the clinical. One of the earliest reports of treatment-
induced senescence in patients, came from a neoadjuvant chemotherapy study in 
breast carcinoma in which approximately 42% of resected tumors stained positive for 
senescence markers [183]. This has been verified in later evaluations of lung cancer 
patients receiving neoadjuvant therapy [184] and in human prostate tumors that were 
monotorized before and after chemotherapy treatment with mitoxantrone, revealing an 
increase in senescent markers after treatment [185]. Sidi et al. concluded also that an 
induction of tumor cell senescence following neoadjuvant therapy was associated with 
a poor clinical outcome [186].  
 
3. DNA Methylation  
Epigenetics is the field of research devoted to those mechanisms affecting expression 
patterns without modifying the DNA sequence. This field of research includes studies of 
DNA methylation; histone tails modifications and non-coding RNAs (Figure 9A)[187]. 
These processes are not mutually exclusive and have an added role in the control of 
genome stability [188].  
 
DNA methylation, the addition of a methyl group to the 5-carbon position of cytosine 
residues (5mC), is the most common covalent modification of human DNA (Figure 9B). 
It occurs almost exclusively at cytosine residues that are followed immediately by a 
guanine (so-called CpG dinucleotides) [189]. Cytosine methylation is observed at CpG 
dinucleotides that tend to cluster into islands containing more than 55% guanine-
citosine (GC) content over a 500 base pair region [190]. The human genome contains 
roughly 29,000 CpG islands that are distributed in a non-random pattern, with a 
preference for the promoter and first exon regions of protein coding genes. These CpG 
islands are observed within the promoters of about more or less 72% of human genes 
[13].
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The DNA methylation patterns are a stable and heritable epigenetic trait of mammalian 
genomes. There are three main proteins involved in establishing and maintaining DNA 
methylation marks within mammalian cells: DNA (cytosine-5-)-methyltransferase 
(DNMT) 1, DNMT3A, and DNMT3B [191]. DNMT1 is responsible for restoring 
methylation pattern on hemi-methylated DNA following replication [190]. In contrast 
DNMT3A and DNMT3B are responsible for de novo methylation. All of them appear to 
hold an indispensable function since mutant mice lacking these genes are not viable 
[192, 193]. Compared with other epigenetic mechanisms, DNA methylation was 
generally considered to be a relatively stable epigenetic modification. Actually the idea 
of an active DNA demethylation is taking strength. Ten-eleven translocation 1–3 
proteins have recently been discovered in mammalian cells to be members of a family 
of DNA hydroxylases that possess enzymatic activity toward the methyl mark on the 
5mC. Tet proteins can convert 5mC into 5-hydroxymethylcytosine, 5-formylcytosine, 
and 5-carboxylcytosine through consecutive oxidation reactions. These modified bases 
may represent new epigenetic states in genomic DNA or intermediates in the process 
of DNA demethylation [194].  
 
In normal cells most CpG islands remain unmethylated and are associated with 
transcriptional active genes, predominantly the so called housekeeping, tumor 
suppressor and caretaker genes [195]. However there are certain CpG islands 
normally methylated, including those associated with imprinted and inactive X 
chromosome genes [196]. In general, there is an inverse correlation between promoter 
methylation status and genes expression (Figure 9C) [197]. Compared with their 
normal counterparts, cancer cells exhibit significant changes in DNA methylation 
patterns, which can generally be summarized as global hypomethylation of the genome 
accompanied by focal hypermethylation events [198]. The origin of these changes is 
largely unknown.  
 
Much more is known about how changes in DNA methylation may lead to changes in 
gene expression that are implicated in carcinogenesis. The most emphasized 
implication of aberrant DNA methylation is the inactivation of tumor suppressor genes. 
The clear association between promoter hypermethylation and transcriptional 
inactivation has led to a revision of Knudson’s two-hit hypothesis for tumor suppressor 
inactivation by adding a new pathway to gene inactivation [199]. In this respect, DNA 
methylation is functionally equivalent to genetic events. De novo DNA methylation 
occur early in tumor progression and lead to abnormal function of important cellular 
pathways, including those controlling cell cycle, apoptosis, and cell-to-cell growth 
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signaling [200]. Changes in DNA methylation may have many cellular consequences 
other than those affecting the transcriptional activity of tumor suppressor genes. For 
example methylation of cytosine strongly increases the rate of cytosine>timine 
transition mutations and is thought to be responsible for about one-third of all disease 
causing mutations in germline cells [201]. 
 
There are different models that explain the correlation between hypermethylation and 
gene transcriptional silencing. One of them is based on the fact that methylation of 
specific DNA sequences can prevent the binding of some ubiquitous transcription 
factors [200]. However this model can explain only a minority of cases, where 
methylation causes genes stable transcriptional silencing. An alternative model 
implicates changes in the architecture of the nucleosomal core as the repressive 
element. This model was reinforced by the identification of a family of proteins that 
preferentially bind to methylated CpGs, the methyl CpG binding proteins (MBDs) [202]. 
At least three of the five known members of this family (methyl CpG binding protein 2, 
MBD2 and MBD3) have been shown to be associated with large protein complex 
containing histone deacetylases (HDAC) 1 and 2 and chromatin-remodeling protein 
[203]. The action of these HDAC and chromatin remodeling activities catalyze the 
removal of acetyl groups from the core histones, converting the open, transcriptionally 
competent chromatin structure into a closed structure that can no longer be accessed 
by the basal transcriptional machinery. The linkage between MBDs, histone 
deacetylases and the chromatin remodeling machinery has provided a basis for 
understanding how DNA methylation may mediate a transcriptionally incompetent 
chromatin state [204]. 
 
Besides controlling gene expression, DNA methylation is complicit in suppressing 
parasitic DNA sequences such as transposonable elements and endogenous 
retroviruses [205]. Active transposable elements are highly mutagenic as they tend to 
insert within expressed genes disrupting its normal function and can cause illegitimate 
recombination events and genomic rearrangements [206]. Interestingly, global 
hypomethylation is a hallmark of all stages of tumor cells with a 20%-60% decrease in 
methylated cytosines. This decrease in methylated DNA coincides with the reactivation 
of transposable elements, mitotic recombination (leading to loss of heterozygosity) and 
aneuploidy [198, 200]. 
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3.1.  DNA Methylation and Chemoresistance 
Chemoresistance can be the result of multiple genes expression alteration in different 
cellular pathways. Regulation by DNA methylation can have a large impact on gene 
expression [196]. A number of recent studies suggest a direct role for epigenetic 
inactivation of genes, in determining tumor chemosensitivity [207, 208]. Key genes 
involved in DNA damage response pathways, such as cell cycle control, apoptosis and 
DNA repair signaling can frequently become methylated and epigenetically silenced in 
tumors. This may lead to differences in intrinsic sensitivity of tumors to chemotherapy, 
depending on the specific function of the gene inactivated. Furthermore, it is proposed 
that chemotherapy itself can exert a selective pressure on epigenetically silenced drug 
sensitivity genes present in subpopulations of cells, leading to acquired 
chemoresistance [207].  
 
In contrast to genetic alterations, epigenetic changes can be modified 
pharmacologically and the re-expression of epigenetically silenced genes may result in 
the suppression of tumor growth and in an increased sensitivity to anticancer drug. In 
fact, 5-Aza-2-deoxycytidine (5-AZA) is already used for the treatment of all subtypes of 
myelodysplastic syndrome [209]. This drug has hypomethylating activity and, possibly, 
exerts its action by reinducing expression of genes silenced by the hypermethylation of 
CpG islands in their promoters [210]. Since the end goal of all chemotherapeutic 
agents is to induce death, loss-of-function in any necessary member of cellular death 
pathway will be manifested as a resistant phenotype. For example the 
hypermethylation of the apoptotic peptidase activating factor 1 promoter silences the 
activity of the gene and, thus, prevents apoptosis. Relief of this repression and 
increasing sensitivity of the cells was observed following treatment with the 
demethylating agent, 5-AZA [211].  
 
In addition, DNA repair capacities can impact drug-sensitivity. Many drugs have their 
effect by causing DNA damage that if left unrepaired, is lethal [110]. An example is the 
hypermethylation of the DNA repair gene MGMT. This enzyme reverses the damage 
induced by DNA alkylating agents (e.g. temozolomide) being a strong prognostic tool 
for determining the treatment response of gliomas, i.e. methylated MGMT confers 
sensitivity to the drugs [54, 212].  
 
Important to refer that it seems that the opposing processes of regional 
hypermethylation and global hypomethylation coexist in the same cells. Both confer a 
selective advantage upon cancer cells by targeting different sets of genes with 
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opposing roles in cellular transformation. Regional hypermethylation targets the 
silencing of genes which suppress tumorigenesis, while global hypomethylation 
probably targets activation of genes which are required for different stages of the 
transformation process [213].  
 
4. Drug Resistance Predictive Biomarkers in Metastasic Colorectal and in Non-
seminoma Cancer  
Tumor chemoresistance is a multifactor process and a reality. A good way to fight 
against it is, apart from the combined treatments with different drugs, the identification 
of molecular markers that allow a personalized treatment, selecting the most suitable 
therapy for each patient. Until now there are a few examples for colorectal and non-
seminoma cancers. At colorectal cancer KRAS mutational status has been established 
as a predictive factor of response to anti-EGFR agents, being the use of these only 
approved in KRAS wild-type tumors [214]. Concerning non-seminoma tumors, the only 
biomarker associated with cisplatin resistance is the presence of the BRAF, V600E 
mutation [215]. What concerns to epigenetic biomarkers, until now nothing is applied in 
the clinics for these two types of tumors. 
 

 
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 Although chemotherapeutic drugs are widely used in order to improve the cancer 
outcome, intrinsic and acquired drug resistance remain the most unpredictable factor 
affecting chemotherapy and a major impediment to successful patient’s treatment 
[107]. Understanding the cellular and molecular mechanisms leading to 
chemoresistance may dramatically impact on the way chemotherapeutic drugs are 
designed and used. Then, it would allow selecting the most suitable personalized 
therapy. 
 
 It has become increasingly clear that many chemotherapeutic agents kill susceptible 
cells through the induction of the physiological cell death program. Accordingly, 
deregulation of any gene involved in the activation or execution of the death processes 
may be a major mechanism of chemoresistance [107]. Tumor suppressor and DNA 
repair genes were classified as important mediators of chemotherapeutic response 
[207]. While inactivation of tumor suppressor genes could lead to drug resistance, 
inactivation of DNA repair genes, drug metabolisms, and detoxification genes might 
lead to drug sensitivity. This can be due to different mechanisms like regional 
hypermethylation and/or global hypomethylation [213].  
 
 The possibility that some genes conferring chemoresistance are reversibly switched 
on/off by DNA methylation is particularly important and may have relevant clinical 
implications. A very potent specific inhibitor of DNA methylation, 5-AZA, has been 
widely used as a demethylating agent in vitro, and is used clinically in the treatment of 
acute leukemia and myelodysplasia [216]. 
 
HYPOTESIS: 
Taking all into account, the present Doctoral Thesis has been devoted to provide 
further knowledge about the cross-talk between genes promoters DNA methylation 
status and tumors chemosensitivity, on a more detailed understanding of the influence 
of its changes in resistance to dacarbazine and to platinum agents, such oxaliplatin and 
cisplatin. We also pretend to explore alternative therapies as an attempt for reverse 
tumors chemoresistance the main cause of patients dead. In order to address these 
goals, we studied two cancer models, colorectal and testicular germ cell tumors. For 
each one we defined specific aims. 
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AIMS 
1. Determine if MGMT gene promoter methylation status influences rate response, 
progression free survival and/ or overall survival in metastasic colorectal cancer 
patients, treated with dacarbazine. 
2. Discover genes responsible for oxaliplatin acquired resistance in a colorectal 
cancer in vitro model. 
3. Uncover new predictive biomarkers for oxaliplatin based chemotherapy treated 
metastasic colorectal cancer patients. 
4. Find candidate genes responsible for testicular germ cell tumors cisplatin 
acquired resistance. 
5. Study the influence of MGMT promoter DNA methylation status in non-
seminoma tumors chemoresistat to cisplatin. 
6. Determine the potential role of novel therapeutic approaches for resensitize to 
cisplatin metastatic refractory non-seminoma tumors. 
 

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DIRECTORS REPORT 
 
To who may concern, we authenticate that the PhD student CÁTIA ALEXANDRA 
MARTINS FREITAS MOUTINHO will present her PhD thesis by scientific publications. 
Her contribution for each publication will be next pointed out. 
 
STUDY I 
“Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT 
Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic 
Colorectal Cancer” 
 
Alessio Amatu, Andrea Sartore-Bianchi, Catia Moutinho, Alessandro Belotti, Katia 
Bencardino, Giuseppe Chirico, Andrea Cassingena, Francesca Rusconi, Anna 
Esposito, Michele Nichelatti, Manel Esteller, and Salvatore Siena 
 
Contribution: Cátia Moutinho was the responsible for DNA extraction from paraffin 
embedded tumors and subsequent MGMT methylation analysis. Besides she 
participated in the analysis and interpretation of general data (e.g., statistical analysis, 
biostatistics, computational analysis), in the manuscript writing and revision. 
 
Journal: Clinical Cancer Research. 2013 April 15; 19(8):2265-72. doi: 10.1158/1078-
0432.CCR-12-3518. Epub 2013 Feb 19. Impact Factor: 7.8 
 
STUDY II 
“Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to 
Oxaliplatin in Colorectal Cancer“ 
 
Catia Moutinho, Anna Martinez-Cardús, Cristina Santos, Valentin Navarro-Pérez,  Eva 
Martínez-Balibrea, Eva Musulen, F. Javier Carmona, Andrea Sartore-Bianchi, Andrea 
Cassingena, Salvatore Siena, Elena Elez, Josep Tabernero, Ramon Salazar, Albert 
Abad, and Manel Esteller 
 
Journal: J Natl Cancer Inst. 2014 Jan 1;106(1):djt322. doi: 10.1093/jnci/djt322. Epub 
2013 Nov 22. Impact Factor: 14.7 
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Contribution: In this paper Cátia Moutinho was the responsible of the experimental 
design, and execution, supervised by Dr. Esteller. She also performed the analysis and 
interpretation of the generated data together, with the manuscript writing and revision.  
 
STUDY III 
“Orthoxenografts of Testicular Germ Cell Tumors Enable Identification of 
Glucosylceramide Synthase as a Cisplatin Resensitizing Target” 
 
Josep M. Piulats, August Vidal, Clara Muñoz, Francisco J, Gacía-Rodriguez, Marga 
Nadal, Cátia Moutinho, , María Martínez-Iniesta, Josefina Mora, Agnés Figueras, 
Elisabet Guinó, Veronica Davalos, Laura Padullés, Àlvaro Aytés, David G. Molleví, 
Sara Puertas, Wilmar Castillo, Victor Moreno, Purificación Muñoz, Ferrán Algaba, Jose 
Carlos Fernandez-Checa, Enric Condom, Francesc Viñals, Josep R. Germà, Manel 
Esteller, Gabriel Capella, Albert Morales, Julian Cerón, Xavier García-del-Muro  and 
Alberto Villanueva 
 
Journal: Submitted to Cancer Cell 
 
Contribution: All the functional in vitro studies for GCS were designed and performed 
by Cátia Moutinho, under Dr. Villanueva supervision. She also participated in data 
analysis, scientific discussion and in manuscript writing. 
 
STUDY IV 
“Loss of MGMT Promoter Methylation and Resistance to Cisplatin in Non-
Seminoma Testicular Germ Cell Tumors” 
Cátia Moutinho, Xavier Garcia-del-Muro, Elisabet Guino, August Vidal, Sara Puertas, 
Clara Munoz, Josep M. Piulats, Alberto Villanueva and Manel Esteller  
 
Contribution: Cátia Moutinho was in charge for the experimental design and 
experimental labor. She also performed the analysis and interpretation of the 
generated data, together with the manuscript writing. All the work was supervised by 
Dr. Villanueva and Dr. Esteller. 
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RESUMEN 
 
Hipótesis: MGMT es una proteína de reparación del ADN que elimina los aductos 
generados por los diferentes fármacos en la posición O6 de la guanina. 
Aproximadamente el 40 % de los cánceres colorectal tiene una deficiencia en esta 
proteína debido mayoritariamente a su silenciamiento por hipermetilación del promotor 
del gen. Agentes alquilantes tales como la dacarbazina, ejercen su actividad 
antitumoral por la metilación del ADN en la posición O6 de las guaninas. Hecho que se 
asocia con un desfase entre los pares de bases, por lo tanto, la actividad de la 
dacarbazina puede ser más eficiente en tumores colorectal que carecen de MGMT que 
los repare. Hemos llevado a cabo un estudio del estatus de metilación del promotor del 
MGMT en el seno de un estudio clínico fase II (DETECT-01trial, EUDRACT número 
2011-002080-21) donde los pacientes fueron randomizados a ser tratados con 
dacarbazina. Se incluyeron pacientes con cáncer colorectal que han fracasado con las 
terapias estándar (oxaliplatino, irinotecan, fluoropirimidinas; cetuximab, panitumumab y 
bevacizumab, si el KRAS no está mutado). 
 
Diseño experimental: Todos los pacientes tenían tejido tumoral para evaluar, en un 
estudio blindado, la hipermetilación del promotor de MGMT. Los pacientes recibieron 
dacarbazina (250 mg/m2) por vía intravenosa cada día, durante cuatro días 
consecutivos, cada 21 días, hasta progresión de la enfermedad o toxicidad intolerable. 
Se utilizó un diseño de Simon two stage test para determinar si la tasa de respuesta 
global sería de 10 % o más. Los objetivos secundarios incluyeron la asociación de la 
respuesta, progresión libre de enfermedad y la tasa de control de la enfermedad, con 
el estado de metilación del promotor de MGMT. 
 
Resultados: Sesenta y ocho pacientes fueron incluidos en el estudio, desde Mayo de 
2011 hasta Marzo de 2012. Los pacientes recibieron una media de tres ciclos de 
dacarbazina (intervalo 1-12). Grados 3 y 4 de toxicidad incluyeron: fatiga (41%), 
náuseas/vómitos (29%), estreñimiento (25%), disminución del recuento de plaquetas 
(19%), y anemia (18%). En general, dos pacientes (2%) alcanzaron una respuesta 
parcial y ocho pacientes (12%) han obtenido una enfermedad estable. La tasa de 
control de la enfermedad (respuesta parcial + enfermedad estable) se asoció 
significativamente con la hipermetilación del promotor del gen MGMT, en los tumores 
correspondientes. 
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Conclusión: Las respuestas clínicas objetivas a la dacarbazina en pacientes con 
cáncer colorectal metastásico se limitan a aquellos tumores que albergaban la 
inactivación epigenética de la enzima de reparación del ADN, MGMT. Sugiriendo 
nuestro estudio la realización de un nuevo estudio clínico estratificando los pacientes a 
ser tratados en función de la metilación de MGMT. 
                                                                                                                          RESULTS 
 
60

ABSTRACT 
 
Purpose: MGMT is a DNA repair protein that removes mutagenic and cytotoxic 
adducts from O6-guanine in DNA. Approximately 40% of colorectal tumors display 
MGMT deficiency due to the promoter hypermethylation leading to silencing of the 
gene. Alkylating agents, such as dacarbazine, exert their antitumor activity by DNA 
methylation at the O6-guanine site, inducing base pair mismatch; therefore, activity of 
dacarbazine could be enhanced in colorectal tumors lacking MGMT. We conducted a 
phase II study with dacarbazine in colorectal tumors who had failed standard therapies 
(oxaliplatin, irinotecan, fluoropyrimidines, and cetuximab or panitumumab if KRAS wild-
type). 
 
Experimental Design: All patients had tumor tissue assessed for MGMT as promoter 
hypermethylation in double-blind for treatment outcome. Patients received dacarbazine 
250 mg/m2 intravenously every day for four consecutive days, every 21 days, until 
progressive disease or intolerable toxicity. We used a Simon two-stage design to 
determine whether the overall response rate would be 10% or more. Secondary 
endpoints included association of response, progression-free survival, and disease 
control rate with MGMT status. 
 
Results: Sixty-eight patients were enrolled from May 2011 to March 2012. Patients 
received a median of three cycles of dacarbazine (range 1–12). Grades 3 and 4 
toxicities included: fatigue (41%), nausea/vomiting (29%), constipation (25%), platelet 
count decrease (19%), and anemia (18%). Overall, two patients 2% achieved partial 
response and eight patients (12%) had stable disease. Disease control rate (partial 
response + stable disease) was significantly associated with MGMT promoter 
hypermethylation in the corresponding tumors. 
 
Conclusion: Objective clinical response to dacarbazine in patients with metastatic 
colorectal cancer is confined to those tumors harboring epigenetic inactivation of the 
DNA repair enzyme MGMT. 
                                                                                                                          RESULTS 
 
61

Introduction 
Globally, nearly 1.25 million patients are diagnosed and more than 600,000 patients die 
from colorectal cancer each year (1). At least 50% of patients develop metastases (2), 
and most of these patients have unresectable tumors (2, 3). 
 
In the last 10 years, thanks to a wider clinical use of a multidisciplinary approach, along 
with the introduction of new cytotoxic drugs and the addition of targeted therapies 
against the angiogenesis (bevacizumab and aflibercept), the EGFR pathway 
(cetuximab and panitumumab), or multiple receptor tyrosine kinases (regorafenib), the 
survival of patients with metastatic colorectal cancer has considerably been 
ameliorated (4–6). Nevertheless, prognosis remains poor and patients carrying KRAS 
mutations (35%–40% of colorectal cancers), which preclude responsiveness to 
cetuximab or panitumumab (6), have limited therapeutic options after failure of 2 lines 
of standard treatments, although a significant percentage of these patients retain a 
good performance status potentially allowing further therapies. There is therefore an 
unmet need of therapeutic options, based on specific molecular alterations that could 
prove their effectiveness also in the wide KRAS-mutated subgroup of colorectal 
cancers. 
 
MGMT is a DNA repair protein that removes mutagenic and cytotoxic adducts from O6-
guanine in DNA. MGMT protects cells against these lesions, transferring the alkyl 
group from the O6-guanine in DNA to an active cysteine within its own sequence. Such 
reaction inactivates one MGMT molecule for each lesion repaired (7). The inactivation 
of tumor suppressor genes by the presence of cytosine methylation encompassing the 
corresponding transcription start site located in a CpG island is gaining "momentum" in 
the management of oncology patients (8) and, in this regard, promoter CpG island 
hypermethylation leads to the transcriptional silencing of MGMT (9). The subsequent 
lack of repair of O6-methylguanine adducts can result in a higher frequency of G:C>A:T 
transitions (10,11). It is known that approximately 40% of colorectal cancers have 
silencing of MGMT. Interestingly, in a retrospective analysis on 244 colorectal cancers 
samples, it has been found that 71% of tumors with G to A mutation in KRAS showed 
MGMT epigenetic inactivation, showing a strong association between the MGMT 
inactivation by promoter hypermethylation and the appearance of G to A mutations at 
KRAS (10). Furthermore, MGMT hypermethylation was also found in 35% of wild-type 
KRAS metastasic colorectal cancers. De Vogel and colleagues (12) found that MGMT 
hypermethylation is associated with G:C>A:T mutations in KRAS, but not in APC, 
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suggesting that MGMT hypermethylation may succeed APC mutations but it precedes 
KRAS mutations in colorectal carcinogenesis.  
 
In cells, loss of MGMT expression leads to compromised DNA repair and may play a 
significant role in cancer progression and response to chemotherapy as it occurs in 
glioma (13–16). The mechanism of action of dacarbazine and temozolomide is DNA 
methylation at the O6-guanine site, inducing base pair mismatch. The methyl group at 
O6-site is removed by MGMT in a one step methyl transfer reaction. Therefore, we 
hypothesized that MGMT inactivation by hypermethylation may confer sensitivity to 
these agents (17). However, discrepant data about the clinical activity of these drugs in 
metastasic colorectal cancer are reported in the literature (18–21). A response rate of 
19%, including one complete response, was reported in 26 fluoropyrimidine-resistant 
patients receiving cisplatin and dacarbazine (19). In another study, 48 patients 
refractory to fluoropyrimidine were treated with dacarbazine, irinotecan, and cisplatin 
obtaining a 33% of response rate (18). Temozolomide is an imidazotetrazine derivative 
of dacarbazine. The combination of lomeguatrib and temozolomide did not show 
activity in unselected metastasic colorectal cancer (20). In a pilot study including 
patients selected by tumor molecular profiling, temozolomide was effective in 2 patients 
with metastasic colorectal cancer exhibiting loss of MGMT expression (22). The latter 
finding was confirmed by a recent report by Shacham-Shmueli and colleagues (23) 
documenting objective response to temozolomide in 2 patients with MGMT-deficient 
metastasic colorectal cancer. On the basis of these findings, we designed a phase II 
trial aimed to assessing the antitumor activity of dacarbazine in patients with 
metastasic colorectal cancer with determined MGMT promoter methylation status and 
refractory to the standard therapies.  
 
Materials and Methods 
Trial design 
The study was designed as a phase II trial (DETECT-01trial, EUDRACT number 2011-
002080-21). Patients were treated with dacarbazine monotherapy until progression or 
unacceptable toxicity for 18 weeks (6 cycles). In case of partial response with clinical 
benefit, treatment was allowed until dose-limiting toxicity. Primary endpoint was to 
assess response rate to dacarbazine according to Response Evaluation Criteria in 
Solid Tumors (RECIST1.1) criteria. Secondary endpoints were to assess: disease 
control rate, progression free survival, identification of KRAS, and MGMT status in 
individual tumor samples as potential molecular biomarkers of response to 
dacarbazine. Written informed consent was obtained from each patient. The study 
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followed the Declaration of Helsinkiand good clinical practice, being approved by Ethic 
Committee of Ospedale Niguarda Ca’ Granda (Milan, Italy).  
 
Patients 
All patients met the following inclusion criteria: age 18 years or more, Eastern 
Cooperative Oncology Group performance status of  1, histologically confirmed 
metastatic colorectal adenocarcinoma. A paraffin-embedded block from archival tumor 
tissue of primary and/or metastases for MGMT status analysis was requested. All 
patients had measurable disease (by RECIST criteria v1.1), and progressed on 
standard treatment with fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab or 
panitumumab (the latter 2 drugs if KRAS wild-type). An adequate bone marrow, liver, 
and renal function was required. 
 
Treatment schedules 
Dacarbazine 250 mg/m2 intravenously everyday for 4 consecutive days, every 21 days, 
was administered until progression, death, unacceptable toxicity, or patient with drawl 
of consemant. Antiemetic agents and supportive care were provided by treating 
physician as per standard clinical practice. In case of G3 hematologic toxicity (absolute 
neutrophil count <1.5x109/L and platelet count <100x109/L) dacarbazine was delayed 
by 1-week interval until recovery. Prophylactic use of colony-stimulating factors was 
allowed as per standard clinical practice. 
 
Evaluation criteria 
Patients were evaluated for primary overall response rate and secondary endpoint 
(disease control rate and progression free survival) according to RECIST criteria v1.1. 
Tumors were measured every 8 ± 1weeks through week 18 and then every 8 ± 1 
weeks until the tumor progressed. Complete response was defined as disappearance 
of all target lesions. Any pathologic lymph nodes (whether target or non target) must 
have reduction in short axis to 10mm or less. An objective response (partial response) 
was defined as a reduction of at least 30 percent in the sum of all target lesions on 
computed tomography or magnetic resonance imaging scanning. Confirmed objective 
response were those for which a follow-up scan obtained at least 4 weeks later showed 
the persistence of the response. Progressive disease was defined as at least a 20% 
increase in the sum of diameters of target lesions, taking as reference the smallest sum 
on study (this includes the baseline sum if that is the smallest on study). In addition to 
the relative increase of 20%, the sum must also show an absolute increase of at least 5 
mm. Stable disease was defined as shrinkage neither sufficient to qualify for partial 
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response nor sufficient increase to qualify for progressive disease, taking as reference 
the smallest sum diameters while on study. Clinical investigators and radiologists were 
blinded as for MGMT status of the tumors.  
 
Safety assessment 
Safety assessments and blood biochemistry including complete blood counts were 
carried out at baseline and at the beginning of each treatment cycle. Any toxicity was 
assessed using the National Cancer Institute (NCI)-CTCAE version 4.0 and recorded at 
every visit until resolved.  
 
Analysis of MGMT promoter methylation status 
Loss of expression of MGMT was defined as promoter hypermethylation 25% or more 
as previously described (9). Tumor samples from patients’ primary tumor were 
obtained from Pathology Department of the Ospedale Niguarda Ca’ Granda or others 
Pathology Departments as referral. Formalin-fixed paraffin-embedded tumor blocks 
were reviewed for quality and tumor content. A single representative block, from either 
the primary tumor or metastasis, depending on availability, was selected for each case. 
White slides (2 cut of 10 μm, if from a tumor tissue paraffin block, or 3 cuts of 10 μm if 
from a biopsy) were sent to Bellvitge Biomedical Research Institute (IDIBELL; 
Barcelona, Spain) for DNA extraction and evaluation of MGMT promoter methylation 
status in blind as for clinical outcome. Genomic DNA was extracted from paraffin tissue 
samples following manufacturer’s instructions (QIAamp DNA FFPE Tissue Kit). DNA 
was then subjected to bisulfate treatment using EZ DNA methylation kit (Zymo 
Research). Briefly, 1 μg of genomic DNA was denaturated by incubating with 0.2 mol/L 
NaOH. Aliquots of 10 mmol/L hydroquinone and 3 mol/L sodium bisulfate (pH 5.0) were 
added, and the solution was incubated at 50ºC for 16 hours. Treated DNA was purified, 
desulfonated with 0.3 mol/L NaOH, repurified on Zymo-Spin columns, and eluted with 
25 μL water. MGMT promoter methylation status was analyzed by MSP. It was carried 
out in a 15 μL volume containing 1 μL of the sodium bisulfite-modified DNA. The 
characteristics of the MSP reactions and the primer sequence have been previously 
described (14). SW620 human colorectal cell line was used as a positive control for 
hypermethylated alleles of MGMT and DNA from RKO cell line used as a negative 
control (Fig. 1). 
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Statistical analysis 
According to clinical considerations and on the basis of the available literature, the 
efficacy of a treatment in this setting of metastasic colorectal cancer chemorefractory 
patients would be considered poor if the overall response rate is 3% or less, whereas it 
could be considered of clinical usefulness if the overall response rate is 10% or more. 
Assuming = 0.05 and =0.20, a Simon Optimal 2-stage design has been then chosen 
to test the null hypothesis that P  0.03 versus the alternative that P 0.10. According 
to this design, if at least 2 of the first 40 patients would have achieved an objective 
response, enrollment would have been extended by 28 patients. Overall, objective 
response rate of dacarbazine monotherapy would have been deemed unacceptable if 
objective response was 4 or less. The association between MGMT promoter 
methylation status and overall response rate and disease control rate was determined 
by 2-sided Student t-tests or Fisher exact test. Progression free survival was estimated 
by Kaplan–Meier product-limit method followed by log-rank test.  
 
Results 
Patients’ characteristics 
Sixty-eight patients were enrolled in our institution from May 2011 until March 2012. All 
patients had progressed on fluoropyrimidines, oxaliplatin, irinotecan, and cetuximab or 
panitumumab (the latter 2 drugs if KRAS wild-type). Eighty seven per cent of patients 
had received prior bevacizumab and 19% patient had received more than 4 lines of 
treatment. Twenty percent of patients received mitomycin C, 4% raltitrexed, and 12% 
previous experimental agents within clinical trials. Clinical characteristics of patients in 
this trial are reported in Table 1. Reasons for discontinuation of dacarbazine treatment 
included hematologic toxicity (1 patient), progression (61 patients), death (4 patients), 
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and withdrawal of consent (2 patients). Cause of death was recorded as metastasic 
colorectal cancer in all deceased patients. 
 
Table 1. Patients characteristics 
Demographics Value (%) 
Clinical 
Characteristics 
No. Of Patients 
(%) 
Age, years  Tumor KRAS status 
Median  63,5 Wild type 35 (47) 
Range 29-81   
  Mutated 33 (49) 
Sex, No. (%)  G12V 7 
Male 47 (69) G12C 5 
Female 21 (31) G12S 1 
   G12D 7 
  G12A 1 
Clinical 
Charachteristics 
No. Of Patients 
(%) G13D 5 
Performance status  Codon not available 7 
0 37 (54)    
1 31 (46) Tumor MGMT methylation status 
  Hypermethylated 26 (38) 
Tumor grade at diagnosis  Unmethylated 39 (58) 
1 2 (3) Not assessable 3 (4) 
2 43 (63)    
3 9 (13) No. of metastatic sites  
Not available 14 (21) 1 2 (3) 
  2 25 (37) 
No. of prior treatments  3 29 (43) 
2 14 (20) 4 11 (16) 
3 17 (25) 5 1 (1) 
4 23 (35)    
5 5 (7) Patients previously treated with  
6 6 (9) Bevacizumab 59 (87) 
7 2 (3) Mitomycin 17 (25) 
  Experimental drugs 8 (12) 
 
Toxicity 
Adverse events are listed in Supplementary Table S1. Hematologic toxicity was the 
most frequent adverse event reported and general toxicity was consistent with the 
known toxicity profile of dacarbazine. We observed 3 hematologic G4 adverse events 
(2 platelet count decreased and one neutrophil count decreased). Hepatic failure with 
increased bilirubin due to progression of disease was observed in 3 patients with 
extensive metastatic liver involvement. 
 
Analysis of MGMT promoter hypermethylation 
Sixty-five of 68 patients were tested for MGMT promoter CpG island methylation, as 
showed in Table 1. Overall, MGMT hypermethylation was found in 40% (26/65) of the 
colorectal neoplasms DNAs analyzed a similar frequency to the previously reported for 
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this tumor type (9). According to the location of the tumor, MGMT promoter status was 
assessed in 69% (45/65) in primary tumor, in 14% (9/65) in metastatic site, and in 17% 
(11/65) in both primary and metastatic site from the same patient. In the latter case, we 
observed concordance in 10 out of 11 pairs, with only one case showing a 
hypermethylated primary with unmethylated liver metastasis, and the result from liver 
metastasis was considered for the purpose of analysis. Sites of metastases were: liver 
75% (15/20), 5% (1/20) ovary, 10% (2/20) lung, 5% (1/20) spleen, and 5% (1/20) 
cutaneous. MGMT hypermethylation was more frequent (61% and 31%, respectively) 
in tumors carrying KRAS mutation with G>A transition (G12D, G12V, or G13D), as 
previously described   (10, 11), although the difference was not statistically significant 
due to the small size (only 26 patients were evaluable for both analysis; P=0.238).  
 
Antitumor activity of dacarbazine 
Overall response rate was 3%, with 2 partial responses. Stable disease was achieved 
in 8 of 68 patients (12%), accounting for a disease control rate (partial response + 
stable disease) of 15%. Median progression free survival was 57 days. Pre-planned 
analysis of secondary endpoints based on assessments of MGMT methylation and 
KRAS mutation status in individual tumors showed that objective response occurred 
only in patients displaying MGMT-methylated tumors (Fig. 2A and Fig. 3). In addition, 
we observed a significantly higher disease control rate (44.0% vs. 6%, P=0.012) in the 
MGMT-hypermethylated group (Fig. 2). 
 
  
A trend toward better progression free survival [Hazard Ratio (HR) =0.66; 95% 
confidence interval 0.40–1.10; P=0.0982] was also found in the MGMT 
hypermethylated cases (Fig. 4A). A similar tendency was found between reduction of 
tumor volume following dacarbazine treatment and MGMT methylation status: tumor 
shrinkage of any size occurred more frequently in patients displaying MGMT 
hypermethylation (Fisher exact test, P=0.093). In contrast, KRAS status was not 
associated with progression free survival, disease control rate, and overall response 
rate (KRAS mutant vs. KRAS wild-type, P=0.735, 0.999, and 0.492, respectively; Fig. 
4B).  
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Discussion 
In this study, we document that dacarbazine is active after failure of standard therapies 
only in those patients with metastasic colorectal cancer whose tumor is harboring 
epigenetic inactivation of the DNA repair enzyme MGMT. Overall, we observed 2 
objective response, accounting for 3% of overall response rate, and 8 stable diseases, 
accounting for 12% of the cases. The observation of a significant association between 
MGMT promoter hypermethylation and these clinical endpoints supports the hypothesis 
that DNA repair-defective metastasic colorectal cancer tumors are more susceptible to 
this chemotherapeutic agent. However, even in the case of MGMT hypermethylation, 
we observed that a fraction of 44% of patients achieved control of disease (stable 
disease + partial response), thus suggesting that a multiparametric signature including 
the DNA methylation associated silencing of MGMT together with other molecular traits 
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would improve the identification of colorectal cancer tumors with defects in DNA repair, 
susceptible to the action of dacarbazine. 
 
The low response rate observed in the present cohort could be linked to the inclusion 
of heavily pretreated patients (median 4 lines of previous treatments). To interpret this 
clinical result in the context of therapy-resistant metastasic colorectal cancer, one 
should consider that second-line treatment with FOLFIRI or FOLFOX combination 
regimens induces overall response rate of 10% to 12% (24–26) and dramatically 
decreases in subsequent lines (6).  It is also known that dacarbazine is activated in 
liver by CYP450 microsomial N-demethylation with formation of 5-[3-hydroxymethyl-3-
methyl-triazen-lyl]-imidazole-4-carboxamide and 5-[3-methyl-triazen-1-yl]-imidazole-4-
carboxamide (MTIC). Rapid decomposition of MTIC produces the major plasma and 
urine metabolite 5-amino-imidazole-4-carboxamide and the reactive species methane 
diazohydroxide, which produces molecular nitrogen and a methyl cation supposed to 
be the methylating species (27). It is therefore conceivable that the multiple (median 4) 
previous lines of cancer treatment as well as the high (79%) rate of liver involvement in 
the present study population may have exhausted the liver function capacity to activate 
dacarbazine. 
 
It was our hypothesis that anticancer activity of dacarbazine could be enhanced by a 
specific defect in DNA repair system as evaluated by MGMT promoter 
hypermethylation in individual tumors. This epigenetic defect occurs in about 35% to 
40% of metastasic colorectal cancers (9) and it is detected in more than 70% of KRAS-
mutated tumors carrying the G>A transitions subtypes of mutation (10, 11), a subgroup 
of metastasic colorectal cancers with limited therapeutic options. Although the present 
trial was not designed, and thus, powered to assess a significant difference in 
progression free survival between MGMT-hypermethylated/unmethylated groups, we 
observed a trend toward better progression free survival in the MGMT hypermethylated 
group, together with a better disease control rate. The 2 patients displaying objective 
response were indeed carrying MGMT-hypermethylated tumors (Fig. 2A) and one of 
them showed a long-lasting maintenance of response of 6 months, which is uncommon 
in the advanced setting of metastasic colorectal cancer.  
 
In conclusion, present data document that specific DNA repair defects can be 
associated with susceptibility to dacarbazine. The use of an alkylating agent that does 
not require hepatic activation may be preferable in heavily pre-treated patients with 
metastatic liver disease. In this regard, temozolomide is an alkylating agent whose 
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activity is also enhanced in tumors with MGMT loss (17) that is hydrolyzed in cells 
producing the active compound MTIC without requiring liver passage. A phase II trial 
with temozolomide has been designed and it is ongoing at our institution to assess the 
efficacy in patients with MGMT hypermethylated metastasic colorectal cancers after 
failure of standard therapies. 
 
REFERENCES 
1. Globocan colorectal cancer fact sheet 2008 [homepage on the Internet]. Lyon, 
France: International agency for research on cancer; 2010 [cited 2012 Jul 10]. 
Available from: http://globocan.iarc.fr/factsheets/ cancers/colorectal.asp. 
2. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et 
al.ESMO consemansus guidelines for management of patients with colon and rectal 
cancer. A personalized approach to clinical decision making. Ann Oncol 2012;23:2479–
516. 
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in 
oncology (NCCN guidelines): colon cancer. version 3.2012 [homepage on the Internet]. 
Fort Washington, PA: National Comprehensive Cancer Network; 2012 [cited 2012 Jul 
10]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. 
4. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. 
Regorafenib monotherapy for previously treated metastatic colorectal cancer 
(CORRECT): an international, multicentre, prospective, randomised, placebo-controlled 
phase 3 trial. Lancet 2013;381:303–12. 
5. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and 
panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254–61. 
6. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.  Biomarkers 
predicting clinical outcome of epidermal growth factor receptor-targeted therapy in 
metastatic colorectal cancer. J Natl Cancer Inst 2009;101:1308–24. 
7. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and 
importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 
1990;50:6119–29. 
8. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and 
challenges. Nat Rev Genet 2012;13:679–92. 
9. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA 
repair gene O6-methylganine- DNA methyltransferase by promoter hypermethylation is 
a common event in primary human neoplasia. Cancer Res 1999;59:793–7. 
10. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, 
et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by 
                                                                                                                          RESULTS 
 
72

promoter hypermethylation is associated with G to A mutations in K-ras in colorectal 
tumorigenesis. Cancer Res 2000;60:2368–71. 
11. Qi J, Zhu YQ, Huang MF, Yang D. Hypermethylation of CpG island in O6-
methylguanine-DNA methyltransferase gene was associated with K-ras G to A 
mutation in colorectal tumor. World J Gastroenterol 2005;11:2022–5. 
12. de Vogel S, Weijenberg MP, Herman JG, Wouters KA, de Goeij AF, van den 
Brandt PA, et al. MGMT and MLH1 promoter methylation versus APC, KRAS and 
BRAF gene mutations in colorectal cancer: indications for distinct pathways and 
sequence of events. Ann Oncol 2009;20:1216–22. 
13. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amista P, et al. 
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy 
in newly diagnosed patients with glioblastoma: correlation with MGMT promoter 
methylation status. J Clin Oncol 2009;27:1275–9. 
14. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha 
V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of 
gliomas to alkylating agents. N Engl J Med 2000;343:1350–4. 
15. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT 
gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 
2005;352:997–1003. 
16. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre- Cruz L, et al. 
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts 
responon-seminoma to temozolomide in primary gliomas. Clin Cancer Res 
2004;10:4933–8. 
17. Esteller M, Herman JG. Generating mutations but providing chemosensitivity: the 
role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 
2004;23:1–8. 
18. Akbulut H, Icli F, Yalcin B, Demirkazik A, Onur H, Buyukcelik A, et al. Activity of 
irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients 
with advanced colorectal carcinoma. Exp Oncol 2004;26:149–52. 
19. Icli F, Arican A, Cay F, Akbulut H, Dincol D, Karaoguz H, et al. Phase II study of 
cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil. 
Oncology 1999;56: 297–300. 
20. Khan OA, Ranson M, Michael M, Olver I, Levitt NC, Mortimer P, et al. A phase II 
trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer 
2008;98:1614–8. 
                                                                                                                          RESULTS 
 
73

21. Ku GY, Krol G, Ilson DH. Successful treatment of leptomeningeal disease in 
colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. J Clin 
Oncol 2007;25:e14–6 
22. Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. 
Pilot study using molecular profiling of patients' tumors to find potential targets and 
select treatments for their refractory cancers. J Clin Oncol 2010;28:4877–83. 
23. Shacham-Shmueli E, Beny A, Geva R, Blachar A, Figer A, Aderka D. Response to 
temozolomide in patients with metastatic colorectal cancer with loss of MGMT 
expression: a new approach in the era of personalized medicine? J Clin Oncol 
2011;29:e262–5. 
24. Bidard FC, Tournigand C, Andre T, Mabro M, Figer A, Cervantes A, et al. Efficacy 
of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based 
regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR 
OPTIMOX1 study. Ann Oncol 2009;20:1042–7. 
25. Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, et al. Capecitabine 
plus oxaliplatin (XELOX) versus 5-FU/folinic acid plus oxaliplatin (FOLFOX-4) as 
second-line therapy in metastatic colorectal cancer: a randomized phase III 
noninferiority study. Ann Oncol 2008;19:1720–6. 
26. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. 
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and 
irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in 
patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706–13. 
27. Reid JM, Kuffel MJ, Miller JK, Rios R, Ames MM. Metabolic activation of 
dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and 
CYP2E1. Clin Cancer Res 1999;5:2192–7.  
 
                                                                                                                          RESULTS 
 
74

SUPPLEMENTARY INFORMATION 
 
Supplementary Table S1. Toxicities. 
Non-hematological 
toxicities 
All Grades Grade 3-4 
No. of patients % No. of patients %
Fatigue 28 41 5 7
Nausea 20 29 5 7
Constipation 17 25 0 0
Blood bilirubin increased 11 16 0 0
Mucositis [217] 3 4 0 0
Flushing 2 3 0 0
Flu like symptoms 1 1 0 0
Dyspepsia 1 3 0 0
Rash 1 3 0 0
Arthralgia 1 3 0 0
       
Hematologic Toxicities 
All Grades Grade 3-4 
No. of patients % No. of patients %
Platelet count decrease 13 19 4 6
Anemia 12 18 1 1
White blood cell decrease 6 9 1 1
Febrile neutropenia 1 1 1 1
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RESUMEN 
 
Antecedentes: Uno de los problemas más importantes en el tratamiento de los 
pacientes de cáncer es la existencia de resistencia primaria (tumores refractarios) y/o 
la resistencia adquirida a los tratamientos de quimioterapia. Esto se asocia a diferentes 
defectos celulares, genéticos y epigenéticos. 
 
Métodos: Para poder identificar posibles diferencias en los perfiles de metilación 
asociados con la adquisición de resistencia al oxalipaltino, líneas celulares pareadas 
sensibles vs. resistentes generadas in vitro se anlizaron con arrays de metilación. El 
gen SRBC, identificado diferencialmente metilado se validó mediante técnicas 
específicas de metilación de promotores y de expresión. Para evaluar el papel 
funcional de la expresión de esta proteína en la sensibilidad al oxaliplatino se 
realizaron experimentos in vitro tanto de sobre-expresión como de inhibición génica. 
La supervivencia libre de progresión de la enfermedad y la supervivencia global en 
pacientes con cáncer colorrectal metastásico se determinaron por curvas de Kaplan-
Meier y con el análisis de regresión de Cox. 
 
Resultados: En nuestro modelo celular se observó que la resistencia adquirida al 
oxaliplatino, depende, al menos en parte, de la metilación del promotor del gen SRBC, 
identificándose su inactivación por metilación con una mayor resistencia. La sobre-
expresión in vitro de este gen o su inactivación conlleva un aumento en la sensibilidad 
o resistencia al oxaliplatino, respectivamente. En las dos cohortes independientes de 
pacientes con cáncer colorectal metastásico (n=131 y n= 58) el promotor del gen 
SRBC se encontraba metilado en un 30% de los tumores primarios. Este hecho se 
asoció con una menor supervivencia libre de progresión (Hazard Ratio (HR)=1,83; 
intervalo de confianza (IC) 95%=1.15-2.92; log-rank P=0.01). Siendo especialmente 
relevante en los casos tratados con oxaliplatino y para los que no estaba indicada la 
cirugía de las metástasis (HR=1.96, IC 95%=1.13-3.40; log-rank P=0.01 y HR=1.90,  
IC=1.01-3.60; log-rank P= 0,045). 
 
Conclusiones: Nuestros resultados proporcionan una base para futuros estudios 
clínicos de validación de la hipermetilación del promotor del gen SRBC, como 
marcador predictivo de resistencia al oxaliplatino en el cáncer colorectal metastásico. 
Así la validación de este potencial marcador en ensayos clínicos estratificando en base 
a la metilación, puede permitir modificar el tratamiento de los pacientes con este 
cambio en su promotor. 
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ABSTRACT 
 
Background: A major problem in cancer chemotherapy is the existence of primary 
resistance and/or the acquisition of secondary resistance. Many cellular defects 
contribute to chemoresistance, but epigenetic changes can also be a cause.  
 
Methods: A DNA methylation microarray was used to identify epigenetic differences in 
oxaliplatin sensitive and resistant colon cancer cells. The candidate gene SRBC was 
validated by single locus DNA methylation and expression techniques. Transfection 
and short-hairpin experiments were used to assess oxaliplatin sensitivity. Progression 
free survival and overall survival in metastasic colorectal cancer patients were explored 
with Kaplan-Meier and Cox regression analyses. All statistical tests were two-sided. 
 
Results: We found that oxaliplatin resistance in colon cancer cells depends on the 
DNA methylation-associated inactivation of the BRCA1 interactor SRBC gene. SRBC 
over-expression or depletion gives rise to sensitivity or resistance to oxaliplatin, 
respectively. SRBC epigenetic inactivation occurred in primary tumors from a discovery 
cohort of colorectal cancer patients (29.8%, 39 of 131), where it predicted shorter 
progression free survival (HR=1.83; 95% confidence interval (CI)=1.15-2.92; log-rank 
P=0.01), particularly in oxaliplatin-treated cases for which metastasis surgery was not 
indicated (HR=1.96; 95% CI=1.13-3.40; log-rank P=0.01). In a validation cohort of 
unresectable colorectal tumors treated with oxaliplatin (n=58), SRBC hypermethylation 
was also associated with shorter progression free survival (HR=1.90; CI=1.01-3.60; 
log-rank P=0.045). 
 
Conclusions: These results provide a basis for future clinical studies to validate SRBC 
hypermethylation as a predictive marker for oxaliplatin resistance in colorectal cancer. 
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INTRODUCTION 
Colorectal cancer is the second most common cause of cancer death in the western 
world (1). In metastasic colorectal cancer, polychemotherapy based on 
fluoropyrimidines plus oxaliplatin or irinotecan are the gold standard treatment, 
combined with biological agents such as cetuximab and panitumumab (2). Oxaliplatin 
forms intra-strand adducts that disrupt DNA replication and transcription (3,4). DNA 
damage induced by oxaliplatin is repaired in part by the nucleotide excision repair 
pathway (5), but the DNA double-strand breaks induced by the drug are also repaired 
by the BRCA1 complex (6-8). In this regard, epigenetic inactivation of the BRCA1 gene 
by promoter CpG island methylation has been associated with increased sensitivity to 
cisplatin and carboplatin in breast and ovarian cancer (9,10). 
 
Genes critical to colorectal tumor biology are frequently inactivated by 
hypermethylation of the CpG dinucleotides located in their 5’-CpG island regulatory 
regions (11-13). We wondered whether this epigenetic alteration was involved in the 
resistance to oxaliplatin in colorectal cancer, where treatment failure due to primary or 
acquired resistance remains a major obstacle to the management of the disease. 
Herein, we demonstrate that the epigenetic inactivation of the BRCA1 interactor SRBC 
gene by promoter CpG island hypermethylation is associated with poor outcome upon 
oxaliplatin treatment. 
 
METHODS 
Cell Lines 
LoVo parental cell line (LoVo-S) and its derived 10-fold oxaliplatin resistant cells (LoVo-
R)(14) were cultured at 37ºC in an atmosphere of 5% (v/v) carbon dioxide in 
Dulbecco’s Modified Eagle’s Medium/Ham’s Nutrient Mixture F12 (DMEM-HAM’s F12) 
medium supplemented with 20% (w/v) fetal bovine serum, 100U penicillin and 100μg/L 
streptomycin (Invitrogen, Carlsbad,CA).The HCT-116, SW48, SW480, SW620, RKO, 
Co115, and HCT-15 colon cancer cell lines were obtained from the American Type 
Culture Collection (Manassas, VA, USA). Cell lines were authenticated by short 
tandem repeat profiling. 
 
Determination of Drug Resistance 
Oxaliplatin (5mg/ml) and 5-FU (50mg/ml) were obtained from TEVA (North Wales, PA, 
USA), and Accord Healthcare SLU (Barcelona, Spain), respectively. Cell viability was 
determined by the 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide 
(MTT) assay. Briefly, 1 x 103 cells were plated onto 96-well plates. Cells were treated 
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for 120 hours with different drugs concentration (oxaliplatin: 0-250μM and 5-FU: 0-
35μM). MTT was added at a final concentration of 0.1%. After 2.5 hours incubations 
(37ºC, 5% carbon dioxide), the MTT metabolic product, formazan was dissolved in 
dimethyl sulfoxide (DMSO) and absorbance was measured at 570 nm. Prism Software 
(La Jolla, CA) was used to calculate drugs half maximal inhibitory concentration (IC50). 
 
DNA Methylation Analyses 
DNA was subjected to bisulfite using EZ DNA methylation kit (Zymo Research, Orange, 
CA) as previously described (15). To perform the genome-wide DNA methylation 
profiling we used the Illumina Infinium HumanMethylation27 BeadChip® (Illumina, ,San 
Diego, CA, USA) microarray following the manufacturer’s instructions (15).The Infinium 
assay quantifies DNA methylation levels at specific cytosine residues adjacent to 
guanine residues (CpG loci), by calculating the ratio (-value) of intensities between 
locus-specific methylated and unmethylated bead-bound probes. The -value is a 
continuous variable, ranging from 0 (unmethylated) to 1 (fully methylated). This 
microarray assesses the DNA methylation level of 27,578 CpG sites located at the 
promoter regions of 14 495 protein-coding genes. DNAs were processed on the same 
microarray to avoid batch effects. The array was scanned by a Bead Array Reader 
(Illumina), and intensity data analyzed using Genome Studio software (version 2011.1, 
Illumina). Further details are described in Supplementary Methods. The data is freely 
available at GeneExpressionOmnibus (http://www.ncbi.nlm.nih.gov/geo/) under GEO 
accession code GSE44446. 
 
We established SRBC CpG island methylation status using three different polymerase 
chain reactions (PCR) based techniques: bisulfite genomic sequencing of multiple 
clones, MSP and pyrosequencing. Further technical details are described in 
Supplementary Methods. The used primer sequences are shown in Supplementary 
Table 1. 
 
Messenger RNA and Protein Expression Analyses 
Messenger RNA extraction, cDNA synthesis, conventional and quantitative real time 
PCR using Hs00376942_m1Taqman Gene Expression assay (Applied Bioystem, 
Madrid, Spain) were performed as previously described (16). Primer sequences are 
shown in Supplementary Table 1. Anti-SRBC (1/1000) from Cell Signaling and anti--
actin-HRP antibody (1/20000) from Sigma (St. Louis, MO, USA) were used to develop 
the western blot analysis. 
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SRBC Transfection and Depletion Experiments 
Human shRNAs and cDNA plasmids for SRBC were obtained from Origene (Rockville, 
MD, USA). After E.coli transformation, we preceded to plasmid DNA purification. Forty- 
eight hours after electroporation, cells transfected with shRNAs (TR317747, Origene) 
were grown in medium containing 0.8 or 0.6 μg/mL of puromycin (LoVo-S and HCT-
116). Cells transfected with SRBC cDNA (SC320781, Origene) were grown with DMEM 
medium containing 0.8 or 0.6 mg/mL geneticin (G418, LoVo-R and HCT-15), to 
perform clonal selection. Once selected, clones were picked, grown and tested by 
western blot. 
 
Patients 
In our study we analyzed two independent Caucasian cohorts of stage IV colorectal 
cancer patients (17). In the discovery set 131 metastasic colorectal cancer primary 
tumors that received oxaliplatin plus fluoropirimidines based therapy, were 
retrospectively included. Formalin-fixed paraffin embedded tumors, obtained by 
surgical resection, came from three different hospitals (ICO-Hospitalet, ICO-Badalona 
and Niguarda Ca' Granda). Clinical features of the patients are showed in Table 1. 
From this cohort, 65 patients could undergo surgery to remove metastases. Following 
neoadjuvant regimen, 34 could be operated and 31 received palliative regimen. The 
rest of patients (n=66) showed unresectable metastases and directly underwent to 
palliative regimen. The greatest time of follow-up of this group was near 10 years. The 
validation cohort consisted in 58 stage IV colorectal cancer patients collected in 
Hospital Vall d’Hebron with a follow-up of near 3 years (Table 1). According to 
discovery set results, we selected patients with unresectable metastases, that received 
oxaliplatin plus fluoropirimidines based therapy in a neoadjuvant (n=20) or palliative 
regimen (n=38). The distribution of patients according to the different clinical features 
was similar in both cohorts. Signed informed consent was obtained from each patient 
and Clinical Research Ethical Committee from ICO-Hospitalet provided approval for the 
study. DNA from all cases was obtained from formalin-fixed paraffin-embedded tissue 
sections (10 μm) by xilol deparafination and digestion by proteinase K (Qiagen, 
Manchester, UK). Tumor specimens were composed of at least 70% carcinoma cells. 
DNA extraction was performed using a commercial kit (Qiagen), following 
manufacturer’s instructions. 
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Table1. Clinical features of the discovery and validation cohorts of stage IV colorectal samples included in the study.* 
Characteristic 
DISCOVERY COHORT (n=131) VALIDATION COHORT (n=58) 
SBRC according to methylation status SBRC according to methylation status 
N % 
Unmethylated Methylated  
         OR (95% CI)  
 N % 
Unmethylated Methylated  
 OR (95% CI) 
N % N % N % N % 
Gender                 
Male 85 64.9% 61 71.7% 24 28.3% 1 (referent) 35 60.3% 29 82.8% 6 17.2% 1 (referent) 
Female 46 35.1% 31 67.4% 15 32.6% 1.13 (0.85 - 1.47) 23 39.7% 15 65.2% 8 34.8% 0.60 (0.32 - 1.10) 
Primary tumor      
Colon 102 77.8% 72 70.6% 30 29.4% 1 (referent) 41 70.7% 32 78.1% 9 21.9% 1 (referent) 
Rectum 29 22.2% 20 68.9% 9 31.1% 0.94 (0.47 - 1.25) 17 28.3% 12 70.6% 5 29.4% 0.76 (0.33 - 1.79) 
Metastatic site      
Liver 81 61.8% 52 64.2% 29 35.8% 1 (referent) 47 81.0% 35 74.5% 12 25.5% 1 (referent) 
Lung 9 6.9% 5 55.5% 4 44.5% 0.72 (0.21 - 2.51) 3 5.2% 2 66.7% 1 33.3% 0.70 (0.07 - 7.12) 
Others 18 13.7% 15 83.3% 3 16.7% 2.39 (0.74 - 7.66) 8 13.8% 7 87% 1 13% 2.10 (0.29 - 16.1) 
Unknown 23 17.6% 20 86.9% 3 13.1% - 0 0% 0 0% 0 0% - 
Chemotherapy schedule      
Oxaliplatin / 5-FU 107 81.7% 74 69.2% 33 30.8% 1 (referent) 41 70.7% 32 78.1% 9 21.9% 1 (referent) 
Oxaliplatin / CAPE 10 7.6% 8 80.0% 2 20.0% 1.71 (0.38 - 7.64) 0 0% 0 0% 0 0% - 
Oxaliplatin / 5-FU / BA 13 9.9% 9 69.2% 4 30.8% 1.01 (0.33 - 3.05) 17 29.3% 12 70.6% 5 29.4% 0.76 (0.33 - 1.79) 
Oxaliplatin / CAPE / BA 1 0.8% 1 100% 0 0% - 0 0% 0 0% 0 0% - 
Chemotherapy regimen      
Neoadjuvant 65 49.6% 41 63.1% 24 36.9% 1(referent) 20 34.5% 15 75.0% 5 25.0% 1 (referent) 
Palliative 66 50.4% 51 77.3% 15 22.7% 1.47 (0.95 - 2.27) 38 65.5% 29 76.3% 9 23.7%      1.02 (0.66 - 1.60) 
Surgery of metastasis      
No 97 74.1% 72 74.3% 25 25.7% 1 (referent) 58 100% 44 75.9% 14 24.1% - 
Yes 34 25.9% 20 58.8% 14 41.2% 0.61 (0.34 - 1.07)  0 0% 0 0% 0 0% - 
Abbreviations:  5-FU = 5-fluorouracil; CAPE = capecitabine; BA= Biological agents 
* None of the relationships were statistically significant after using the two-sided Chi-square test, considering  p<0.05 as statistical significant threshold. 
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Statistical Analysis 
In both independent cohorts we analyzed SRBC promoter methylation status and its 
association with response rate, progression free survival, and overall survival. The 
associations between categorical variables were assessed by 2 tests or Fisher exact 
test whenever required. Kaplan–Meier plots and log-rank test were used to estimate 
progression free survival and overall survival. The association between epigenetic 
variant and clinical parameters with progression free survival and overall survival was 
assessed through univariate and multivariable Cox proportional hazards regression 
models. The proportional hazards assumption for a Cox regression model was tested 
under R statistical software (Boston, MA) (cox.zph function). Statistical analysis was 
performed by using SPSS for Windows, (Armonk, NY), and P values less than .05 were 
considered statistically significant. All statistical tests were two-sided. 
 
RESULTS 
Identification of Epigenetics Changes Associated With oxaliplatin Resistance 
Using a DNA Methylation Microarray  
To address in an unbiased manner whether epigenetic changes can be associated with 
oxaliplatin resistance, we adopted a whole genomic approach by comparing the DNA 
methylation status of 27 000 CpG sites (15) of an oxaliplatin-sensitive colon cancer cell 
line (LoVo-S) and an oxaliplatin-resistant clone (LoVo-R) that we derived by exposure 
to increasing concentrations of the drug (14).  
 
This approach yielded only three differentially methylated target genes: SRBC (protein 
kinase C delta binding protein), FAM111A (family with sequence similarity 111, 
member A) and FAM84A (family with sequence similarity 84, member A) 
(Supplementary Figure 1A). The most noteworthy gene with the highest difference in 
DNA methylation was SRBC; thus, it was the logical option to pursue. However, we 
also studied initially the other two genes. For FAM111A, bisulfite genomic sequencing 
of multiple clones showed that indeed the CpG site included in the DNA methylation 
microarray was distinctly methylated in LoVo-S and LoVo-R cells; however, the 
remaining sites of the CpG island were unchanged (Supplementary Figure 1B). Thus, 
we excluded this gene from further experiments. For FAM84A, bisulfite genomic 
sequencing confirmed the differential methylation of the CpG island, but both 
conventional and quantitative real time PCR did not show any difference in gene 
expression (Supplementary Figure 1, D and E). Thus, we also excluded this second 
gene from further analyses. For the main target gene, SRBC, the DNA methylation 
microarray data showed that it had a CpG site located in its 5’-CpG island (155 base 
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pair position) that was hypermethylated in LoVo-R but unmethylated in LoVo-S 
(Supplementary Figure 1A). Interestingly, SRBC CpG island methylation-associated 
silencing has already been found in cancer (18, 19 ), including colorectal tumors (20). 
From a functional standpoint, it is biologically plausible that SRBC is responsible for the 
different sensitivity to oxaliplatin because its protein interacts with the product of the 
BRCA1 gene (18), which is widely accepted as being a mediator of response to DNA 
damage induced by platinum compounds (21).  
 
To further demonstrate the presence of SRBC 5’-CpG island methylation in resistant 
cells, we undertook bisulfite genomic sequencing analyses. We found CpG island 
hypermethylation in LoVo-R but mostly an unmethylated CpG island in LoVo-S (Figure 
1A). Importantly, SRBC expression was diminished in LoVo-R, showing CpG island 
methylation, whereas it was expressed in the unmethylated LoVo-S at the messenger 
RNA and protein levels (Figure 1B). SRBC re-expression was observed upon 
treatment with the DNA demethylating agent 5-AZA in LoVo-R cells (Figure 1B). 
 
SRBC Epigenetic Inactivation and Oxaliplatin Resistance 
 We next sought to demonstrate that the epigenetic inactivation of this gene functionally 
contributed to oxaliplatin resistance. We restored the expression of SRBC in LoVo-R by 
stably transfecting an exogenous expression vector (Figure 1C). Upon SRBC 
transfection, the cells proved to be statistically significantly more sensitive to the 
antiproliferative activity of oxaliplatin measured by the MTT assay (Figure 1D) than 
were the empty vector-transfected cells (LoVo-R + SRBC 1 and 2: P=0.02 and P< 
0.001, respectively). In sharp contrast, we observed that SRBC stable down-regulation 
by the short hairpin RNA approach in SRBC-expressing and unmethylated sensitive 
cells (LoVo-S) (Figure 1C) had the opposite effect: a considerable enhancement of the 
resistance to the antiproliferative effect mediated by oxaliplatin (Figure 1D) (LoVo-S 
short hairpin SRBC A and B: P=0.04 and P<0 .001, respectively). The observed effects 
were specific for oxaliplatin because the in vitro depletion or enhancement of SRBC 
activity did not change the sensitivity to 5-FU (Figure 1D), other drug commonly used 
in colorectal cancer. 
                                                                                                                                                                                                                    RESULTS                        
 
84

                                                                                                                          RESULTS                             
 
85

We extended our study to seven additional colon cancer cell lines (Co115, HCT-15, 
HCT-116, SW48, SW480, SW620, and RKO), in which we found SRBC promoter CpG 
island hypermethylation (Figure 2A) and the associated loss of expression only in 
HCT-15 cells (Figure 2B). Interestingly, these cells were the only ones showing 
resistance to oxaliplatin (IC50 ± standard deviation = 3.81 ± 0.18 M); the remaining 
cells were sensitive to the drug (Figure 2C) (IC50 values ranging from 0.30 to 0.83 M). 
As we did with LoVo-S and LoVo-R, we also sought to demonstrate that SRBC 
epigenetic inactivation functionally contributed to oxaliplatin resistance in these cells. 
We restored the expression of SRBC in the resistant cell line HCT-15 by stably 
transfecting an exogenous expression vector (Supplementary Figure 2A). Upon 
SRBC transfection, the cells proved to be statistically significantly more sensitive to the 
antiproliferative activity of oxaliplatin (HCT15+SRBC: P=0.02) (Supplementary Figure 
2B). The opposite effect was observed with SRBC stable downregulation using the 
short hairpin RNA approach in SRBC-expressing and unmethylated sensitive cells 
(HCT-116): a noteworthy increase in the resistance to the antiproliferative effect 
mediated by oxaliplatin was found (Supplementary Figure 2B) (HCT-116 short hairpin 
SRBC A and B: P<0.001). The described effects were specific for oxaliplatin because 
the in vitro depletion or enhancement of SRBC activity did not change the sensitivity to 
5-FU (Supplementary Figure 2B). Western blot analyses showed that the level of 
expression of the SRBC protein in the transfected clones was similar to that observed 
in unmethylated colon cancer cell lines (Supplementary Figure 2A). 
 
SRBC Hypermethylation and Progression Free Survival in oxaliplatin-Treated 
Cases of Unresectable Colorectal Cancer  
Given these in vitro findings that colon cancer cells with SRBC methylation-associated 
silencing were resistant to oxaliplatin, we wondered whether the same effect could be 
observed in clinical samples. The study of a first clinical cohort of 131 stage IV 
colorectal adenocarcinoma patients (termed discovery cohort) (Table 1), all of whom 
were treated with oxaliplatin in combination with a fluoropyrimidine, showed SRBC 
methylation in 29.8% (n=39 of 131) of the case patients analyzed by both methylation-
specific PCR and pyrosequencing analyses (Figure 3A; Supplementary Figure 3). 
The described occurrence of SRBC hypermethylation in colorectal tumors was identical 
to the one available in the The Cancer Genome Atlas datasets (30.2%; n=70 of 232). 
Considering the whole population of studied advanced colorectal cancer case patients 
(n=131), we observed that SRBC hypermethylation was associated with progression 
free survival (HR=1.83; 95% CI=1.15 to 2.92; log-rank P=0.01) (Figure 3B). For the 
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105 case patients for whom overall survival information was available, SRBC 
hypermethylation was not associated with this variable (Figure 3C). 
 
According to Cox regression multivariable test, surgery of metastases showed to be an 
independent progression free survival (HR=0.43; 95% CI=0.24 to 0.76; log-rank P= 
0.004) and overall survival (HR=0.16; 95% CI=0.04 to 0.52; log-rank P=0.003) 
prognostic factor (Supplementary Figure 4). Taking this into account, our cohort was 
stratified in relation to this clinical feature and was divided into two groups: patients that 
underwent metastases resection (n=34) and patients with unresectable metastases 
(n=97). Subdividing the discovery cohort into these resectable or unresectable groups, 
SRBC hypermethylation did not have any predictive effect in progression free survival 
and overall survival for those case patients that received oxaliplatin as neoadjuvant 
therapy followed by the successful resection of the metastases (Supplementary 
Figure 5). 
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However, the scenario was completely different in the context of patients with 
colorectal adenocarcinomas with unresectable metastases who received oxaliplatin as 
neoadjuvant therapy and were subsequently not eligible for surgery (n=31) or patients 
with tumors that were originally classified as unresectable and were given oxaliplatin as 
palliative chemotherapy (n=66). For these 97 oxaliplatin-treated advanced colorectal 
cancer case patients with unresectable metastases, SRBC CpG island 
hypermethylation was statistically significantly associated with shorter progression free 
survival (HR=1.96; 95% CI=1.13 to 3.40; log-rank P=0.01) (Figure 3D). In this set of 
case patients, for whom overall survival data were available for 79 patients, we also 
observed that SRBC hypermethylation was statistically significantly associated with 
shorter overall survival (HR=2.01; 95% CI=1.13 to 3.40; log-rank P=0.04). These 
interesting results prompted us to study the SRBC methylation status in a second 
independent set of colorectal cancer patients with unresectable metastasis who also 
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received oxaliplatin-based therapy (n=58) (Table 1). In this validation cohort, we 
confirmed that the presence of SRBC hypermethylation was associated with shorter 
progression free survival (HR=1.90; 95% CI=1.01 to 3.60; log-rank P=0.045) (Figure 
4). Thus, the clinical data are similar to the results from the aforementioned cell 
cultures that suggest increased chemoresistance of SRBC hypermethylated colorectal 
tumors to oxaliplatin treatment.  
 
DISCUSSION 
The preexistence (primary resistance) or the de novo development (secondary 
resistance) of cellular mechanisms to escape the antitumoral effects mediated by the 
anticancer compounds probably involve a wide repertoire of genetic and epigenetic 
(22) events. From a genetics perspective in colorectal cancer, it has been described 
that the presence of KRAS mutations and gene amplification of the EGFR or MET 
genesis associated with resistance to overall anti-EGFR therapies (23,24,25). 
However, from an epigenetics perspective, very little is known. In spite of promising 
pharmacoepigenetics biomarkers, such as the example of MGMT hypermethylation 
and good response to temozolamide in gliomas (26), have been described for other 
tumor types, the examples in colorectal neoplasms are scarce, even more so if we just 
focus on resistance biomarkers. Herein, we provide an example to help fill this niche by 
showing that SRBC hypermethylation predicts resistance to the commonly used agent 
oxaliplatin in metastatic colorectal cancer, a disease stage that represents the second 
most common cause of death from cancer (1).  
 
A role of SRBC in mediating different sensitivity to oxaliplatin can be clearly justified by 
its protein interaction with the product of the BRCA1 gene (18). The BRCA1 protein 
exerts an important role in DNA double-strand break repair through homologous 
recombination 2, so its deficiencies can impair the capacity of cancer cells to repair 
DNA cross-links caused by chemotherapy drugs such as platinum derivatives (3–
7).Two independent studies reported greater primary chemotherapy sensitivity to 
platinum based chemotherapy agents in patients with ovarian cancer who were carriers 
of BRCA1 germline mutations (5,6). These observations have also been extended to 
BRCA1 epigenetic silencing in sporadic breast and ovarian tumors, where it also 
predicts a good response to cisplatin and carboplatin (9,10,and 27). However, the 
biology of mammary tumors is very different from colorectal malignancies, and in all 
cases of colon cancer, the BRCA1 promoter has always been found in an 
unmethylated status (28–30). Interestingly, in addition to its BRCA1-related roles, 
SRBC might have other functions related to the observed chemoresistance phenotype, 
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such as its interaction with caveolin 1, which may putatively affect intracellular vesicle 
traffic of the drug (31). 
 
It is worth mentioning two possible avenues of further research. First, there is the 
possibility to detect SRBC hypermethylation by sensitive user-friendly techniques, such 
as methylation-specific PCR and pyrosequencing, which could be useful in the clinical 
setting. Instead of always requiring the use of the surgical tumor sample, stool or 
serum/plasma DNA could be useful alternative biological materials to predict oxaliplatin 
resistance in colorectal cancer patients. In this regard, DNA methylation changes are 
also amenable for the development of new powerful molecular techniques, such as 
those recently referred to as liquid biopsies (32). Second, our observation that 
sensitivity to oxaliplatin can be restored by the re-expression of the SRBC gene could 
represent a revival of the DNA demethylating agents in the therapy of solid tumors. 
With little therapeutic options against metastatic colorectal cancer once it has become 
insensitive to oxaliplatin, DNA methylation inhibitors, such as 5-AZA, could be used to 
resensitize these tumors to the oxaliplatin therapy. This idea has been recently 
explored in non–small cell lung carcinoma patients who had reached the last line of 
chemotherapy. The subsequent administration of 5-AZA was able to rescue previous 
chemosensitivity (33). 
 
Limitations of our study to be addressed in further research include the lack of 
knowledge about the molecular mechanisms linking SRBC activity and DNA damage 
repair triggered by oxaliplatin, the use of non quantitative DNA methylation assays that 
will require transformation to quantitative DNA methylation tests to get specific cut offs 
for a future clinical application, and the extension of our colorectal cancer patient data 
source to stage II and III tumors and samples from other geographical origins.  
 
In conclusion, we have demonstrated that DNA methylation-associated silencing of the 
BRCA1 interactor gene SRBC is associated with the acquisition of chemoresistance to 
the DNA damaging agent oxaliplatin in colorectal cancer both in vitro and in vivo. The 
validation of SRBC hypermethylation as a predictive marker will require further 
prospective studies. If successful, clinical trials would also be necessary to develop 
strategies to overcome or prevent the development of SRBC-mediated epigenetic 
resistance. 
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SUPPLEMENTARY METHODS 
Analysis of the DNA methylation microarray data 
The methyl array data analysis was performed by 
GenomeStudiohttp://www.illumina.com/gsp/genomestudio_software.ilmn) and then 
processed using R (http://www.r-project.org/). All methylation values measured by 
microarray were presented as beta value, ranging from 0 to 1. Normalizations were 
performed using quantile normalization, on data previously adjusted by color balance 
between the two channels and corrected by background level. 
 
We adopted multivariate outlier analysis to analyze our beta methylation data. We use 
the methylation data matrix as a main body made up of the mass none differentially 
methylated (NDM) CpGs “contaminated” with outliers constituting the few differential 
methylated (DM) CpGs. We model the former with a multivariate normal distribution 
and estimate its centre and covariance matrix with the Minimum Covariance 
Determinant estimator, and quantify the departure from the major NDM distribution with 
the robust Mahalanobis distance and a corresponding X2 test p-value. The CpGs with 
small p-values are outliers to the majority of the data, and can be extracted as DM 
CpG. To adjust for the multiple test error, we used a False Discovery Rate (FDR) 
approach, according to Benjamini and Hochberg. 
 
The Infinium HumanMethylation27 Bead Chip interrogates 27,578 CpG sites from 
14,495 genes. The ratio of the average intensity of methylated probes to the average 
intensity of both methylated and unmethylated probes for a specific CpG provides an 
estimate of the fraction of DNA methylated that has been suggested to follow a beta 
distribution due to its potential bimodality. The differential methylation test uses a 
multivariate outlier analysis, assuming multivariate normal distribution, a generalization 
of the one-dimensional (univariate) normal distribution (which is reasonable when 
focusing on a two-group comparison on a single site or region) to higher dimensions. 
 
DNA Methylation Analysis of Single Locus 
We established SRBC CpG island methylation status using three different PCR 
based techniques. We used bisulfite-modified genomic DNA, which induces chemical 
conversion of unmethylated, but not methylated cytosine. First, DNA methylation status 
was analyzed by bisulfite genomic sequencing of the SRBC CpG island using primers 
encompassing the transcription start site. Primer sequences are shown in 
Supplementary Table 1. Both DNA strands were sequenced and at least eight clones 
were analyzed per sequence. The second analysis used methylation-specific PCR 
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using primers specific for either the methylated or modified unmethylated DNA. Primer 
sequences are shown in Supplementary Table 1. The PCR annealing temperature 
was 59ºC and 36 cycles of PCR were performed. DNA from normal lymphocytes 
treated in vitro with SssI methyltransferase was used as a positive control for 
methylated alleles (IVD). DNA from normal lymphocytes (NL) and normal colon 
mucosa were used as a positive control for unmethylated alleles. Pyrosequencing was 
the third analysis performed. PCR was realized under standard conditions with 
biotinylated primers and the PyroMark Vacuum PrepTool (Biotage, Sweden) was used 
to prepare single-stranded PCR products according to manufacturer’s instructions. 
Primer sequences are shown in Supplementary Table 1. PCR products were 
observed at 2% agarose gels before pyrosequencing. Reactions were performed in a 
PyroMark Q96 System version 2.0.6 (Qiagen) using appropriate reagents and 
protocols, and the methylation value was obtained from the average of the CpG 
dinucleotides included in the sequence analyzed. 
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Supplementary Table 1: Primers Sequences 

Primers Sequence 
Annealing 
temperature 
(ºC) 
Product Size
(bp) 
Bisulfite Sequencing Primers 
SRBC_BS_F AGTTTTAGTTGTGATTTAGGTAGG 56 327 
SRBC_BS_R CCCCTCTAATTATCTCTTTACC 
FAM111A_BS_F TGTTTTTTTAGGGGTAAGGGTA 57 268 
FAM111A_BS_R AACAACCTTTTCCCAAAAAA 
FAM84A_BS_F TTTTTTGTGYGTTTTGTTTT 58 103 
FAM84A_BS_R AATTTCTTCTCCATACCCAAAC 
Methylation Specific PCR
SRBC_MSP_UF TTTTTGAAAGTGTTTTGTTTTTT 59 187 
SRBC_MSP_UR TTCCATAACTCACCCTTTACAA 
SRBC_MSP_MF TTGAAAGCGTTTCGTTTTTC 59 189 
SRBC_MSP_MR TCCGTAACTCGCCCTTTAC 
Semi-quantitative PCR 
SRBC_qPCR_F GTTCTGCTCTTCAAGGAGGA 60 154 
SRBC_qPCR_R CTCTGTACCTTCTGCAATCC 
FAM84A_qPCR_F GCGAGTTGCCCACAGGGGAC 60 136 
FAM84A_qPCR_R CGCTCTTGAGGCCCACCAGT 
Pyrosequencing primers   
BioPyro_SRBC_R [Byn]ACCAACAAACTTCCCAAC 60 
Pyro_SRBC_F AGGGYGTGGGGATGTTGGT 
PyroSeq_SRBC primer AAGYGTTTYGTTTTTYGTTGTTTYGYGTYGGGGGTTTGT 
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STUDY III 
“Orthoxenografts of Testicular Germ Cell Tumors Enable Identification of 
Glucosylceramide Synthase as a Cisplatin Resensitizing Target” 
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RESUMEN 
Para investigar la base genética de la resistencia al cisplatino, hemos desarrollado un 
modelo de ratón representativo de tumores testiculares germinales del tipo no 
seminoma, sensibles/resistentes al cisplatino. Los tumores humanos han sido 
ortotópicamente trasplantados al ratón, orthoxenografts. Aplicando un enfoque 
genético global, se identificaron cambios recurrentes en todos los tumores refractarios 
(ganancias: 9q22.11 - q33.3, 9q32 - q33.1, 15q23 - q24.1 y 15q26.3, pérdida: Xp22.3). 
Clínicamente, la presencia de las ganancias de 9q32 - q33.1 se asoció con una peor 
supervivencia global en una serie de tumores de células germinales metastásicos, que 
incluían pacientes con resistencia al cisplatino. Perfiles de expresión génica de la 
región 9q32 - q33.1 y estudios funcionales in vitro e in vivo destacan la relevancia de 
GCS, ATP6V1G1, POLE3, PAPPA y CTR1/2 como genes de resistencia relacionados 
al cisplatino y candidatos prometedores para las terapias de resensibilización-dirigida. 
Como prueba de concepto, se presentan fuertes evidencias preclínicas que la 
inhibición de GCS con DL-treo-PDMP en modelos orthoxenograft resistentes al 
cisplatino resensibiliza los tumores al cisplatino, proporcionando de este modo una 
justificación para el reposicionamiento de este inhibidor en el desarrollo de futuros 
ensayos clínicos. 
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SUMMARY 
To investigate genetic basis of cisplatin resistance, we have developed in nude mice a 
representative panel of matched orthotopically transplantable subject-derived 
nonseminomatous (NSE) cisplatin-sensitive/resistant tumors, named orthoxenografts. 
Using genome-wide approach, recurrent changes were identified across refractory 
tumors (gains: 9q22.11-q33.3, 9q32-q33.1, 15q23-q24.1 and 15q26.3; loss: Xp22.3). 
Clinically, the presence of 9q32-q33.1 gains was associated with poorer overall survival 
in a series of metastatic germ cell tumors, which included cisplatin-refractory patients. 
Gene expression profiling of 9q32-q33.1 region and functional in vitro, and in vivo RNAi 
knockdown assays of their Caenorhabditis elegans ortholog genes highlights the 
relevance of GCS, ATP6V1G1, POLE3, PAPPA and CTR1/2 as cisplatin resistance-
related genes, making them promising candidates for targeted cisplatin-sensitizing 
therapies. As a proof-of-concept, we present strong preclinical evidences that drug 
inhibition of glucosylceramide synthase (GCS) with DL-threo-PDMP in cisplatin-
resistant orthoxenograft models newly sensitizes tumors to cisplatin, thereby providing 
a drug-repositioning rationale for development of future clinical trials.  
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INTRODUCTION 
Testicular germ cell tumors of adolescent and young adults (TGCTs) are the most 
common malignancy in young men 1-3. They can be classified as seminomas [123], 
which represent around 40% of cases, or nonseminomas (NSEs) (60%). SEs are radio- 
and chemo-sensitive tumors, and are highly curable at all stages. With the exception of 
teratomas, NSEs are highly sensitive to cisplatin-based chemotherapy and, when 
combined with surgery, patients achieve high cure rates 4. In contrast with most 
advanced solid tumors, approximately 80-90% of metastatic GCTs will achieve 
complete cures after standard doses of cisplatin chemotherapy 5,6. Nevertheless, 10-
15% of patients die from cisplatin refractoriness and from the absence of alternative 
effective resensitizing therapies. 
 
Cisplatin resistance has been attributed in GCTs to various mechanisms 2,3, although 
the molecular basis underlying treatment failure in refractory patients is understood 7. 
Perhaps it is this success in treating advanced testicular cancer that has meant that 
few studies of underlying treatment failure in refractory patients have been conducted 8. 
Additionally, the absence of relevant preclinical animal models reproducing human 
testicular GCT properties has made it difficult to identify any underlying resistant 
mechanism and to develop novel therapeutic approaches. Knowing why a curable 
cisplatin-treated tumor becomes resistant could help in the search for improved 
treatments for other tumors that are less successfully treated with cisplatin 8. Here we 
report the perpetuation of serially cisplatin-refractory orthotopic transplantable patient-
derived nonseminomatous tumor grafts in mice, named orthoxenografts, as a system to 
investigate cisplatin refractoriness from a genetic perspective and for the preclinical 
development of novel targeted therapies based on overcoming cisplatin-resistance. 
 
RESULTS 
Establishment and characterization of engrafted NSE tumors  
Fourteen of 40 primary human NSE tumors (35%) were grown as orthotopic implants, 
named orthoxenografts, in nude mice (Supplementary Table S1). Tumors included 
three choriocarcinomas (CHs) (Fig. 1a), four embryonal carcinomas (ECs), three yolk 
sac tumor (YS) and four mixed tumors. Five orthoxenografts were derived from several 
extragonadal tumor locations, and in four cases from patients treated with cisplatin-
based chemotherapy (Supplementary Table S1 and Fig. S1a, b and c). None of the 
22 implanted pure gonadal seminomas (SEs) grew in nude mice. Of the mixed tumors, 
comprising both SE and NSE components, only the NSEs grew in mice. 
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A very close correlation was found between the primary tumor and its paired 
orthoxenograft with respect to histological appearance (Supplementary Table S1), 
and their genetic and epigenetic characteristics. They were kept stable throughout 
serial passages. Immunohistochemical expression of conventional clinical diagnostic 
markers for GCTs was evident, enabling the successful classification of the tumors 
(Fig. 1a; Supplementary Fig. S1a, b and c). The early embryonic markers OCT4 and 
NANOG (Fig. 1b and Supplementary Fig. S1d) were exclusively detected in pure EC, 
and EC of mixed tumors. As described for primary tumors 2,9, we did not detect the 
presence of any gene point mutation and any tumor exhibited a microsatellite instability 
phenotype (MSI) (Supplementary Table S2). Likewise 10,11, there was a good 
correlation respect to  the methylation status of 5’ CpG promoter islands in a group of 
selected genes and this remained stable throughout mouse-to-mouse passages 
(Supplementary Table S3). Orthoxenografts also reproduce in mice the dissemination 
patterns observed in humans (Supplementary Fig. S1e and Supplementary Table 
S1). Finally, as occurred in patients 2,12, the secreted -hCG and/or AFP could be 
readily detected in mouse serum as follow-up markers (Supplementary Table S1 and 
Fig. 1C). 
 
Orthoxenografts of NSE recapitulate the responses to cisplatin treatment in 
humans  
We studied the pattern of responses to chemotherapy for nine orthoxenografts. Mice 
were treated with low (2 mg/kg) and high (5 mg/kg) doses of cisplatin, and their short- 
and long-term responses were evaluated. All tumors had a good short-term response 
to low doses of cisplatin (Fig. 1c, left panel and Supplementary Fig. S2 and S3), as 
indicated by a significant reduction in tumor weight in eight cases and complete 
response in the tumor TGT21BX (Supplementary Fig. S2a). A good correlation 
between tumor weight and reduction or absence of serum -hCG and/or AFP levels 
was found, supporting its use as a dynamic surrogate marker of treatment efficacy 
(Fig. 1C, right panel and Supplementary Fig. S2 and S3). Differences among tumor 
weight and serum markers observed in TGT21AX after treatment can be explained by 
the predominance of a teratoma with a few microscopic islands of viable cells 
(Supplementary Fig. S2b and S2c), while those in TGT34X (Supplementary Fig. 
S3c) were due to a high percentage of necrosis. Administration of higher doses of 
cisplatin (5 mg/kg) was associated with a better response in all cases (Fig. 1c; 
Supplementary Fig. S2 and S3). Additionally, there was a complete response in 
tumors TGT21AX (Supplementary Fig. S2b) and TGT34X (Supplementary Fig. 
S3c). 
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To investigate long-term cisplatin responses, a subgroup of the treated mice was kept 
alive post-chemotherapy until tumor regrowth was observed. Tumors regrew in seven 
out nine cases, over a period of 15 to 135 days, independently of the cisplatin dose in 
most instances. However, high doses of cisplatin prevented tumor relapse in TGT34X 
(Supplementary Fig. S3c), whereas in TGT39X both treatments yielded a long and 
sustained response, as was confirmed by constant levels of AFP over a latency period 
of 90 days (Supplementary Fig. S3d). Histological and immunohistological analysis of 
relapsed masses demonstrated the presence of a viable tumor in most cases, and the 
maintenance of cell heterogeneity, as indicated in mixed tumors by the presence of 
different components. As observed in patients 12, cisplatin induced increasing teratoma 
differentiation in TGT21AX (Supplementary Fig. S2c).  
 
In vivo development of representative NSE orthoxenograft models of cisplatin 
refractoriness  
To investigate cisplatin resistance against the same genetic background (sensitive vs. 
resistant) we developed several cisplatin refractory tumor models. Thus, five engrafted 
tumors, which had not been exposed to cisplatin before implantation (TGT1X, TGT12X, 
TGT21BX, TGT34X and TGT38X), were treated with cisplatin. After five iterative cycles 
of treatment in different mice, and applying increasing doses of cisplatin, refractory 
tumors were obtained (Fig. 1d). During the process, a progressive shortened time-lag 
between tumor treatment and tumor regrowth was noted, and the mice to mice 
passage time stabilized after five cycles of treatment in all cases (Fig. 1f). To 
demonstrate cisplatin resistance, we performed paired short-term response assays 
between untreated (TGTX) and resistant (TGTXR) tumors at cycle #5 (Fig. 1d). High 
levels of resistance were observed in all tumors at both cisplatin doses, these being of 
particular note in the case of TGT21BXR and TGT34XR, which were derived from 
highly sensitive tumors. No major differences in the histological (Supplementary Fig. 
S4) and immunohistochemical patterns were observed between original and cisplatin-
resistant tumors. 
 
Recurrent chromosomal imbalances are associated with acquired cisplatin 
resistance  
We investigated whether the acquisition of cisplatin resistance was associated with the 
selection of specific genomic imbalances and genetic alterations against the relatively 
stable genetic background of GCTs. No additional mutations or changes in the MSI 
status in resistant engrafted tumors were detected (Supplementary Table S2). Fine-
scale comparative whole-genome mapping using array-based comparative genomic 
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hybridization (CGH) was performed in four paired untreated parental engrafted tumors 
and their resistant counterparts. Genomic stability of engrafted tumors was confirmed 
by the low number of chromosome changes identified in untreated tumors. As shown in 
Fig. 2a, few additional recurrent genomic changes were consistently detected in 
resistant tumors. Gains at 9q were found in three of four cases, and in two at 9q21.11-
q33.3. There was also a small gain (5.1 Mbp) overlapping the 9q32-q33.1 sub-region in 
another case (Fig. 2b).  Gains at 15q23-q24.1 and 15q26.3 were identified in two 
tumors. All gains were confirmed by FISH analysis (data not shown). The loss of the 
Xp22.33 region was identified in three of four tumors (Supplementary Fig. S5). We 
subsequently focused our attention on studying the 9q short (5.1 Mbp) overlapping 
9q32-q33.1 region, since several genes within this region had been previously found to 
be associated with drug response (Supplementary Table S4).   
 
Amplification at 9q32-q33.1 is associated with an increased risk of death in 
advanced GCT patients  
To evaluate the clinical relevance of the mouse results, we investigated the gains at 
9q32-q33.1 by FISH in a tissue microarray (TMA), comprising a series of tumors from 
75 patients with metastatic GCTs (63 NSEs and 12 SEs) homogeneously treated with 
cisplatin-based chemotherapy in our research center. The series included 24 patients 
(22 NSEs and 2 SEs) refractory to first-line cisplatin-based chemotherapy. 
Amplification at 9q32-q33.1 was identified in 18 of 75 (24%) cases, including 16 NSEs 
(5 CEs, 2 CHs, 1 YS, 2 TEs and 6 mixed tumors) and two pure SEs (Fig. 2c). Those 
results were consistent for tumor sample replicates, as in the different histological 
tumor components in the majority of tumors. Nevertheless, amplified and non-amplified 
areas coexisted in five cases (2 pure CEs and 3 mixed tumors)  (Fig. 2c and 
Supplementary Table S5).  
 
Analysis of overall survival (OS) adjusted for histology (SE and NSE) showed that 
amplification at the 9q32-q33.1 region was associated with a 2.79-fold greater risk of 
death in patients with metastatic GCTs (p = 0.036; hazard ratio (HR) = 2.79; 95% 
confidence interval (CI) = 1.11–7.0) (Table 1 and Fig. 2d, left panel). A higher risk of 
death was revealed when considering only patients with NSE (n = 63) (p = 0.026; HR = 
3.03; 95% CI = 1.18–7.76), but there was no difference in those with SE (p=0.54). OS 
subgroup analyses in NSE patients showed a trend towards good and intermediate 
prognosis; the relationship was statistically significant when we analyzed the two 
groups together (p = 0.014; HR = 5.16; 95% CI = 1.47-18.12). Amplification was also 
associated with shorter progression-free survival (PFS) (p = 0.043; HR = 2.46; 95% CI 
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= 1.07–5.63) (Table 1 and Fig. 2d, right panel); this relationship was significant even 
when the NSE group alone was analyzed (p = 0.024, HR = 2.8, 95% CI = 1.19–6.57). 
There was a trend for tumors harboring the 9q32-q33.1 amplification to have a worse 
cisplatin response. Fifty percent of tumors with the amplification were considered 
resistant to first-line chemotherapy compared with 26.3% of tumors without it (p = 
0.060). Up to 27.8% of tumors with the 9q32-q33.1 amplification did not achieve a 
tumor marker complete response or progressed during first-line treatment (p = 0.007) 
(Supplementary Table S6).  
 
Identification of a group of cisplatin resistance-related genes at 9q32-q33.1  
Next, to find cisplatin resistance-related genes in 9q32-q33.1 region,  the profiling 
expression patterns of the 60 genes and two miRNAs annoted were generated by 
quantitative PCR (qPCR) (Fig. 3 and Supplementary Fig. S6) in the five paired 
(sensitive vs. resistant) engrafted tumors. Thirty-seven genes were expressed in GCTs 
and recurrent changes occurred in eleven of them: eight genes (ATP6V1G1, POLE3, 
EDG2, FLJ31713, GCS, PAPPA, TNC, and ZNF883) were overexpressed in cisplatin-
refractory tumors, while three genes (CTR1, CTR2, and AKNA) were underexpressed. 
These changes were mainly correlated with tumor resistance rather than specifically 
with the presence of amplification. Nevertheless, despite the small number of samples 
analyzed, overexpression and 9q32-q33.1 amplification were correlated with the 
presence of PAPPA, an IGF-binding protein protease (IGFBP) involved in the IGF 
Table 1 Analysis of 9q32-q33.1 amplification in metastatic germ cell tumors  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: WT, No amplification at 9q32-33.1; HR, hazard ratio; CI, confidence interval. 
* P values are from multivariate Cox models adjusted for pathological diagnostic classification.
  
Overall Survival Progression-Free Survival 
  n 
 
% HR 95% CI P HR
 
95% CI 
 
P       
Chromosome copy number at 9q31-q32.1 
(n=75) 
  
        
 WT  57 
 
76 1  0.036 *  1  
 
0.043 * 
 Amplification 18 24 2.79 (1.11 - 7.0)   2.46 (1.07 - 5.63)  
      
Stratified analysis        
  Pathological classification        
  Nonseminoma (n=63)         
   WT 47 74.6 1  0.026  1  0.024 
   Amplification 16 25.4 3.03 (1.18 - 7.76)   2.8 (1.19 - 6.57)  
      
  Seminoma (n=12)         
   WT 10 83.3 1     (0 - Inf) 0.54  1 (0 - Inf) 0.38 
   Amplification 2 16.7 0    0   
      
 IGCCCG classification        
  NSE with good prognosis (n=33)        
   WT 27 81.8 1  0.096  1  0.22 
   Amplification 6 18.2 5.89 (0.82 - 42.52)   3.29 (0.55 - 19.71)  
        
  NSE with intermediate prognosis (n=14)        
   WT 10 71.4 1  0.15  1  0.28 
   Amplification 4 28.6 3.41 (0.68 - 17.02)   2.33 (0.52 - 10.44)  
        
  NSE with bad prognosis (n=16)        
   WT 10 62.5 1  0.88  1  0.30 
   Amplification 6 37.5 0.9 (0.21 - 3.79)   2 (0.55 - 7.21)        
  Grouping NSE according to good and intermediate 
prognosis (n=47)
       
   WT 37 78.7 1  0.014  1   
   Amplification 10 21.3 5.16 (1.47 - 18.12)   3.28 (1.03 - 10.37) 0.056 
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release process, and POLE3, also known as CHRAC17, a histone-fold protein, which forms part of the CHRAC chromatic-remodeling complex. 
Although changes in the expression levels of miRNA4688 and miRNA455 were observed among the different resistant tumors (Supplementary 
Fig. S7a), we did not found a clear association with resistance or with amplification.  
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Knockdown of Caenorhabditis elegans ortholog genes, GCS, ATP6V1G1, AMBP 
and CTR1/CTR2, by RNAi impaired worm cisplatin response  
We investigated the individual contribution of the 9q32-q33.1 genes to cisplatin 
resistance/sensitivity in the nematode Caenorhabditis elegans by RNAi their 
corresponding ortholog genes. We identified C. elegans ortholog genes in 15 of the 37 
genes expressed in engrafted tumors; 12 genes were selected on the basis of our 
previous qPCR results to be knocked down by feeding RNAi (Fig. 4a). Cisplatin-
induced toxicity was subsequently evaluated in these worms by measuring the track 
locomotor activity over 24 hours of cisplatin exposure (Fig. 4b, 4c and Supplementary 
Fig. S8). We observed a clear correlation with sensitivity/resistance to cisplatin with 
ctg-1 and ctg-3 (GCS orthologs) and F27C1.2 (CTR1/CTR2 ortholog). In the case of 
ctg genes, the functional redundancy was overcome by doing ctg-3 RNAi in the ctg-
1(ok1045) mutant background. mig-6 (AMBP ortholog) and vha-10 (ATP6V1G1 
ortholog) also contribute to cisplatin resistance,  but not other genes as gpc-1 (GNG10 
ortholog) or ten-1 (TNC ortholog)(Supplementary Fig S8). Although, the role of mig-6 
and vha-10 genes under cisplatin exposure may need further exploration since their 
RNAi inactivation by itself produces an effect on locomotor activity in the absence of 
cisplatin. Functional redundancy probably explains the absence of association with 
cisplatin response for nfyb-1 (POLE3/CHARC17 ortholog) 13 in C. elegans, while we did 
not identity a specific worm ortholog for PAPPA gene. 
 
Next, by the absence of an ortholog gene or by the difficult to study in worms its role in 
cisplatin response, the expression changes of candidate genes POLE3, PAPPA, 
ATP6V1G1, AKNA and AMBP were determined by qPCR in a set of three paired 
sensitive vs. cisplatin-derived resistant testicular germ cell tumor cell lines (SuSaS vs 
SuSaR, 833KS vs 833KR and GC27S vs GC27R), confirming their association with 
cisplatin resistance for the majority of them (Supplementary Fig S7b).  
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DL-threo-PDMP, a competitive inhibitor of GCS, re-sensitizes refractory NSE 
orthoxenografts to cisplatin  
Our study enabled six candidate (GCS, POLE3, PAPPA, ATP6V1G1, AMBP and 
CTR1/2) targets to be identified that are of use for developing novel therapeutic 
approaches for overcoming cisplatin resistance. As a proof-of-concept we decide to 
deep into the therapeutic value of one of these genes/proteins at the preclinical level. 
GCS was chosen on the grounds that: (i) it increased mRNA expression in all cisplatin 
refractory orthoxenografts; (ii) it increased GCS enzymatic activity (2.5-3-fold induction) 
occurs in 4 out 5 cisplatin-refractory orthoxenografts (Fig. 5a); (iii) its knockdown by 
RNAi in worms confers cisplatin sensitivity; (iv) its central role in the pathway of 
sphyngolipid synthesis; and (v) specific inhibitors of it are available, some of which are 
currently in clinical use for other pathologies.  
 
NSE testicular germ cell line SuSAS and its paired cisplatin resistant SuSaR were used 
as cellular models to deep into the functional relationship among GCS 
expression/activity and cisplatin resistance. Significant differences among protein 
expression and activity levels measuring glycosilceramide formation were observed for 
both cell lines (Fig. 4d). At low doses of cisplatin (5 μM) SuSaR cells exhibit increased 
GCS activity through the time (Fig. 4d). Transfected SuSaS cells overexpressing GCS 
has a significant cisplatin-resistance increase (5-fold) (Fig. 4e); while shRNAi 
knockdown of the endogenously overexpressed GSC gene (70% of inhibition) in 
SuSaR cells correlates with a partially (57.6%) cisplatin resensitization (Fig. 4e). 
Likewise, the treatment of SuSaR cells with the specific GCS inhibitor DL-thhreo-PDMP 
(PDMP) (Fig. 4f) mimics this cisplatin sensitization (44.8%). Effect mediated by a 
significant increase in the intracellular levels of ceramide for combined cisplatin+PDMP 
treatment (Fig. 4f). Thus, we demonstrate that impaired GCS expression/activity in 
vitro resensitizes cisplatin-resistant NSE cell line newly to cisplatin treatment. 
 
Engrafted animals with cisplatin-refractory TGT1XR and TGT38XR orthoxenografts, 
which exhibit increase GCS expression and enzyme activity (Fig. 5a), were treated 
daily with PDMP, a competitive inhibitor of GCS  for 21 days (Fig. 5b). As a single 
agent PDMP did not produce a significant response with respect to the vehicle-treated 
animals, and no significant differences were observed among individual PDMP and 
cisplatin treatments. Nevertheless, both tumors experienced significant tumor weight 
reductions (TGT38XR, 73.5% and TGT1XR, 42.8%) for combined PDMP+cisplatin 
treatment (Fig. 5b).  
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Glucosylceramide synthase activity also associated with acquired cisplatin 
resistance in orthoxenografts of epithelial ovarian cancer  
Finally, we investigate whether the identified association among GCS and cisplatin 
resistance was specific of germ cell tumors, or it happens in other cisplatin treated 
tumors. Thus, GCS expression/ activity were determined in six paired cases of 
sensitive and cisplatin-resistant orthoxenografts of epithelial ovarian cancer (EOC). In 5 
out 6 (83.3%) serous tumors a median increase of 52.5% ± 9.4 GCS activity and 
RNA/protein levels (data not shown) were also observed in the resistant 
orthoxenografts respect to its paired sensitive tumors (Fig. 5c). Furthermore, PDMP 
treatment of OVA17XR, having high levels of GCS activity, has a cisplatin resensitizing 
effect (Fig. 5d) (tumor weight reduction of 76,5% in combined cisplatin+PDMP 
treatment). Together, the GCS inhibitor PDMP resensitizes cisplatin-refractory 
orthoxenografts to cisplatin treatment, providing a promising therapeutic opportunity for 
GCT refractory cases, and a strong preclinical rationale for further clinical trials.  
 
DISCUSSION 
In this paper we report the generation of a unique series of orthotopically engrafted 
nonseminomatous tumor, named orthoxenografts, including several paired cisplatin-
sensitive/resistant tumors and endogenous refractory cases. Preclinical models 
enabled several cisplatin resistance-related chromosomal regions to be identified, as 
the development of novel therapeutic approaches to overcome cisplatin refractoriness. 
We then focused on the recurrent gained 9q32-q33.1 region, demonstrating that its 
presence in metastatic GCTs was associated with poorer overall survival. Combined 
differential expression profiling studies, and functional RNAi gene knockdown in C. 
elegans and in vitro cell lines we identified and validate a group of cisplatin resistance-
related genes.  Finally, as proof-of-concept we preclinically validated the PDMP as a 
therapeutic strategy that resensitizes to cisplatin treatment producing a change that 
overcomes cisplatin refractoriness.  
 
Rao et al 14, analyzing human refractory GCTs samples, provided the first evidence of 
chromosomal amplification associated with cisplatin resistance by comparing unpaired 
tumors obtained from relapse-free patients with chemotherapy-resistant tumors. Our 
approach of comparing against the same genetic background (paired sensitive vs. 
cisplatin-refractory tumor cases) identified fewer recurrent changes across the different 
refractory tumors. The genetic concurrence observed among pure primary refractory 
tumors analyzed Rao et al 14 and our refractory-derived orthoxenografts by the 
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identification of 9q and 15q amplified regions strongly reinforced their relevance as 
models for studying the genetic basis of cisplatin refractoriness. 
 
Until now, the presence of the b-raf (V600E) mutation in some refractory NSE has been 
the only molecular marker associated with cisplatin resistance 15 in GCT. Here we have 
demonstrated that the presence of the 9q32-q33.1 amplification was associated with 
increased risk of progression and death in one of the largest cohort of patients with 
metastatic GCTs, of whom, 32% are truly refractory to cisplatin treatment. Thus, their 
presence as early high-risk patients marker  may be especially important in the good 
prognostic group and may allow clinicians to include them under more aggressive 
protocols, or to offer alternative drug treatments. Although it is a single retrospective 
analysis it is important to note its relevance, given how difficult is to obtain 
representative GCT series that include patients with a poor prognosis, and refractory 
tumors. 
 
Differential expression profiling of the 9q32-q33.1 region among orthoxenografts 
highlights the complexity of the mechanism for developing cisplatin tumor resistance. 
We found two groups of genes coexisting in refractory tumors: (i) those whose 
expression changes correlate with 9q32-q33.1 gain status (PAPPA, POLE3, and 
AKNA), and mainly (ii) those that do not, and are associated solely with cisplatin 
refractoriness (GCS, EDG2, ZNF883, FLJ31713, TNC, ATP6V1G1, CTR1, and CTR2). 
Together, functional results of RNAi experiments in C. elegans and in paired 
sensitive/resistant cell lines strongly suggest that targeting GCS, ATP6V1G, CTR1/2, 
PAPPA or POLE3 should be useful strategies for treating unresponsiveness in cisplatin 
tumors. Targeting GCS, due is central role in the glycosphingolipid synthesis pathway, 
has emerged as a novel approach for treating metabolic diseases such as Gaucher, 
Niemam-Pick and diabetes. In this context, several GCS inhibitors are in clinical use or 
under development, including Miglustat, PDMP and EXEL-0346 among others 16-19. In 
the present work we deep into the relevance of targeting GCS as a novel approach to 
resensitize tumors to cisplatin. Here we demonstrate the relevance of the over-
expression/increased GCS activity as a biological mechanism that mediate tumor cell 
protection against cisplatin exposure, and they denoted the significance of sphingolipid 
metabolism through cisplatin-induced tumor cell death. Thus, we hypothesize that 
PDMP or other GCS inhibitors blocking the conversion of ceramide to 
glucosylceramide should open an important therapeutic window in patients with 
refractory tumors by fuel ceramide pools after cisplatin treatment strengthen the cell-
death pathways. In this way, our preclinical results in advanced refractory cisplatin 
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orthoxenografts of GCTs and EOC tumor models demonstrate that PDMP resensitizes 
to cisplatin treatment, providing a firm preclinical rationale of drug repositioning and for 
developing further clinical trials in the field. 
 
In summary, we report the generation of cisplatin-refractory orthoxenografts of germ 
cell tumors as preclinical models and demonstrate their proficiency identifying cisplatin-
resistance genes. As a proof-of-concept, we present strong preclinical evidence that 
they are outstanding tools to provide the rationale for the design of future trials for the 
treatment of patients with cisplatin resistant/refractory tumors.  
 
 
MATERIAL AND METHODS 
Material Methods are in Supplementary Material 
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SUPPLEMENTARY INFORMATION 
 
MATERIAL AND METHODS 
Human primary testicular germ cell tumors implantation and perpetuation in 
nude mice as orthoxenografts 
Primary tumor samples were obtained after surgical resection (Hospital Universitari de 
Bellvitge and Fundació Puigvert, Barcelona (Spain and placed at room temperature in 
DMEM medium supplemented with 10% fetal bovine serum and penicillin/streptomycin. 
Fresh surgical specimens of 62 human GCTs were implanted in nude mice. Twenty-
two tumors were classified as pure SEs, 21 as pure NSEs, and 19 as mixed tumors 
containing different proportions of SE and NSE components. NSE includes pure 
histologies (yolk sac tumor, YS; choriocarcinoma, CH; embryonal carcinoma, EC), and 
mixed tumors containing one or more histological subtypes. Animals were housed in a 
sterile environment, cages and water were autoclaved and bedding and food was -ray 
sterilized. Tumors were implanted in the testis of five-week old male nu/nu Swiss mice 
(Charles River, France) weighting 18-22 g. After anesthesia by isofluorane inhalation, a 
median laparatomy was performed and the testes were mobilized. Tumor pieces were 
anchored to the testis surface with prolene 7.0 sutures. After implantation, mice were 
inspected twice a week, and if no tumor growth was apparent, mice were sacrificed six 
months after implantation. Serial tumor passaging was performed in two to five 
animals. Time lags varied for each tumor, depending upon their growth kinetics 
(Supplementary Table S1). Four orthoxenografts were derived from patients 
previously treated with cisplatin-based chemotherapy. All patients gave written consent 
to participate in the study. The Ethics Committee of the hospitals approved the study 
protocol, and the animal experimental design was approved by the IDIBELL animal 
facility committee.  
 
Immunohistochemistry tumor characterization 
Tissues taken for histological studies were fixed in 10% buffered formalin and 3-μm 
slices of paraffin-embedded tissues were used for immunohistochemistry (IHQ) 
studies. Primary antibodies were monoclonal antibodies for TP53 (clone BP53-12-1, 
dilution 1:1000, Biogenex); PLAP (clone PL8-F8, dilution 1:30, Biogenex); EMA (clone 
E29, dilution 1:100, Dako); Vimentin (clone V9, dilution 1:2000, Dako); CD-30 (clone 
Ber-H2, dilution 1:20, Dako); EGFR (clone 31G7, dilution 1:50, Zymed); Ki-67 (clone 
BGX-297, dilution 1:40, Biogenex); Cam 5.2 (dilution 1:100, Becton Dickinson) and 
polyclonal antibodies for -hCG (dilution 1:5000, Dako); CD117 (dilution 1:50, Dako); 
AFP (dilution 1:3, Dako); OCT3/4 (dilution 1:300, Santa Cruz) and NANOG (dilution 
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1:50, RD). Reactions were visualized using the EnVision anti-mouse antibody system, 
and developed using the DAB-Plus Kit (Dako, Copenhagen, Denmark). Slides were 
counterstained with Harry’s modified hematoxylin. 
  
Determination of mouse serum levels of tumor markers 
Serum concentrations of alpha-fetoprotein (AFP) and the -subunit of human chorionic 
gonadotropin (-hCG) concentrations were measured as subrogate tumor growth 
markers in the serum of nude mice using commercially available two-site enzyme 
chemiluminometric assays automated on the Immulite	 2000 analyzer 1,2. 
 
Genetic characterization of engrafted NSE tumors 
DNA was extracted following standard phenol-chloroform protocols, while total RNA 
was extracted using TRIZOL reagent following the manufacturers’ instructions 
(Invitrogen). Nude mouse tissues were included in all PCR experiments to avoid mouse 
DNA and RNA contamination.  
 
Presence of point mutations: Mutations in TP53 (exons 4-10); K-ras (codon 12 and 13), 
b-raf (exons 11 and 15), EGFR (exons 18, 19, 20 and 21), c-Kit (exons 9, 11, 13 and 
17), PDGFR (exons 12 and 14), PDGFR (exon 12) and PI3KCA (exons 9 and 20) 
were analyzed. All exons were amplified in independent PCR reactions using human 
intronic primers to avoid amplification of mouse DNA. PCR reactions were carried out 
using 100-200 ng of genomic DNA in a mixture containing PCR buffer, 100 mM 
deoxynucleotide triphosphates, 0.5 μM of each primer and 1 unit of Taq DNA 
polymerase (Invitrogen). RNA was reverse-transcribed to cDNA using pd(N)6 and the 
M-MLV retrotranscriptase kit (Invitrogen) and the entire coding Smad4 region was 
analyzed in five overlapping reactions. Primer sequences and PCR conditions are 
available on request. The presence of gene mutations was detected by direct 
sequence and/or single-strand chain polymorphism (SSCP). Homozygous deletions or 
microdeletions in p15, p16 and Smad4 were evaluated in agarose gels and were 
defined by the absence of PCR product in three independent experiments. 
 
5’ CpG promoter methylation studies: The DNA bisulfite reaction was carried out on 2 
μg of restriction-digested DNA for 16 h at 55ºC. 5’ CpG promoter islands of APC, 
MGMT, DAPK, CDH1 and RASSF1 were analyzed by the methylation-specific 
polymerase chain reaction (MSP) 3-5. Primers and PCR conditions are available on 
request. MSP results were confirmed after sequencing individual clones using the 
TOPO system (Invitrogen).  
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Microsatellite instability (MSI) analysis: Genetic instability was analyzed using 
Bethesda’s set of five microsatellite markers (D2S123, BAT25, BAT26, D5S346 and 
BAT40).  
 
Primary response of engrafted NSEs to cisplatin treatments  
Small fragments of engrafted tumors were reimplanted in the testicles of 30 nude mice, 
as described above. When palpable intra-abdominal masses and increased levels of 
serum tumor marks had both been detected, usually 7–30 days after implantation, mice 
were randomized into three groups: (i) control group (n = 10), treated with vehicle; (ii) 
low-dose treatment group (n = 20) (2 mg/kg of cisplatin); and (iii) high-dose treatment 
group (n = 20) (5 mg/kg of cisplatin). Each treatment group was randomly divided into a 
short-term response group (n = 10), defined by tumor weight at the time of sacrifice of 
the control group, and a long-term response group (n = 10), defined by recurrent tumor 
mass regrowth post-chemotherapy. Cisplatin was intravenously administered (i.v.) 
once a week for three consecutive weeks (days 0, 7 and 14). Animals were sacrificed 
seven days after the final dose (day 21) to examine their short-term response.  
 
Generation in mice of refractory engrafted NSE to cisplatin treatment  
Five engrafted tumors, TGT1, TGT12, TGT21B, TGT34 and TGT38, from patients 
without prior exposure to cisplatin, were allowed to grow until intra-abdominal palpable 
masses were noted. Animals were administered with cisplatin i.v. at a dose of 2 mg/kg 
for 3 consecutive weeks (days 0, 7 and 14) (cycle#1 of treatment). Post-cisplatin 
relapse tumors were harvested, prepared as previously described, and engrafted in 
new animals. This process was repeated up to five times by treating tumor-bearing 
mice with stepwise increasing doses of cisplatin: cycle#2, 3 mg/kg; cycle#3, 3.5 mg/kg; 
cycle#4, 4 mg/kg; and cycle#5, 5 mg/kg (Fig 2d), as recently we described for ovarian 
tumors 6. Dynamic CDDP responses were evaluated after assessing -hCG and/or 
AFP serum levels, as described above.  
 
Whole genome analysis by NimbleGen CGH arrays 
The CGH oligonucleotide array was carried out by NimbleGen Systems, Inc., at their 
facility in Wisconsin [13]. Array design descriptions were: 2006-07-
27_HG18_WG_CGH, single array CGH design for whole human genome (hg18; NCBI 
Build 36). Methods of DNA labeling array construction, hybridization, array 
normalization and data analysis have been described in detail by Seltzer et al. 7.  
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FISH analysis 
FISH was done by standard methods. We used the UCSC genome browser to select 
three bacterial artificial chromosomes (BACs) from the K32 BAC library (kindly 
provided by Dr L. Pérez-Jurado). BAC RP11-582I20 is contained in the amplified 9q32-
9q33.1 region while RP11-616C16 flanks it at its distal end. FISH results were 
analyzed under an Olympus BX60 microscope and images were captured with a 
Cytovision (Applied Imaging) workstation. One hundred non-overlapping nuclei were 
scored for each sample. 
 
Quantification of gene and miRNA expression  
Total RNA was extracted using Trizol (Invitrogen, San Diego, CA), following the 
manufacturer’s instructions, and reverse-transcribed to cDNA. Quantitative RNA and 
miRNA analyses was performed as described. Quantitative real-time RT-PCR analyses 
were performed using the Light-Cycler 2.0 Roche System and LightCycler FastStart 
DNA Master SyBR Green I kit (Roche). All the primers were designed specifically to 
amplify human RNA.  Primer sequences and PCR conditions are available on request. 
Experiments were performed in triplicate using three independent RT reactions. Gene 
expression was normalized with respect to -actin.  
 
For miRNA, RNA samples were DNase-treated with Turbo DNA-free (Ambion, Austin, 
TX), and determined as described 8. Reactions were performed in triplicate and 
incubated in an Applied Biosystems 7900HT Fast Real-Time PCR system in 384-well 
plates. All data were normalized with endogenous controls: PPIA, HPRT1 and RPLPO. 
The relative miRNA levels were calculated using the formula 2-Ct   9. 
 
Patients and Samples  
Eighty-eight consecutive patients diagnosed with metastatic germ cell tumors and 
treated at the Institut Català d’Oncologia between 1989 and 2004 were initially included 
in this study 10. Thirteen cases were not evaluated because of the lack of paraffin-
embedded tissue blocks. Patient demographics and clinical characteristics of the 75 
patients finally evaluated are listed in Supplementary Table S7. Sixty-three patients 
(84%) had NSE tumors and 12 (16%) had SE tumors. Four patients presented with 
mediastinal extragonadal disease. Sixty per cent of the patients were classed as 
having a good prognosis, 19% as having an intermediate prognosis and 21% as being 
of poor prognosis according to the IGCCCG categorization. Twenty-four patients were 
considered resistant, defined by progression or relapse despite adequate first-line 
chemotherapy treatment. Cases with mature teratoma only in the resected post-
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chemotherapy mass and without posterior tumor relapse were considered sensitive. 
Tumor samples from primary tumors and/or resected metastases obtained before 
chemotherapy were included in a newly generated TMA, as described 10.  
 
Cell culture, transfection and in vitro shRNAi knockdown experiments 
The human NSE cell lines SuSaS (from teratocarcinoma origen), GC27S (from 
embryonic carcinoma origen) and 833KS (“S” for sensitive to CDDP) and their matched 
SuSaR, GC27R and 833KR (“R” for CDDP-resistant derived cell line) were growth for 
different experiments as described 11, 12. For overexpression experiments, SuSaS cells 
were transfected with plasmid pCMV6-XL5-GCS containing the whole GCS human 
cDNA from Origene (SC118052; Rockville, USA). Knockdown expereriments were 
realized in SuSaR with four pre-designed small hairpin RNAs (shRNA) for the human 
GCS gene from Qiagen (KH02376P; Manchester, UK) that were transfected with the 
jetPrime transfection kit (Polyplus, Strasbourg), following manufacturer instructions. 
GCS expression levels was analyzed by Western blot at 24, 48, 72 and 96 hours post-
transfection  by anti-GCS (1/1000)(ProteinTech, Chicago, USA) using as a control the 
anti--actin-HRP antibody (1/20000)(Sigma, St. Louis, USA). The chosen time to 
perform the experiments was 48 hours.  
 
In vitro determination of drug resistance assays 
Cisplatin (1mg/ml) dissolved in NaCl (TEVA, North Wales, USA), and DL-threo-PDMP 
(Sigma, St. Louis, USA) in dimethyl sulfoxide (DMSO) at a final concentration of 59 mM 
were assessed. Cell viability was determined by MTT assay. Briefly, 1 x 103 cells were 
plated onto 96-well plates, after 4 hours of transfection, fresh medium was added and 
cells were treated for 48 hours with different drugs concentration ranged from 0 to 20 
μg/ml doses. MTT was added at a final concentration of 0.1% and after 2.5 hours of 
incubation (37ºC, 5% CO2), metabolic product formazan was dissolved in DMSO and 
the absorbance measured at 570 nm. Prism Software (La Jolla, USA) was used to 
calculate drugs half maximal inhibitory concentration (IC50).  
 
C. elegans gene knockdown by RNAi and cisplatin-response assay 
The C. elegans N2 strain (wild type), and the rrf-3 (pk1436) and cgt-1 (ok1045) mutant 
strains were provided by the Caenorhabditis Genetic Centre (CGC). The bacterial RNAi 
clones used were obtained from the ORFeome-based RNAi library 13 and the JA library 
14. RNAi feeding was done as described 15, 16. Synchronized worm populations in the L1 
state were cultured in NGM plates containing 50 μg/ml ampicillin and 3 mM IPTG and 
seeded with thick bacterial lawns of each selected bacterial RNAi clone. Then, at the 
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young-adult stage, they were transferred to a 96-well plate with S-medium containing 
50 μg/ml ampicillin, 3 mM IPTG and 750 μg/ml cisplatin fresh made (Sigma). Cisplatin-
induced toxicity was evaluated by measuring worm locomotor activity over a 24-h 
period by an automated tracking system (wmicrotracker) 17, 18. All assays were 
performed at 20ºC in triplicate, tracking 20 worms per well each time in each of five 
replicates. For the genes tested, the efficiency of worm RNAi was confirmed by qPCR 
(data not shown). 
 
Determination of GCS activity and determination of ceramide levels 
Tumor samples were homogenized in lysis buffer (Tris-HCl 10 mM, EDTA 1mM, 0.1% 
Triton X-100 at ph 7.4) and centrifuged at 600g for 5 minutes. GCS activity was 
determined from NBD-C6-ceramide and UDP-glucose, the conversion product 
separated by TLC with chloroform/methanol/32% ammonia (70:30:5, v/v), and 
quantified by densitometry (Préférence/DVS, Sebia) as described before previously 19. 
Briefly, for each assay 200 μg of protein extract was suspended in reaction buffer (5 
mM MgCl2, 5 mM MnCl2, and 1 mM EDTA in 50 mM HEPES, pH 7.2) and the 
substrate mixture containing 10 μM NBD-C6-ceramide and 250 μM UDP-glucose. After 
a 30 min incubation at 37°C, reactions were terminated by adding 2.5 ml of 
chloroform/methanol (2:1, v/v), the samples were centrifugated (1000 x g, 5 min), the 
lower phases dried under nitrogen and subjected to TLC by using 
chloroform/methanol/32% ammonia (70:30:5, v/v) as the mobile phase. 
 
Ceramide was quantified after labeling of cells to isotopic equilibrium with [14C]palmitic 
acid (2 μCi/ml) (Amersham, Piscataway, NJ) for 24h. Ceramide was resolved in LK6D 
gel 60A TLC plates using chloroform/acetic acid (90:10). 
 
Statistical analysis  
For the clinicopathological features, P values were calculated using the X2 test. 
Survival curves were estimated using the Kaplan-Meier method, and differences 
between individual curves were evaluated by multivariate Cox proportional hazards 
regression modeling. Analyses were adjusted for pathological diagnostic classification. 
Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Likelihood 
ratio tests were used to assess the prognostic value of genomic amplification of 9q32-
q33.1 by FISH in the TMA of metastatic GCTs. Values of P<0.05 were considered 
significant. 
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Supplementary Table S1 Summary of characteristics of primary nonseminoma (NSE) tumors growing as xenografts in nude mice.  
a Tumor histology: YS, yolk sac; EC, embryonal carcinoma; CH, choriocarcinoma; TE, teratoma; SE, seminoma. 
b Stage at first diagnosis (Stage II to IV based on International Germ Cell Cancer Collaborative Group (IGCCCG)). 
c Primary tumor was simultaneously implanted in the testicles and subcutaneous tissues of nude mice. The tumor was considered perpetuated after at least six consecutive passages in nude mice. 
d Time-lag between passages was calculated on the basis of the first six passages, for a median of 15 mice implanted with each tumor. 
 e Levels of alpha-fetoprotein (AFP) and/or -subunit of human chorionic gonadotropin (-hCG) were analyzed as tumor growth markers in the nude mouse serum. 
f Synchronous lung micrometastases were detected when nude mice were sacrificed. 
g Liver macrometastases, peritoneal implants and lymph node affection were observed when nude mice were sacrificed. 
h Orchiectomy was performed to confirm the dissemination patterns when palpable intra-abdominal masses were detected in 5 to 10 mice for each tumor. Animals were sacrificed 6-8 months after surgery, or when 
they lost weight: h1, metachronic lung metastasis; h2, metachronic peritoneal implants; h3, metachronic liver metastases; h4, metachronic lymph node. 
J Xenografted tumors TGT38X and TGT44X characteristics were previously described 20,21. 
None, absence of metastasis; ND, not determined.  
 
Human Primary Tumor 
  
Orthoxenografts 
 
Primary tumor 
location 
 
 
 
Tumor 
 
 
 
Histology a 
 
 
Stage b  
 
CDDP-
treated 
 
 
Histology 
Xenograft perpetuated c Time-lag 
between 
passages 
(days) d 
  
Mouse serum 
markers e 
Pattern of distal 
dissemination  
Orthotopic 
growth 
Subcutaneous 
growth 
 
Testicle TGT1X 
 
YS Stage I No  YS Yes No 69  ± 17 AFP Lung f, h1 
 TGT11X 
 
YS, EC, CH, TE Stage I No  YS, EC, CH No 
 
No ND ND ND 
 TGT12X 
 
EC Good prognosis No  EC Yes No 97 ± 25 -hCG, AFP None 
 TGT14X 
 
EC 
SE  
Stage I No  EC Yes No 56 ± 17 -hCG Peritoneal implants g, h2 
Lymph node affection g, h4 
 TGT21AX 
 
YS, EC, CH, TE 
SE  
Stage I No  YS, EC, CH 
 
Yes Yes 49 ± 11 -hCG, AFP None 
 TGT21BX 
 
YS, EC, CH, TE 
SE 
Stage I No  YS, EC, CH 
 
Yes 
 
Yes 64 ± 14 -hCG, AFP None 
 TGT34X 
 
EC Bad prognosis No  EC Yes No 51 ± 8 -hCG, AFP Lymph node affection g,h4 
 TGT38X J 
 
CH Bad prognosis No  CH Yes 
 
No 20 ± 6 -hCG Lung f, h1 
 TGT40X 
 
YS, TE Stage I No  YS Yes No 42 ± 8 AFP None 
 
Lymph node TGT39X 
 
YS, EC, TE  Bad prognosis Yes 
 YS, EC 
 
Yes No 
 
59 ± 13  -hCG, AFP 
 
Liver g, h3 
Peritoneal implants g,h2 
 TGT41X 
 
CH Refractory No  CH Yes No 18 ± 4 -hCG 
 
ND  
 TGT44X J 
 
YS, TE 
 
Refractory Yes  YS Yes No 50 ± 8 AFP ND 
 
 
Lung  
metastasis 
TGT17X 
 
CH Refractory Yes  CH Yes No 24 ± 5 -hCG 
 
Lung f ,h1 
  
 
Brain 
metastasis 
 
TGT42X 
 
EC 
 
Refractory 
 
Yes 
  
EC 
 
Yes 
 
No 
 
62 ± 10 
 
-hCG, AFP 
 
 
ND 
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Supplementary Table S2 Genetic analyses of paired primary tumors, xenografted NSE, and xenografted tumors with acquired resistance to CDDP. 
 
 
a We analyzed: codons 12 and 13 of K-ras; exons 11 and 15 of b-raf; exons 18, 19, 20 and 21 of EGFR; exons 9 and 20 of PI3KCA; exons 4 to 10 of TP53; exons 9, 11, 13 and 
17 of c-Kit ; exons 12 and 14 of PDGFR; exon 12 of PDGFR; and whole p15, p16 and Smad4. 
b Microsatellite instability (MSI) status was determined by the Bethesda panel including D2S123, BAT25, BAT26, D5S346 and BAT40 markers. 
c Xenografted tumors with acquired CDDP resistance were analyzed at cycles #3 and #5 of chemotherapy treatment. 
wt, presence of wild-type sequence; -, absence of microsatellite instability.
   Tumors with acquired resistance c 
 
TGT1X TGT11X 
 
TGT12X TGT14X TGT17X TGT21AX TGT21BX TGT34X TGT38X 
 
TGT39X TGT41X TGT1XR TGT12XR TGT21BXR TGT34XR 
 
TGT38XR 
 
 
Point mutations a               
 
K-ras wt wt 
 
wt wt wt wt wt wt wt
 
wt wt  wt wt wt wt
 
wt 
 
b-raf 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
  
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
EGFR 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
  
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
PI3KCA 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
  
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
TP53 
 
wt
 
wt 
 
wt 
 
wt
 
wt
 
wt
 
wt
 
wt
 
wt
 
wt
 
wt
  
wt
 
wt
 
wt
 
wt
 
wt 
 
p15 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
  
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
p16 
 
wt
 
wt 
 
wt 
 
wt
 
wt
 
wt
 
wt
 
wt
 
wt
 
wt
 
wt
  
wt
 
wt
 
wt
 
wt
 
wt 
 
Smad4 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
  
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
c-Kit 
 
wt
 
wt 
 
wt 
 
wt
 
wt
 
wt
 
wt
 
wt
 
wt
 
wt
 
wt
  
wt
 
wt
 
wt
 
wt
 
wt 
 
PDGFR- 
 
wt
 
wt 
 
wt 
 
wt
 
wt
 
wt
 
wt
 
wt
 
wt
 
wt
 
wt
  
wt
 
wt
 
wt
 
wt
 
wt 
 
PDGFR- 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
 
wt 
  
wt 
 
wt 
 
wt 
 
wt 
 
wt 
    
MSI b - - - - - - - - - - - - - - - -     
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Supplementary Table S3 Epigenetic analyses of paired primary and xenografted NSE 
tumors.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
          Histology         YS     EC  EC  CH    MX    MX    EC    CH   MX    CH 
 
Methylation status of 5’ CpG promoter islands determined by MSP analysis (     methylated; 
     unmethylated). APC, adenomatous polyposis coli, RASSF1A, TMS, PYCARD (PYD and 
CARD domain-containing), MGMT, O-6-methylguanine-DNA methyltransferase, DAPK, 
death-associated protein kinase and CDH1, type 1, E-cadherin. P, primary human tumor; X, 
xenografted tumor at third and fifth mouse passages; YS, yolk sac; EC, embryonal 
carcinoma; CH, choriocarcinoma; MX, mixed tumor.  
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Supplementary Table S4 
Sixty genes located at 9q32-q33.1, a region of 5.1 M bp. Build 36.3 from NCI. 
112675875 112840186 EDG2 9q31.3 
endothelial differentiation, lysophosphatidic acid G-protein-coupled 
receptor, 2 
113129584 113130534 OR2K2 9q31.3 olfactory receptor, family 2, subfamily K, member 2 
113162794 113286846 KIAA0368 9q31.3 KIAA0368 
113327260 113379945 ZNF483 9q31.3 zinc finger protein 483 
113365073 113401532 LTB4DH 9q31.3 leukotriene B4 12-hydroxydehydrogenase 
113404932 113415654 C9orf29 9q31.3 chromosome 9 open reading frame 29 
113433453 113456452 bA16L21.2.1 9q31.3 DNAJ-like protein 
113433487 113472330 LOC552891 9q31.3 hypothetical protein LOC552891 
113463682 113472347 GNG10 9q31.3 guanine nucleotide binding protein (G protein), gamma 10 
113488722 113585600 C9orf84 9q31.3 chromosome 9 open reading frame 84 
113699027 113735260 GCS 9q31 UDP-glucose ceramide glucosyltransferase 
113842882 113977377 SUSD1 9q31.3-q33.1 sushi domain containing 1 
113975623 113976072 LOC100129332 9q32 hypothetical LOC100129332 
114020536 114135733 ROD1 9q32 ROD1 regulator of differentiation 1 (S. pombe) 
114083089 114083509 EPF5 9q32 EPF5 pseudogene 
114164716 114165217 LOC644996 9q32 similar to 60S ribosomal protein L32 
114182172 114274505 HSDL2 9q32 hydroxysteroid dehydrogenase like 2 
114286618 114294681 LOC100133204 9q32 similar to chromosome 9 open reading frame 147 
114289069 114462527 KIAA1958 9q32 KIAA1958 
114488607 114520208 C9orf80 9q32 chromosome 9 open reading frame 80 
114552955 114677088 SNX30 9q32 sorting nexin family member 30 
114681021 114692866 SLC46A2 9q32 solute carrier family 46, member 2 
114761235 114764362 LOC100129193 9q32 similar to hCG1795014 
114799221 114814293 LOC169834 9q32 hypothetical protein LOC169834 
114843995 114858817 ZFP37 9q32 zinc finger protein 37 homolog (mouse) 
114906824 114913864 LOC100128385 9q32 hypothetical protein LOC100128385 
114914042 114921947 C9orf109 9q32 chromosome 9 open reading frame 109 
114953059 114966243 SLC31A2 (CTR2) 9q31-q32 solute carrier family 31 (copper transporters), member 2 
114967621 115023462 FKBP15 9q32 FK506 binding protein 15, 133kDa 
115023689 115066593 SLC31A1 (CTR1) 9q31-q32 solute carrier family 31 (copper transporters), member 1 
115069109 115077690 CDC26 9q32 cell division cycle 26 homolog (S. cerevisiae) 
115077795 115094877 PRPF4 9q31-q33 PRP4 pre-mRNA processing factor 4 homolog (yeast) 
115099194 115101141 RNF183 9q32 ring finger protein 183 
115117751 115142388 WDR31 9q32 WD repeat domain 31 
115151633 115173334 BSPRY 9q32 B-box and SPRY domain containing 
115175519 115178162 HDHD3 9q32 haloacid dehalogenase-like hydrolase domain containing 3 
115188413 115203391 ALAD 9q33.1 aminolevulinate, delta-, dehydratase 
115209342 115212773 POLE3 (CHRAC17) 9q33 polymerase (DNA directed), epsilon 3 (p17 subunit) 
115212843 115231703 C9orf43 9q32 chromosome 9 open reading frame 43 
115246832 115399839 RGS3 9q32 regulator of G-protein signaling 3 
115418339 115418830 FLJ31713 9q32 hypothetical protein FLJ31713 
115652788 115672935 LOC100132609 9q32 hypothetical LOC100132609 
115678383 115858696 ZNF618 9q32 zinc finger protein 618 
115862228 115880536 AMBP 9q32-q33 alpha-1-microglobulin/bikunin precursor 
115893739 115901158 KIF12 9q32 kinesin family member 12 
115958052 116112796 COL27A1 9q32 collagen, type XXVII, alpha 1 
116011534 116011629 MIRN455 9q32 microRNA 455 
116125157 116128578 ORM1 9q31-q32 orosomucoid 1 
116131890 116135357 ORM2 9q32 orosomucoid 2 
116136250 116196506 AKNA 9q32 AT-hook transcription factor 
116204181 116307551 DFNB31 9q32-q34 deafness, autosomal recessive 31 
116293663 116293843 LOC100131877 9q32 hypothetical LOC100131877 
116389815 116400973 ATP6V1G1 9q32 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 
116413527 116448524 C9orf91 9q32 chromosome 9 open reading frame 91 
116456401 116548297 LOC100129633 9q32 similar to hCG1651427 
116591421 116608229 TNFSF15 9q32 tumor necrosis factor (ligand) superfamily, member 15 
116647695 116650692 LOC645266 9q32 similar to PRP4 pre-mRNA processing factor 4 homolog B 
116704945 116732591 TNFSF8 9q33 tumor necrosis factor (ligand) superfamily, member 8 
116822626 116920307 TNC 9q33 tenascin C (hexabrachion) 
116943918 117204744 DEC1 9q32 deleted in esophageal cancer 1 
117955892 118204421 PAPPA 9q33.2 pregnancy-associated plasma protein A, pappalysin 1 
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Twenty-six genes located at 15q23-q24.1, a region of 1.7 M bp. Build 36.3 from NCI 
 
69220842 69862776 THSD4 15q23 thrombospondin, type I, domain containing 4 
69889948 69897654 NR2E3 15q22.32 nuclear receptor subfamily 2, group E, member 3 
69898125 69907176 LOC100132473 15q23 hypothetical protein LOC100132473 
69905405 70197476 MYO9A 15q22-q23 myosin IXA 
70197808 70220358 SENP8 15q23 SUMO/sentrin specific peptidase family member 8 
70239202 70277180 GRAMD2 15q23 GRAM domain containing 2 
70278424 70310738 PKM2 15q22 pyruvate kinase, muscle 
70320576 70350682 PARP6 15q23 poly (ADP-ribose) polymerase family, member 6 
70364123 70399579 BRUNOL6 15q24 bruno-like 6, RNA binding protein (Drosophila) 
70422832 70455457 HEXA 15q23-q24 hexosaminidase A (alpha polypeptide) 
70455567 70456379 C15orf34 15q24.1 chromosome 15 open reading frame 34 
70458553 70464260 LOC400389 15q24.1 hypothetical gene supported by AK026491; NM_000976 
70477722 70487762 TMEM202 15q24.1 transmembrane protein 202 
70530158 70530833 LOC100130579 15q24.1 hypothetical protein LOC100130579 
70553721 70662877 ARIH1 15q24 
ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein, 1 
(Drosophila) 
70666611 70666707 MIRN630 15q24.1 microRNA 630 
70684573 70691719 LOC646665 15q24.1 golgi autoantigen, golgin subfamily a, 6 pseudogene 
70687876 70716282 LOC100129119 15q24.1 hypothetical protein LOC100129119 
70716473 70730171 LOC646670 15q24.1 similar to COMM domain containing 4 
70734092 70746791 GOLGA 15q24.1 golgin-like protein 
70755176 70765543 HIGD2BP 15q24.1 HIG1 domain family, member 2B pseudogene 
70765588 70817869 BBS4 15q22.3-q23 Bardet-Biedl syndrome 4 
70830763 70863114 ADPGK 15q24.1 ADP-dependent glucokinase 
70978467 70979746 LOC729686 15q24.1 similar to nucleophosmin 1 isoform 1 
71131928 71384599 NEO1 15q22.3-q23 neogenin homolog 1 (chicken) 
71400988 71448230 HCN4 15q24-q25 hyperpolarization activated cyclic nucleotide-gated potassium channel 4  
 
Six genes located at 15q26.3, a small region of 0.5 M bp. Build 36.3 from NCI 
  
 
Twenty five genes are located at Xp22.33, a region of 2.7 M bp. Build 36.3 from NCI.  
 
97956185 98071524 
 
MEF2Ax 15q26 myocyte enhancer factor 2A 
98070287 98074525 LOC100129079 15q26.3 hypothetical protein LOC100129079 
98085133 98091149 LYSMD4 15q26.3 LysM, putative peptidoglycan-binding, domain containing 4 
98116151 98151146 LOC644800 15q26.3 similar to Golgi autoantigen, golgin subfamily a, 2 
98147884 98164655 C15orf51 15q26.3 chromosome 15 open reading frame 51 
98164259 98165704 LOC400464 15q26.3 similar to FLJ43276 protein 
110310 112812 CXYorf11 Xp22.33; Yp11.32 chromosome X and Y open reading frame 11 
132991 160020 PLCXD1 Xp22.33; Yp11.32 phosphatidylinositol-specific phospholipase C, X domain containing 1 
161426 170887 GTPBP6 Xp22.33; Yp11.32 GTP binding protein 6 (putative) 
214970 267627 PPP2R3B Xp22.33; Yp11.3 protein phosphatase 2 (formerly 2A), regulatory subunit B'', beta 
505079 540146 SHOX Xpter-p22.32;Yp11.3 short stature homeobox 
834110 840111 LOC100132775 Xp22.33 hypothetical LOC100132775 
877093 889906 LOC100132256 Xp22.33 hypothetical LOC100132256 
889945 890836 LOC442442 Xp22.33;Yp11.32 60S ribosomal protein L14-like 
1274894 1291529 CRLF2 Xp22.3; Yp11.3 cytokine receptor-like factor 2 
1305011 1306462 LOC100132270 Xp22.33 hypothetical LOC100132270 
1347701 1388827 CSF2RA Xp22.32 and Yp11.3 
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-
macrophage) 
1415509 1461582 IL3RA Xp22.3 or Yp11.3 interleukin 3 receptor, alpha (low affinity) 
1465045 1470998 SLC25A6 Xp22.32 and Yp11.3 
solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 6 
1472923 1473639 LOC729629 Xp22.33 hypothetical protein LOC729629 
1480380 1492584 CXYorf2 Xp22.33; Yp11.3 chromosome X and Y open reading frame 2 
1482032 1531844 ASMTL Xp22.3; Yp11.3 acetylserotonin O-methyltransferase-like 
1541465 1616000 P2RY8 Xp22.33; Yp11.3 purinergic receptor P2Y, G-protein coupled, 8 
1670486 1681413 SFRS17A Xp22.32; Ypter-p11.2 splicing factor, arginine/serine-rich 17A 
1674348 1721974 ASMT Xp22.3 or Yp11.3 acetylserotonin O-methyltransferase 
2147547 2428975 DHRSX Xp22.33; Yp11.2 dehydrogenase/reductase (SDR family) X-linked 
2414455 2429008 ZBED1 Xp22.33;Yp11 zinc finger, BED-type containing 1 
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2521398 2544212 LOC100130595 Xp22.33 similar to hCG1653094 
2546623 2566764 LOC401577 Xp22.33:Yp11.31 hypothetical protein LOC401577 
2619228 2669350 CD99 Xp22.32; Yp11.3 CD99 molecule 
2680115 2743968 XG Xp22.33 Xg blood group 
                                                                                                                          RESULTS                             
146

Supplementary Table S5 Tumors with amplification at 9q32-q33.1 in metastatic 
GCTs. 
 
Patient 
 
Histology a Status of 9q32-q33.1 b Cisplatin response 
 
# 1 
 
CE High amplification Resistant 
  
#2 CE High amplification Sensitive 
 CE Low amplification  
 CE NA  
  
#3 SE NA Resistant 
 CE High amplification 
  
#4 YS High amplification Resistant 
 CE High amplification  
 CH High amplification  
 SE High amplification 
  
#5 SE High amplification Sensitive 
 CH High amplification  
 TE Low amplification  
  
#6 CH Low amplification Resistant 
  
#7 CH High amplification Resistant 
 CH Low amplification  
  
#8 CE Low amplification Resistant 
 YS NA  
 TE High amplification  
  
#9 SE High amplification Sensitive 
  
#10 CE High amplification Sensitive 
  
#11 YS Low amplification Resistant 
  
#12 SE Low amplification  
  
#13 TE Low amplification Resistant 
  
#14 TE Low amplification Sensitive 
  
#15 CE High amplification Sensitive 
 CE NA  
  
#16 CE Low amplification Sensitive 
  
#17 CE High amplification Sensitive 
 CE NA  
 TE/CE NA  
 CH NA  
  
#18 CE Low amplification Resistant 
 TE Low amplification  
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Supplementary Table S6 Patients classified with respect to 9q32-q33.1 amplification status.  
 
a IGCCCG International Germ Cell Cancer Collaborative Group.  
b EP, etoposide/cisplatin; BEP, bleomycin/etoposide/cisplatin; BOMP/EPI, 
bleomycin/vincristine/methotrexate/ 
  cisplatin-etoposide/cisplatin/ifosfamide 
c CR, complete remission characterized by tumor mass reduction by CT scan and negative value of serum 
tumor marks; PR-, partial remission characterized by normalization of CT scan and negative value of 
serum tumor markers; PR+, partial remission characterized by reduction of tumor mass by CT scan and 
positive value of serum tumor markers; SD, stable disease; PD, progressive disease. 
d Patients who achieved durable complete response with first-line cisplatin-based chemotherapy were 
considered sensitive. Patients who had either a poor response or relapsed after first-line chemotherapy 
were considered resistant to cisplatin. 
e  Amplification at 9q determined by FISH using two different probes (see Material and Methods). 
  
9q32-q33.1 status e 
 
  
Non-amplification 
(N = 57) 
 Amplification 
(N = 18) 
 
 
 
 
Number % Number 
 
% 
 
P 
 
Age, years      
 
0.25 
Median 27.6  29.1  
Range (15 - 56)  (16 - 53)     
Histology     0.52 
Seminoma 10 17.5  2 11.1  
Nonseminoma 47 82.5  16 88.9     
Localization       0.96 
Testis 54 94.7  17 94.4  
Mediastinum 3 5.3  1 5.6     
IGCCCG stage at diagnosis of metastasis a      0.26 
Good 37 64.9  8 44.4  
Intermediate 10 17.5  4 22.2  
Bad 10 17.5  6 33.3     
First line of chemotherapy treatment b      0.83 
EP 9 15.8  2 11.1  
BEP 35 61.4  10 55.6  
Taxol-BEP 2 3.5  1 5.6  
BOMP/EPI 11 19.3  5 27.8     
Response to first line of chemotherapy treatment c      0.007 
Good response (CR, PR-) 54 94.7  13 72.2  
Poor response (PR+, SD, PD) 3 5.3  5 27.8  
   
Sensitivity to cisplatin d      0.060 
Sensitive 42 73.7  9 50.0  
Resistant 15 26.3  9 50.0 
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Supplementary Table S7 Clinicopathological characteristics of patients, by response to cisplatin.   
 
a IGCCCG International Germ Cell Cancer Collaborative Group.  
b EP, etoposide/cisplatin; BEP, bleomycin/etoposide/cisplatin; BOMP/EPI, bleomycin/vincristine/methotrexate/ 
  cisplatin-etoposide/cisplatin/ifosfamide. 
c CR, complete remission characterized by tumor mass reduction by CT scan and negative valor of serum tumor 
marks; PR-, partial remission characterized by normalization of CT scan and negative valor of serum tumor 
markers; PR+, partial remission characterized by reduction of tumor mass by CT scan and positive  valor of 
serum tumor markers; SD, stable disease; PD, progressive disease). 
d Relapse >24 months after first diagnosis. 
 
 
Sensitive (N = 51)  Resistant  (N = 24) 
 
Characteristic No. %  
 
No. 
 
%  
 
Age, years      
Median 27.9  28.1 
Range (16 – 56 )  (15 - 53) 
  
Histology      
Seminoma 10 19.6  2 8.3 
Nonseminoma 41 80.4  22 91.7 
   
Localization       
Testis 51 100  20 83.3 
Mediastinum 0 0  4 16.7 
      
IGCCCG stage at diagnosis of metastasis a      
Good 38 74.5  7 29.2 
Intermediate 7 13.7  7 29.2 
Bad 6 11.8  10 41.7 
   
First line of chemotherapy treatment b      
EP 9 17.6  2 8.3 
BEP 33 64.7  12 50.0 
Taxol-BEP 2 3.9  1 4.2 
BOMP/EPI 7 13.7  9 37.5 
   
Response to first line of chemotherapy treatment c      
Good response (CR, PR-) 51 100  16 66.7 
Poor response (PR+, SD, PD) 0 0  8 33.3 
   
Late relapsed     
Non 0   22 91.7 
Yes 0   2 8.3 
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“Loss of MGMT Promoter Methylation and Resistance to Cisplatin in Non-
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RESUMEN 
Para explorar si los cambios de metilación en el promotor del gen MGMT tienen un 
papel en la resistencia al cisplatino, primero estudiamos el estado de metilación en 
células humanas de cáncer testicular de células germinales del tipo no seminoma, 
resistentes y sensibles al cisplatino. En segundo lugar estudiamos su estado de 
metilación en orthoxenografts emparejados y finalmente en tumores primarios 
humanos, de pacientes metastasicos tratados con quimioterapia basada en cisplatino. 
En general, se encontró que la hipermetilación del promotor de MGMT se relaciona 
con la sensibilidad al cisplatino. La resistencia está presente cuando el promotor 
MGMT está hipermetilado y consecuentemente el gen no es expresado. Clínicamente, 
la presencia de MGMT hipermetilado se relaciona con una mejor supervivencia global 
(p=0,025) en los pacientes con cáncer testicular de células germinales metastásico. La 
inhibición de la enzima MGMT con O6-benzilguanina in vitro e in vivo aumenta la 
sensibilidad al cisplatino y a la temozolomida, siendo este un posible enfoque 
quimioterapéutico para resensibilizar tumores humanos resistentes del tipo no 
seminoma.
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SUMMARY 
To explore if MGMT promoter methylation changes have a role in cisplatin 
chemoresistance, first we study it methylation status in cisplatin sensitive and paired 
resistant human non-seminoma cancer cell lines. Secondly in xenograft paired tumors 
and after in human non-seminoma primary tumors, from metastasic patients treated 
with cisplatin-based chemotherapy. In general we found that cisplatin sensitive 
samples are related with MGMT promoter hypermethylation associated with its loss of 
expression. Resistance is present when MGMT promoter is not methylated and 
expressed. Clinically, the presence of MGMT promoter methylation is related with 
better overall survival (p=0.025) in metastasic patients with testicular germ cell cancer. 
Inhibition of MGMT with O6-benzylguanine in vitro or in vivo increases the sensitivity to 
cisplatin and temozolomide, being this a possible chemotherapeutic approach to re-
sensibilize human non-seminoma refractory tumors. 
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INTRODUCTION 
Testicular cancer is the most commonly diagnosed malignancy among young men 
aged 15 to 40 years, and its incidence has doubled in the past 40 years. An annual 
increase of 3–6% is reported for Caucasian populations. Testicular germ cell tumors 
represent over 95% of the testicular cancers and histopathologically are classified into 
two major groups of seminomas or non-seminomas [1]. Patients with testicular germ 
cell tumors, even those with advanced metastatic disease, are often successfully 
treated with cisplatin-based chemotherapeutic regimens [2,3]. However, 15–20% of 
patients is refractory to this treatment and succumbs to progressive disease [4]. Some 
non-seminoma patients, who initially respond to treatment can exhibit a late relapse 
and have a poor prognosis [3, 4].  
 
MGMT is a DNA repair protein that removes mutagenic and cytotoxic adducts from O6-
guanine in DNA [5, 6].  Alkylation of DNA at the O6 position of guanine is an important 
step in the formation of mutations in cancer, primarily due to the tendency of the O6-
methylguanine to pair with thymine during replication, resulting in the conversion of 
G>C to A>T pairs in DNA [7]. Furthermore, the O6-alkylguanine-DNA adduct may 
crosslink with the opposite cytosine residues, blocking DNA replication [8]. The MGMT 
protein rapidly reverses the formation of adducts at the O6 position of guanine via 
transfer of the alkyl adduct to a cysteine residue within the protein, in a reaction that 
inactivates one MGMT molecule for each lesion repaired [5]. This averts the formation 
of lethal cross-links and other mutagenic effects. Loss of MGMT function is most 
frequently due to epigenetic changes, specifically gene promoter region methylation [9]. 
MGMT has important implications in cancer treatment since its expression correlates 
inversely with sensitivity to alkylating drugs, being MGMT activity a major mechanism 
of chemotherapy resistance [10]. 
 
Taking the previous into account, we aim to discover if changes in MGMT promoter 
methylation status can be responsible for cisplatin intrinsic or acquired resistance in 
testicular germ cell tumors, especially in non-seminomas.  
 
MATERIAL and METHODS 
Cell Lines and Drugs Treatment 
Human non-seminoma cancer cell lines (SUSA-S and SUSA-R) were cultured in 
Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 20% (w/v) 
fetal bovine serum, 100U/penicillin and 100μg/L streptomycin (Invitrogen, Carlsbad, 
CA), at 37ºC in an atmosphere of 5% (v/v) dioxide carbon in air. Cell lines were 
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authenticated by short tandem repeat profiling. Cisplatin (50mg/L) was obtained from 
TEVA (North Wales, PA), temozolomide and O6-benzylguanine were obtained from 
Sigma (St. Lois, MO). Temozolomide was diluted in dimethyl sulfoxide (20mg/ml) and 
O6-benzylguanine diluted in methanol (80μM).  
 
Xenograft Tumors and Drugs Treatment 
All analysed non-seminoma xenograft tumors were generated in a previous work [11]. 
Two acquired and two intrinsic xenograft cisplatin resistant tumors were unfrozed in 
DMEM medium supplemented with 10% fetal bovine serum and penicillin/streptomycin, 
at room temperature. Animals were housed in a sterile environment, cages and water 
were autoclaved and bedding and food was X-ray sterilized. Tumors were implanted in 
the testis of five-week old male nu/nu Swiss mice (Charles River, France) weighting 18-
22 g. After anesthesia by isofluorane inhalation, a median laparatomy was performed 
and the testes were mobilized. Tumor pieces were anchored to the testis surface with 
prolene 7.0 sutures. After implantation, mice were inspected twice a week, and if no 
tumor growth was apparent, mice were sacrificed six months after implantation. Then 
for each tumor, mice were randomized into eight groups: control group, cisplatin, O6-
benzylganine, temozolomide, cisplatin+O6-benzylguanine, cisplatin temozolomide, 
temozolomide+O6-benzylguanine, cisplatin+O6-benzylguanine+temozolomide. O6-
benzylguanine and cisplatin were intravenously administered (i.v.). Temozolomide was 
given by oral administration. The different drugs were given once a week for three 
consecutive weeks (days 0, 7and 14). O6-benzylguanine was administrated always one 
hour before cisplatin and temozolomide. Animals were sacrificed seven days after the 
final dose (day 21).  
 
All patients gave written consent to participate in the study. The Ethics Committee of 
the hospitals approved the study protocol, and the animal experimental design was 
approved by the IDIBELL animal facility committee. 
 
Patients and Clinical Samples 
We analyzed 72 testicular germ cell tumors from metastasic patients treated with 
cisplatin based therapy. Formalin-fixed paraffin-embedded tumors obtained by surgical 
resection came from ICO-Hospitalet hospital. Clinical features of the patients are 
showed in Table I. Signed informed consent was obtained from each patient, and the 
Clinical Research Ethical Committee from ICO-Hospitalet provided approval for the 
study. DNA extraction was performed using a commercial kit (Qiagen) following the 
manufacturer’s instructions. 
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Table1.  Clinicalpathological features of patients, by MGMT DNA promoter methylation status  
           
    MGMT methylation status       
 N  %  Unmethylated (U)  Methylated (M) OR (95% CI) P****    
    N %  N %      
Histology          0.413    
  Seminoma 15 20.8  5 27.8  10 18.5  1.00    
  Non-seminoma 57 79.2  13 72.2  44 81.5  1.69    
            
Localisation            
  Testis 72 100%  18 25%  54 75%      
            
IGCCCGa stage at diagnosis of the metastasis    0.923    
  Good 49 68.1  12 66.7  37 68.5  1.00    
  Intermediate 13 18.1  3 16.7  10 18.5  1.08    
  Bad 10 13.9  3 16.7  7 13  0.76    
            
First Line of Chemotherapy          0.430    
  Epb 14 19.4  5 27.8  9 16.7  1.00    
  BEPc 44 61.1  8 44.4  36 66.7  2.50    
  Taxol-BEP 3 4.2  1 5.6  2 3.7  1.11    
  BOMP/EPId 11 15.3  4 22.2  7 13  0.97    
            
Response to First Line of Chemotherapy *     1.00    
  Good (CRe, PRf-) 60 93.8  15 93.8  45 93.75  1.00    
  Poor (PRg+, SDh, PDi) 4 6.25  1 6.25  3 6.25  1.00    
             
Sensitivity to Cisplatin**             
  Sensitive 56 77.8  12 66.7  44 81.5  1.00 0.204    
  Resistant 16 22.2  6 33.3  10 18.5  0.45    
            
Late relapse***          0.368    
  Yes 1 6.7  0 0.0  1 10.0  1    
  No 14 93.3  5 100.0  9 90.0  0    
            
aIGCCCG International Germ Cell Cancer Collaborative Group; bEP-etoposide/cisplatin; cBEP-bleomycin/etoposide/cisplatin; dBOMP/EPI- bleomycin/vincristine/methotrexate/ cisplatin-
etoposide/cisplatin/ifosfamide; eCR, complete remission characterized by tumor mass reduction by CT scan and negative valor of serum tumor marks; fPR- partial remission characterized by 
normalization of CT scan and negative valor of serum tumor markers; g-PR+, partial remission characterized by reduction of tumor mass by CT scan and positive valor of serum tumor markers; hSD, 
stable disease;iPD, progressive disease. 
*Information available for only 64 patients. **Patients who achieved durable complete response with first-line cisplatin-based chemotherapy. Patients who had either a poor response or relapsed after 
first-line chemotherapy; *** Relapse >24 months after first diagnosis; **** P-value was assessed according Chi-Square test; p<0.05 as statistical significant. 
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Genomic DNA Extraction and Bisulfite Conversion 
Genomic DNA was extracted from human cancer cell lines using DNAsol method, 
according the manufactures protocol. For frozen and paraffin tissue samples, were 
used commercial DNA extraction kits, following manufacturer’s instructions (QIAamp 
DNA Mini Kit and QIAamp DNA FFPE Tissue Kit). DNA was subjected to bisulfite using 
EZ DNA methylation kit (Zymo Research, Orange, CA) as described previously [12]. 
Briefly 1ug of genomic DNA was denaturated by incubating with 0.2 M NaOH. Aliquots 
of 10 mM hydroquinone and 3M sodium bisulfate (pH 5.0) were added, and the solution 
was incubated at 50ºC for 16h. Treated DNA was purified on a Zymo-Spin I column, 
desulfonated with 0.3 M NaOH, repurified on a Zymo-Spin column and resuspended in 
25 μl water. Following bisulfate treatment, all DNA were stored at -20ºC. 
 
Genomic DNA Bisulfite Sequencing and MSP 
The DNA methylation status of MGMT promoter was analyzed by bisulfite sequencing 
and by MSP. Both were performed in a 25μl volume containing 1μl of the sodium 
bisulfite modified DNA. For bisulfite sequencing both strands were sequenced and at 
least 20 clones were analyzed per sequence. The characteristics of the MSP reactions 
and the primer sequence have been described previously [10]. SW620 human cancer 
cell line DNA was used as a positive control for methylated alleles of MGMT, and DNA 
from normal lymphocytes used as a negative control, as previously described [13]. 
 
Cell viability and Proliferation Assays  
Cell viability and proliferation was determined by the MTT assay. Briefly, 1 x 103 cells 
were plated onto 96-well plates. At different time points (24, 48, 72, 96 and 120 hours), 
MTT (5mg/ml in phosphate-buffered saline-PBS) was added at 0.1% final 
concentration. After 3 hours incubation (37ºC, 5% dioxide carbon), the MTT metabolic 
product, formazan, was dissolved in dimethyl sulfoxide and absorbance at 570 nm was 
measured. Prism Software was used to calculate drugs IC50. Cell viability and 
proliferation assays were made for 120 hours. All the other treatments were made for 
48 hours.  
 
Cell Cycle Analysis 
After 48 hours of the respective treatment, floating and attached cells were collected, 
and washed with phosphate-buffered saline solution. The cell cycle was assessed with 
propidium iodide-stained cells (distribution of cells in G0/G1, S and G2/M phases) by 
flow cytometry. Approximately 2x106 cells were fixed in ice-cold 70% ethanol overnight 
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at -20ºC. Cells were subsequently washed and resuspended in phosphate-buffered 
saline solution. After 30 minutes, DNA was stained with 25 mg/mL propidium iodide 
(Sigma, St Louis, MO) in a reaction solution containing 50 mg/mL RNAse A (Sigma, St 
Louis, MO) for 30 minutes at 37ºC in the dark. Fluorescence emitted from the 
propidium iodide–DNA was measured for individual cells using a FACS flow cytometer 
(FACSCalibur; BD Bioscience). 
 
Apoptosis and Necrosis Determination 
First we perform a western blot for PARP protein (explained in the next point), we 
determine caspase-3 and -7 activities using the Caspase-Glo® 3/7 Assay (Promega, 
Madison, WI) and we determine the possibility of chromatin cleavage using DNA ladder 
kit as manufacturer’s instructions. For determine necrosis we used the 
Apoptotic/Necrotic/Healthy Cells Detection Kit (Pomokine,Heidelberg, Germany). Cells 
were grew directly on a coverslip, washed twice with 1X Binding Buffer and stained 
with a mix of 3 fluorocromes ( FITC-Annexin V+ Ethidium Homodimer III+ Hoechst 
33342) over 15 minutes. Cells were then fixed with 2% formaldehyde, washed 2 times 
and mounted each coverslip onto a slide with mowiol (Sigma, St Louis, MO). Finally we 
observed cells under a fluorescence microscope (DMI6000, acquisition software LEICA 
application suite advanced fluorescence (LAS AF). Data were analyzed using FlowJo 
software.  
 
Western Blot 
A standard protocol was used to extract cells total protein. Anti-MGMT (1/1000) was 
acquired from Cell Signaling (Boston, MA), Anti-PARP (1/2000) from BD Pharmigen 
(San Diego,CA) and H2AX.P (1/1000) from Abcam (Cambridge, UK). An anti--actin-
HRP antibody (1/20000) was purchased from Sigma (Sigma, St Louis, MO). 
 
Immunoflurescence 
Cells were cultured directly on coverslips and fixed with 4% paraformaldehyde in 
phosphate-buffered saline solution for 20 minutes at room temperature. Cells were 
permeabilized with 0.1% Triton X-100 in phosphate-buffered saline solution for 5 
minutes and blocked with 1% bovine serum albumin for 1 hour. Double immunostaining 
with primary antibodies for  tubulin (1/1000, Abcam; Cambridge, UK) and pericentrin 
(1/1000, Abcam; Cambridge, UK) were performed by simultaneous incubation for 1 
hour. We also used H2AX.P in an independent experiment (1/1000; Abcam; 
Cambridge, UK). Finally, 1/1000 dilutions of appropriate fluorescent-labeled secondary 
antibodies from Invitrogen (Carlsbad, CA) (anti-rabbit IgG, A11011; anti-mouse IgG, 
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A21235) were used. The coverslips were mounted on glass slides using mowiol 
(Sigma) with DAPI. Multi-color immunofluorescence imaging was then performed on a 
(DMI6000, acquisition software LEICA application suite advanced fluorescence (LAS 
AF; Leica Microsystems, Germany).Data were analysed by Fiji program. For determine 
the amount of multipolar mitotic spindles, 100 mitotic spindles were counted for each 
condition. The counting was repeated 3 independent times. 
 
Statistical Analysis 
Survival curves were estimated using the Kaplan-Meier method, and differences 
between individual curves were evaluated by multivariate Cox proportional hazards 
regression modeling. Hazard Ratio and 95% confidence intervals were calculated.  
Values of P<0.05 were considered significant. 
 
RESULTS  
MGMT Epigenetic Silencing and Cisplatin Sensitivity 
In order to analyze if changes in MGMT promoter methylation status can modulate 
cisplatin sensitivity in non-seminoma testicular germ cell tumors, we studied one pair of 
human cancer cells lines composed by a sensitive (SUSA-S; IC50=75.3 ng/mL) and a 
resistant derivate (SUSA-R; IC50=596.2 ng/mL) to cisplatin. Bisulfite sequencing 
methylation profiles revealed a loss of CpG methylation in the resistant cell line, in 
comparison with sensitive counterpart (28% vs. 3%) (Fig. 1A).This fact was associated 
with a significant increase in MGMT protein level in the resistant cell line (Fig. 1B).  
 
Inhibition of MGMT Changes Sensitivity to Cisplatin and to Temozolomide 
Considering the increased level of MGMT in resistant cells, we decided to evaluate the 
effect of its inactivation in the modulation of cisplatin sensitivity. Inhibition of MGMT 
upon O6-benzylguanine treatment lead to a decrease in cisplatin IC50 in SUSA cancer 
cells (2 fold), becoming them more sensitive when compared with the vehicle treatment 
(Table II and Fig. 2A). Based on previously publications, where cells lacking MGMT 
were sensitive to temozolomide, we add this chemotherapeutic drug to our cells 
treatments. Furthermore, addition of O6-benzylguanine in cell culture significantly 
sensitizes cells to cisplatin and/or temozolomide drugs (Fig. 2B). 
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Table II: IC50 for SUSA cell lines 
Cell Lines IC50 
Drugs SUSA_S SUSA_R 
CDDP (ng/ml)  75,3 598,2 
TMZ (μg/ml)  55.9 204.1 
CDDP (ng/ml)+ MeTOH  68,3 595,7 
CDDP(ng/ml)+ O6-BG (μM) 23,4 282,7 
 
MGMT Inhibition and Co-treatment with Cisplatin and/or Temozolomide Leads to 
Cell Death, Necrosis and Mitotic Cell Arrest 
In order to elucidate the causes of the decrease in proliferation rates, we performed 
flow cytometry analyses in SUSA treated cells, to detect possible alterations in cell 
cycle. A significant increase in the sub-diploid population was detected upon 
temozolomide+O6-benzylguanine (5% vs. 52% and 30%) and cisplatin+O6-
benzylganine+temozolomide (5% vs. 44% and 49%) treatments (Fig. 3A). To evaluate 
the possible mechanism responsible for this cellular death, we analyzed apoptotic 
markers including PARP cleavage, caspase 3/7 activity, DNA degradation and Anexin  
V; however, none of them revealed the presence of a apoptotic process (Supp. Fig. 
1A, 1B, 1C and 2). Therefore, we proceeded to study necrosis. We performed a 
double cellular immunostaining using Anexin V and ethidium homodimer III. Co-
treatment of cisplatin with O6-benzylguanine increased the percentage of necrotic cells, 
more evident with the addition of temozolomide (Supp. Fig. 2).  
 
In addition to the increase of the sub-diploid peak, we also observed an arrest in G2-M 
in all cellular treatments, with exception for cells treated only with O6-benzylguanine 
(Fig. 3 B). Considering that a mechanism that leads to G2-M cell cycle arrest is the 
mitotic catastrophe, we decided to analyze this phenomenon by immunocytochemistry. 
A significant increase in prometaphase and metaphase upon cisplatin or/and 
temozolomide treatment was observed. Moreover, these cells presented a high amount 
of mitotic multipolar spindles (Fig. 3C and 3D). The presence of double strand breaks 
was also evaluated and the highest values were found in the triple treatment 
cisplatin+O6-benzylguanine+temozolomide (Sup. Fig. 3A and 3B). 
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Changes of MGMT Promoter Methylation Status in Generated Cisplatin Resistant 
Non-seminoma Xenograft Tumors 
In view of the previous in vitro results we evaluated the role of the epigenetic regulation 
of MGMT in cisplatin resistant non-seminoma orthoxenograft tumors. Analogous to the 
profiles observed in the cell lines, we detected a loss of methylation in 4 out of 6 of the 
cisplatin resistant generated non-seminoma xenografts, when compared with the 
original tumors (Fig.4A and Table III). We also studied a set of human intrinsic non-
seminoma cisplatin resistant tumors, where MGMT promoter was mainly unmethylated 
(4 out of 6) (Fig.4A and Table III).The loss of CpG methylation in resistant tumors 
resulted in the re-expression of MGMT protein (Fig. 4B). Because previously it was 
described an association between MGMT and MLH1 promoters hypermethylation in 
temozolomide resistant cases [14], we also studied this second DNA repair gene in our 
cases. We only detected 2 out of 6 
methylated tumors in the human 
non-seminoma cisplatin intrinsic 
resistant tumors, those tumors that 
were also methylated for MGMT 
(Supp.Table I).  
 
MGMT Promoter Methylation 
Status as a Prognostic 
Biomarker in Human Testicular 
Germ Cell Tumors Patients   
We analyzed MGMT promoter 
methylation in 72 testicular germ 
cell tumor patients and we 
observed a positive correlation 
between MGMT promoter 
hypermethylation and high overall 
survival (p=0.025) (Fig. 4D). 
These results suggest MGMT 
promoter methylation status as a 
prognosis marker in this type of 
tumors.  
 
Table III: Methylation status of MGMT promoters 
 
 Sensitivity 
to cisplatin 
MGMT 
methylation 
status 
 
Cispaltin generated 
refractory xenograft 
tumors  
P1 *  
Sensitive  methylated
Resistant unmethylated 
P2  
Sensitive  unmethylated 
Resistant  unmethylated 
P3  
A -Sensitive methylated 
B-Sensitive methylated 
B-Resistant  unmethylated 
P4  
Sensitive  unmethylated 
Resistant  unmethylated 
P5*  
Sensitive  methylated 
Resistant  unmethylated 
P6  
Sensitive  methylated 
Resistant  unmethylated 
Primary human 
endogenously cisplatin 
resistant tumors 
R1*  Resistant  methylated 
R2  Resistant unmethylated 
R3  Resistant unmethylated 
R4*  
A- Resistant methylated 
B- Resistant  methylated 
R5  Resistant unmethylated 
R6  Resistant unmethylated 
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New Chemotherapy Proposal for Human Non-seminoma Refractory Cisplatin 
Tumors 
Once confirmed the clinical relevance of MGMT DNA promoter methylation in 
sensitivity to cisplatin agent, we proceeded to test the use of O6-bezylguanine to inhibit 
MGMT expression in 3 cisplatin refractory non-seminoma xenograft models: 2 
generated cisplatin resistant xenógrafts and 1 non-seminoma cisplatin intrinsically 
resistant. The inhibition of MGMT was confirmed by western blot (Supp. Fig. 5A).The 
triple combination cisplatin+O6-benzylguanine+temozolomide resulted in a high 
decrease of tumor growth (Fig. 4C and Supp. Fig. 5B). Additionally, the tumor with 
MGMT hypermethylation (tumor R4) showed a high sensitivity also to temozolomide 
alone (Supp. Fig. 5B). However, the tumors treated only with temozolomide re-growth 
faster than those tripled treated (cisplatin+O6-benzylguanine+temozolomide). 
 
DISCUSSION 
Chemoresistance to conventional chemical drugs is a well recognized issue that 
hampers many of the clinical expectations to improve the survival of oncology patients. 
Intrinsic and/or acquired resistance appears due to cellular mechanisms that permit 
cells to escape the chemical antitumoral effects. This involves a wide “repertoire” of 
genetic and epigenetic events. What concerns to the epigenetic events, little is known 
about its influence in non-seminoma tumors resistance to cisplatin. In testicular germ 
cell tumors MGMT was described to be frequently inactivated by promoter 
hypermethylation [15-17], especially in the cisplatin sensitive ones [18]. In non-
seminoma tumors we found the same that in the previous study. MGMT promoter 
methylation was present in sensitive tumors. 
 
MGMT is a tumor suppressor gene that encodes O6-methylguanine-DNA 
methyltransferase and plays an important role in DNA repair, removing DNA adducts 
formed by alkylating agents. So, cells that express this protein present a defense 
system against alkylating agents, being more difficult to kill them, in comparison with 
MGMT knock-out cells. This was initially described in human gliomas in relation to 
temozolomide. Although in this type of tumor there is an exception. If besides MGMT 
methylation, MLH1 methylation is also present, the patients are resistant to 
temozolomide [14]. We also found the same in two non-seminoma tumors.  
 
A possible way of revert resistance to temozolomide is the use of a MGMT inhibitor that 
competes for the same target (O6-methyl adducts). O6-benzylganine is a potent, 
specific and irreversible blocker of MGMT that enhances the cytotoxic action of 
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alkylating agents (e.g. cisplatin, temozolomide) [19]. However the clinical trials are not 
very clear in the benefit for the use of this compound [20, 21], with our study we afford 
scientific data that indicate the possibility O6-benzylguanine be applied as a treatment 
option to revert non-seminoma resistant cisplatin tumors. Besides, the combined used 
of temozolomide can also increase the cure rate in non-seminoma refractory tumors.  
 
In preclinical studies temozolomide has demonstrated antitumor activity against human 
non-seminoma cell lines [22], being one reason for testing this in the clinics. However 
three clinical phase II studies were already performed without positive outcome [23-26]. 
Based on our results we think that the major limitation to the successful treatment of 
these patients was the absence of information about MGMT promoter methylation, as a 
major issue to include patients in those studies. Therefore, a further rationale for testing 
this new agent again is first study of MGMT promoter methylation and then decide if 
the chemotherapy schedule should include an MGMT inhibitor, like O6-benzylganine 
drug. Other reason for testing temozolomide and when needed a MGMT inhibitor, is 
that these chemical agents have clinical activity against brain tumors [27]. Brain 
metastases occur in 8-15% of patients with testicular tumors, almost always associated 
with relapse at other sites or as a terminal event [23, 28]. Temozolomide may provide 
in this way a more effective treatment for testis tumors which have metastasized to the 
brain. 
 
Dolan et al, described that cisplatin, temozolomide and O6-benzylguanine as 
chemotherapeutic drug, cause cellular dead [19]. Although they do not refer which 
dead mechanism is behind that. Our results indicate that the use of these three agents 
lead to mitosis catastrophe and necrosis. Mitotic catastrophe occurs when cells cannot 
carry on mitosis. One of many problems that can lead to this process is the 
accumulation of DNA damage. We believe that inhibiting MGMT action in these cells, 
make them more sensitive to these alkylating agents since cells are not able of repair 
their DNA efficiently. If the repair mechanism fails, O6-methylguanine results in the 
formation of toxic double strand breaks, due to faulty MMR during proliferation, fact that 
we also found. About the other dead mechanism, necrosis normally results from a 
severe cellular insult. It was described that happens as a consequence of extreme 
stress, such as heat, osmotic shock, and mechanical stress, freeze thawing and high 
concentration of hydrogen peroxide. In these conditions, cell death occurs quickly due 
to the direct effect of the stress on the cell, and therefore this cell death process has 
been described as accidental and uncontrolled [29]. We think that this happens in non-
seminoma cell lines, because treating them with DNA damage agents and at the same 
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time block a pathway of DNA repair should be a shock for the cells, not having them 
time to enter in a controlled cell death program, apoptosis.  
 
Despite the high cure rate obtained with combination chemotherapy of testicular germ 
cell tumors, the management of patients with an adverse prognosis at presentation, or 
of those who fail to respond to first-line chemotherapy, remains a therapeutic challenge 
[28]. MGMT methylation is already used as a predictive temozolomide response 
biomarker in glioblastomas [10]. It is worth to mention the possibility to extend this to 
non-seminoma patients. If methylated a possible chemotherapeutic schedule could be 
O6-benzylguanine plus cisplatin and temozolomide. However further studies should be 
performed. 
 
In conclusion, we have demonstrated that the loss of MGMT promoter DNA 
methylation is associated with the acquisition of chemoresistance to the DNA 
damaging agent cisplatin in non-seminoma tumours both in vitro and in vivo. The 
validation of MGMT methylation as a predictive marker will require further prospective 
studies. If successful, clinical trials would also be necessary to develop strategies to 
overcome or prevent the development of MGMT-mediated epigenetic resistance. 
 
REFERENCES 
1. Holmes Jr L., E. C., Garrison O, Foldi BX, Ogungbade GO, EssienEJ,Ward D 
(2008). "Testicular cancer incidence trends in the USA (1975-2004): plateau or 
shifting racial paradigm?" Public Health 122: 862–872. 
2. LH., E. (2002). "Curing metastatic testicular cancer." ProcNatlAcadSci U S A 
99: 4592–4595. 
3. Giuliano CJ, F. S., Spinella MJ. (2006). "Testicular germ cell tumors: A 
paradigm for the successful treatment of solid tumor stem cells." Curr Cancer 
Ther Rev 2: 255–270. 
4. El-Helw L, C. R. ( 2005). "Salvage, dose intense and high-dose chemotherapy 
for the treatment of poor prognosis or recurrent germ cell tumours ." Cancer 
Treat Rev 31: 197-209. 
5. AE., P. (1990). "Properties of mammalian O6-alkylguanine-DNA transferases." 
Mutat Res 233: 165-175. 
6. 22. Pegg AE, D. M., Moschel RC (1995). "Structure, function, and inhibition of 
O6-alkylguanine-DNA alkyltransferase." Prog Nucleic Acid Res Mol Biol 51: 
167-223. 
                                                                                                                          RESULTS                             
    
167

7. Coulondre C, M. (1977). "Genetic studies of the lac repressor. III. Additional 
correlation of mutational sites with specific amino acid residues." JH. Mol Biol. 
117: 525-567. 
8. Erickson, L. ( 1991). " The role of O-6 methylguanine DNA methyltransferase 
(MGMT) in drug resistance and strategies for its inhibition." SeminCancer Biol. 
2: 257-265. 
9. Esteller M, C. P., Baylin SB, Herman JG (2001). "A gene hypermethylation 
profile of human cancer." Cancer Res. 61: 3225-3229. 
10. Esteller M, G.-F. J., Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin 
SB, Herman JG (2000). "Inactivation of the DNA repair gene MGMT and the 
clinical response of gliomas to alkylating agents." N Engl J Med 343: 1350-
1354. 
11. Piulats J, Vidal A, et al. “Orthoxenografts of Testicular Germ Cell Tumors 
enable identification of glucosylceramide synthase as a cisplatin resensitizing 
target”. Submitted to Nature Medicine. 
12. Bibikova M, Le J, Barnes B, et al. “Genome-wide DNA methylation profiling 
using Infinium assay.” (2009).Epigenomics. 1:177–200. 
13. Amatu, A. Sartore-Bianchi, A. Moutinho, C. Belotti, A. Bencardino, K. Chirico, 
G. Cassingena, A. et al. (2014). “Promoter CpG island hypermethylation of the 
DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase 
II study for metastatic colorectal cáncer” Clin Cancer Res. 19: 2265-72 
14. Plumb, J. A. Strathdee, G. Sludden, J. Kaye, S. B. Brown, R. (2000). “Reversal 
of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-
induced demethylation of the hMLH1 gene promoter.”Cancer Res 60: 6039-44 
15. Sanjay Koul, J. M. M., Gopeshwar Narayan, Jane Houldsworth, Jennifer Bacik, 
Deborah L Dobrzynski, Adel M Assaad1, Mahesh Mansukhani, Victor E Reuter, 
George J Bosl, Raju SK Chaganti and Vundavalli VVS Murty (2004). "Role of 
promoter hypermethylation in Cisplatin treatment response of male germ cell 
tumors." Molecular Cancer 3: 1-12. 
16. Koul S, H. J., Mansukhani MM, Donadio A, McKiernan JM, Reuter VE, Bosl GJ, 
Chaganti RS, and Murty VV (2002). "Characteristic promoter hypermethylation 
signatures in male germ cell tumors. ." Mol Cancer Epidemiol Biomarkers Prev 
8. 
17. Smith-Sørensen B, L. G., Skotheim RI, Fossa° SD, Fodstad Ø, Stenwig, A-E, 
Jakobsen KS, and Lothe RA (2002). "Frequent promoter hypermethylation of 
the O6-methylguanine-DNA methyltransferase (MGMT) gene in testicular 
cancer." Oncogene 21: 8878 - 8884. 
                                                                                                                          RESULTS                             
 
168

18. Honorio S, A. A., Nicolas Wernert, Marcus Rothe, Eamonn R Maher, Farida 
Latif (2003). "Frequent epigenetic inactivation of the RASSF1A tumour 
suppressor gene in testicular tumours and distinct methylation profiles of 
seminoma and non-seminoma testicular germ cell tumours." Oncogene 22: 
461-466. 
19. Dolan, M. E., and Pegg, A. E. (1997). "O6-Benzylguanine and its role in 
chemotherapy." Clin. Cancer Res  3: 837-847. 
20. Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, 
Balis FM, Berg SL, et al. (2012) “A phase II study of O6-benzylguanine and 
temozolomide in pediatric patients with recurrent or progressive high-grade 
gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study”.J 
Neurooncol.106: 643-9. 
21. Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM. (2009). 
“Pharmacokinetics of temozolomide administered in combination with O6-
benzylguanine in children and adolescents with refractory solid tumors”. Cancer 
Chemother Pharmacol. 65: 137-42. 
22. Pera MF, K. B. a. M. J. (1995). "Exceptional sensitivity of testicular germ cell 
tumour cell lines to the new anti-cancer agent, temozolomide." British Journal of 
Cancer 71: 904-906. 
23. Antonadou D, P. M., Sarris G, Coliarakis N, Economou I, Karageorgis P, 
Throuvalas N (2002). " Phase II randomized trial of temozolomide and 
concurrent radiotherapy in patients with brain metastases." J Clin Oncol 20: 
3644-3650. 
24. Kondagunta GV, B. J., Schwartz L, Sheinfeld J, Bajorin D, Vuky J, Mazumdar 
M, Bosl GJ, Motzer RJ (2004). "Phase II trial of temozolomide in patients with 
cisplatin-refractory germ cell tumors." Invest New Drugs 22: 177-179. 
25. Maroto P., H. R., Garcia del Muro X., Horwich A., Paz Ares L., Aparicio J., 
Germa-Lluch J.R (2011). "Brief Report: Phase II Multicenter Study of 
temozolomide in Patients with Cisplatin-Resistant Germ Cell Tumors." 
Oncology 80: 219-222. 
26. Newlands, E. S., Blackledge, G. R., Slack, J. A., Rustin, G. J. Smith, D. et al. 
(1992). “Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 
362856)”. Br J Cancer 65:287-281. 
27. Raia V, S. S., Kable N, Tanwar R, Rao K, Dawar R and Rath GK. (1993). "Brain 
metastasis as the site of relapse in germ cell tumor of the testis." Cancer 
Epidemiol Biomarkers Prev 72: 2182-2185. 
                                                                                                                          RESULTS                             
    
169

28. Horwich A, W. C., Cornes P, Gilderdleve J and Dearnaley D. (1993). " 
Increasing the dose intensity of chemotherapy in poor-prognosis metastatic 
non-seminoma." Eur. Urol. 23: 219-222. 
29. Vandenabeele, P. Galluzzi, L. Vanden Berghe, T.Kroemer, G.(2010)
“Molecular mechanisms of necroptosis: an ordered cellular explosion” 
Nat Rev Mol Cell Biol.11:700-14  
 
                                                                                                                                                                                                                    RESULTS 
 
170

SUPPLEMENTARY INFORMATION 
 
 
  
 
 
 
 
 
                                                                                                                                                                                                                    RESULTS 
 
171

 
 
 
                                                                                                                                                                                                                    RESULTS 
 
172

  
                                                                                                                                                                                                                    RESULTS 
 
173

 

 175

 










RESULTS and DISCUSSION SYNTHESIS 
 
 
 
 
 
 
 
  
 

 
                                                          RESULTS and DISCUSSION SYNTHESIS 
 
177

CHEMORESISTANCE IN COLORECTAL CANCER 
The preexistence or the de novo development of cellular mechanisms to escape the 
antitumoral effects mediated by the anticancer compounds, involves different genetic 
and epigenetic events [220]. From an epigenetics perspective, little is known. 
Regardless of promising pharmacoepigenetics biomarkers, such as the example of 
MGMT hypermethylation and good response to temozolomide in gliomas have been 
described [54], for other tumor types like colorectal neoplasms examples are limited, 
specially if we just center our attention on resistance biomarkers. Herein, in the first 
part of this thesis we provide two examples that help fill this niche. In one hand we 
show that hypermethylation of MGMT predicts sensitivity for dacarbazine and in the 
other, that SRBC hypermethylation predicts resistance to oxaliplatin, both in metastasic 
colorectal cancer, a disease stage that represents the second most common cause of 
death from cancer [221]. 
 
STUDY I: 
“Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT 
Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic 
Colorectal Cancer” 
 
Dacarbazine represents an effective chemotherapeutic agent for treatment of 
Hodgkin's lymphoma [222] and was the mainstay of treatment for metastatic melanoma 
until the recent approval of ipilimumab and vemurafenib [223].  
 
MGMT promoter methylation status predicts metastasic colorectal cancer tumors 
response to dacarbazine 
MGMT plays an important role in DNA repair, removing DNA adducts formed by 
alkylating agents. In the present study, MGMT promoter methylation was found in 38% 
of the colorectal tumors analysed, similar to the previously reported for this tumor type 
(35-40%) [224]. 
 
A low response rate to dacarbazine was observed (2 patients met clinical parameters 
with objective response and 8 with stable diseases) in our study. This could be linked 
to the fact that the patients included in this study are heavily pre-treated patients 
(median four lines of chemotherapy). Dacarbazine is activated in liver by CYP450 
microsomial N-demethylation with formation of 5-[3-hydroxymethyl-3-methyl-triazen-l-
yl]-imidazole-4-carboxaliplatinmide and 5-[3-methyl-triazen-1-yl]-imidazole-4-carboxamide 
(MTIC). It is therefore conceivable that the patients included in this study may have 
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exhausted the liver function capacity to activate dacarbazine. In this regard 
temozolomide, other alkylating agent whose activity is also enhanced in tumors with 
MGMT loss and that is hydrolyzed in cells producing the active compound MTIC 
without requiring liver passage, can be a good option for a new clinical trial [225]. In 
fact a new Phase II clinical trial (TEMECT EudraCT Number: 2012-003338-17) is 
already being performed. In this ongoing study, patients in whom standard therapies 
failed should be treated with temozolomide if present MGMT promoter gene 
methylated. Actually temozolomide is mainly used for the treatment of malignant 
glioblastomas and melanomas. In the meanwile of our Phase II clinical trial, others 
described a similar one, with deceptive results. Efficacy of temozolomide for colorectal 
cancer patients with confirmed MGMT promoter DNA methylation was inconclusive. 
However none achieved a complete response response, almost 45% achieved a stable 
disease [226].  
 
When looked in more detail, in our study with dacarbazine, the patients that displayed 
the objective responses were the ones carrying MGMT promoter hypermethylated 
tumors, showing one of them a long-lasting maintenance response (more than six 
months), which is uncommon in the advanced setting of metastasic colorectal cancer. 
Important to reinforce that these patients failed standard chemotherapy schemes and 
any other treatment option is a great achievement. What concerns to progression free 
survival, a trend toward to a better progression free survival, was shown in the first 
cases (p=0.098). 
 
The association between MGMT promoter hypermethylation and these referred clinical 
endpoints supports the hypothesis that DNA-repair defective metastasic colorectal 
cancer tumors are more susceptible to dacarbazine. The same was already described 
for human gliomas, in relation to temozolomide, an analogue of dacarbazine [54]. 
Tumors that express MGMT have a specific system for repair O6-methyl adducts, the 
principal damage caused by alkylating agents. Thus tumors that present MGMT 
inactivation have high probability of response, since the insuficient DNA repair leads to 
point mutations or even chromosomal aberrations and subsequent cellular death [227, 
228]. 
 
MGMT methylation is related with KRAS G>A mutations in metastasic colorectal 
cancer patients  
In this trial despite KRAS mutational status did not influence patient selection, we 
check for a possible correlation between this issue and MGMT promoter methylation 
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status. As previously described we found that MGMT hypermethylation was more 
frequent in tumors carrying KRAS mutation with guanine-adenine transition (G12D, 
G12V or G13D) [229]. MGMT transfers methyl groups from the O6 position of guanine 
in DNA to a cysteine residue in its active site, thereby inactivating MGMT itself [230]. 
Inactivated MGMT molecules are ubiquitinated and degraded by the proteasome [231]. 
If the methyl group is not removed from guanine, this base can pair with thymine during 
DNA replication which leads to transition of guanine-cytosine to adenine-thymine. 
However this difference was not statistically significant due to the sample small size for 
which we had both information (n=26; p=0.238). In contrast to MGMT promoter 
methylation, KRAS mutational status was not associated with response rate, 
progression free survival or overall survival. 
 
STUDY II:  
“Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to 
Oxaliplatin in Colorectal Cancer” 
 
Small methylation differences between oxaliplatin sensitive and resistant paired 
human colon cancer cell lines 
With the use of our first in vitro model, where the resistant cell line was derived from 
the sensitive one, by increasing oxaliplatin concentrations, we try to cut out most part of 
the genetic variability and focus our study only on genes promoter DNA methylation 
changes. After our general approach with 27K Methylation Illumina, only three 
promoter genes were found differentially methylated between oxaliplatin sensitive and 
resistant cell lines: SRBC, family with sequence similarity 111, member A (FAM111A) 
and family with sequence similarity 84, member A (FAM84A). The gene with the 
highest difference in promoter DNA methylation was SRBC. This was the only gene 
later validated. This small methylation difference between sensitive and resistant cell 
lines could be due to the reduced coverage from the 27K plataform or due the 
restricted thresholds that we applied. For example we only chose genes that presented 
differences higher than 75% of methylation between the two samples. With this criteria 
we thought that the probability of the selected genes be implied in chemoresistance 
acquisition, would be greater. Nonetheless this does not discard the importance of 
genes with smaller methylation differences. Other question was that the chosen probes 
were localized between minus 300 or plus 300 base pairs from the transcription start 
site. Promoter genes are canonical defined to be localized between minus 1000 base 
pairs from the transcription start site until the end of the first exon. Based on this, 
maybe we lost other genes that were differentially methylated. Other fact to have in 
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account is that chemoresistance process can appear due to different mechanisms 
beside genes promoter DNA methylation, like genetic alterations or simply due to 
changes in proteins expression (e.g. alterations in non-coding RNAs or histone 
modifications). 
 
SRBC expression is regulated by DNA methylation in colorectal cancer  
The oxaliplatin resistant human colon cancer cell lines (LoVo-R and HCT15) were the 
only presenting SRBC promoter hypermethylation and diminished protein expression. 
This data is in agreement with previous reports, where SRBC promoter 
hypermethylation led to a reduction of messenger RNA and protein expression in 
human colorectal cancer, ovary and gastric cancer cell lines [232]. To be shore that 
promoter hypermethylation was the cause of SRBC inactivation in resistant cells, LoVo-
R cell line was treated with 5-AZA, a demethylating agent. 5-AZA is an analog of 
cytosine that is converted into nucleotide triphosphates in vivo. Thus it is able to 
incorporate into the DNA and influence it structure and stability. Two models have been 
proposed to explain the mechanisms by which 5-AZA reactivates silenced genes by 
demethylating CpG islands in the promoters. First, after being incorporated into DNA, 
5-AZA forms an irreversible and covalent bond with DNMT1, protein which is mainly 
responsible for the maintenance of DNA methylation. This therefore leads to 
demethylation when DNA is replicated [233]. Second, 5-AZA is reported to induce 
DNMT1 degradation trough an ubiquitin-proteosome-dependent pathway that results in 
gene re-expression [234]. Upon treatment these resistant cells re-expressed SRBC. 
The same was reported for other colorectal cancer human cell lines by Xu, et al [235]. 
Before move forward we wondered how was SRBC promoter methylation satus and its 
expression in normal colon mucosa. In normal tissues, SRBC was not methylated and 
was expressed (data not shown). This was in agreement with data published before, 
where in normal breast, lung, stomach and colorectal tissues, SRBC was expressed 
and gene promoter was not methylated [232, 235, 236]. 
 
SRBC promoter methylation plays a role in colorectal cancer resistance to 
oxaliplatin 
In order to demonstrate that the epigenetic inactivation of SRBC gene functionally 
contributed to oxaliplatin resistance, we restored it expression in colorectal cancer 
resistant cells and inhibited it in the sensitive ones. Upon SRBC transfection, resistant 
cells became more sensitive to oxaliplatin, in sharp contrast with sensitive cells that 
after SRBC downregulation by the short hairpin RNA approach, became considerable 
more resistant. The observed effects were specific for oxaliplatin because the in vitro 
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depletion or enhancement of SRBC did not change the sensitivity to 5-FU, other drug 
commonly used in colorectal cancer treatment. Getting or having SRBC promoter 
methylated seems to be an advantage to resistant cells. With HCT15 and HCT-116 
cells we studied intrinsic resistance. Important to note that sensitivity changes to 
oxaliplatin, were higher in LoVo-S and LoVo-R cells than in HCT15 and HCT-116. 
Endogenously HCT15 and HCT-116, beside SRBC methylation differences presented 
already a different genetic background. This fact for shore led to alterations in different 
pathways that in HCT15 can be reinforcing resistance to oxaliplatin. Thus, the simple 
fact of re-introduce or silence SRBC in these cells was not enough to produce so great 
changes in oxaliplatin sensitivity.  
 
A role of SRBC in mediating different sensitivity to oxaliplatin can be clearly justified by 
its protein interaction with the product of the BRCA1 gene [235]. The BRCA1 protein 
exerts an important role in DNA double-strand break repair through homologous 
recombination 2, so its deficiencies can impair the capacity of cancer cells to repair 
DNA cross-links caused by chemotherapy drugs such as platinum derivatives [100, 
237].Two independent studies reported greater primary chemotherapy sensitivity to 
platinum based chemotherapy agents in patients with ovarian cancer who were carriers 
of BRCA1 germline mutation [237, 238]. These observations have also been extended 
to BRCA1 epigenetic silencing in sporadic breast and ovarian tumors, where it also 
predicts a good response to cisplatin and carboplatin [239-241]. However, the biology 
of mammary tumors is very different from colorectal malignancies and in all cases of 
colon cancer, the BRCA1 promoter has always been found in an unmethylated status 
[242]. This makes us hypothesise that SRBC could act as a BRCA1 inhibitor, and due 
to its promoter hypermethylation, BRCA1 stays active and as consequences cells are 
more resistant to oxaliplatin. Yet a better study about the molecular mechanisms linking 
SRBC activity and DNA damage repair triggered by oxaliplatin should be investigated. 
Interestingly, in addition to its BRCA1-related roles, SRBC might have other functions 
related to the observed chemoresistance phenotype, such as its interaction with 
caveolin 1, which may putatively affect intracellular vesicule traffic of the drug [243].  
 
Our in vitro findings let us think that this gene could be a good candidate as a 
predictive biomarker for oxaliplatin-based treated colorectal patients. We choose 
metastasic patients, because they present less therapeutic options. 
 
SRBC Hypermethylation predicts short progression free survival in oxaliplatin 
treated patients with unresectable metastasis 
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In the clinical set we started with a discovery cohort (n= 131), composed by stage IV 
colorectal adenocarcinoma patients, all of whom were treated with oxaliplatin in 
combination with a fluoropyrimidine. In this cohort we found 29.8% of primary tumors 
methylated. A similar percentage (30.2%) was found after analyze a dataset from The 
Cancer Genome Atlas (n=232). However data published before revealed a higher 
percentage (47.5%) [235]. What concerns to the correlation between SRBC 
methylation and clinical endpoints as response rate, progression free survival and 
overall survival, in the discovery cohort we only found a significant association with 
short progression free survival (p=0.01). 
 
According to Cox regression multivariable test, surgery of metastases showed to be an 
independent progression free survival (p=0.004) and overall survival (p=0.003) 
prognostic factor. This was expected, since patients that under go metastasis surgery 
present an advantage when compared with subjects with unresectable metastasis. 
Taking this into account, our discovery cohort was stratified in relation to this clinical 
feature and was divided into two groups: patients that underwent metastases resection 
(n=34) and patients with unresectable metastases (n=97). After subdivide this cohort 
SRBC hypermethylation was only statistically significant associated with shorter 
progression free survival (p=0.01) in patients that received oxaliplatin as neoadjuvant 
therapy and were subsequently not eligible for surgery or patients with metastasis that 
were originally classified as unresectable and were given oxaliplatin as palliative 
chemotherapy. In this last set of patients, for whom overall survival data was available 
(n=79), we also observed that SRBC hypermethylation was significantly associated 
with shorter overall survival (p=0.04). To validate this data we study a second 
independent set of colorectal cancer patients with unresectable metastasis, who also 
received oxaliplatin based therapy (n=58). With this validation cohort, we only 
confirmed that the presence of SRBC hypermethylation was associated with shorter 
progression free survival (p=0.045). Based in our in vitro and clinical data, we think that 
SRBC promoter methylation is more important for oxaliplatin resistance acquisition that 
for intrinsic one. Patients with primary tumors in which SRBC promoter is methylated, 
progress faster when receive oxaliplatin-based chemotherapy. Maybe because tumor 
cells with this alteration present a selective advantage to proliferate under oxaliplatin 
action.  
 
The validation of SRBC promoter DNA methylation as a predictive biomarker requires 
further prospective studies. If successful, clinical trials would also be necessary to 
develop strategies to overcome or prevent the development of SRBC-mediated 
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epigenetic resistance. In this regard, research into DNA demethylating agents that 
might re-sensitize cancer cells to oxaliplatin is reasonable. This can represent a revival 
of the DNA demethylating agents in the therapy of solid tumors. With few therapeutic 
options against metastasic colorectal cancer once it has become insensitive to 
oxaliplatin, DNA methylation inhibitors, such as 5-AZA and 5-aza-2-deoxycytidine, 
could be used to resensitize these tumors to the oxaliplatin therapy. This idea has been 
recently explored in non–small cell lung carcinoma patients who had reached the last 
line of chemotherapy. The subsequent administration of 5-AZA was able to rescue 
previous chemosensitivity, with low toxicity rates [244]. Other option shows up from a 
recent publication that links SRBC promoter hypermethylation with NF-kB over-
expression. Since in the clinical stage, inhibitors of NF-kB are already applied in 
chemotherapy schemes, first it will be interesting to investigate if NF-kB expression in 
our in vitro model is related with SRBC methylation status. If yes, secondly study the 
possible reversion of oxaliplatin resistance by the use of NF-kB inhibitors. A good 
option for test these new drugs combinations will be the establishment of colorectal 
orthoxenografts. These are mice models where a piece of patient’s tumor is implanted, 
in mice corresponding tumor organ. This allows the perpetuation of the tumor and test 
different chemotherapeutic schedules in order to study tumors response and 
pharmacological behavior.  
 
If in the future SRBC promoter methylation will be accepted as a predictive marker, in 
order to simplify its analyses, DNA methylation in circulating tumor cells or stool, 
approaches less invasive for patients, should be optimized and implemented. These 
detection techniques will be also important in order to do a prospective study and 
monitorise SRBC promoter methylation status in patients under oxaliplatin-based 
treatments.  
 
In general, to patients with unresectable metastasic colorectal cancer is typically 
administered a first-line chemotherapy regimen based in oxaliplatin or in irinotecan. 
Basically the choice remains on established protocols. The Europeans normally apply 
FOLFOX scheme. With chemotherapy selection in mind, it will be worth to study SRBC 
promoter methylation status in a cohort composed by patients that received irinotecan-
based treatment. If SRBC promoter methylation keeps predicting short progression free 
survival exclusively for oxaliplatin treated patients, in the future we can put patients 
which present SRBC promoter methylation directly under a first line irinotecan-based 
chemotherapy. Other point that will be interesting is to investigate SRBC promoter 
methylation in paired primary tumors and metastasis and also in posterior treatment 
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relapse tumors. The extension of our study to stage II, stage III colorectal cancer 
patients, and to different geographical origins patients are also important points for 
further investigation. 
 
Other possible avenue of future research derived from our findings is the possibility to 
extend the observations to other tumor types, beyond colorectal cancer. The described 
existence of SRBC hypermethylation in lung, breast and ovarian carcinomas [235, 236, 
245] might prompt the development of translational assays to determine if the 
epigenetic inactivation of this gene is also associated with lower sensitivity to platinum-
derivatives in these neoplasms.  
 
STUDY OF CHEMORESISTANCE IN TESTICULAR GERM CELL TUMORS 
Although the elevated sensitivity of testicular germ cell tumors to cisplatin-based 
therapies (80%), there is still a subset (15-20%) of young men that will not be cured 
and will die [102]. With our work we afford two potential genes, GCS and MGMT that 
can be pharmacologically regulated in order to reverse cisplatin resistance of these last 
cases, and resensibilize tumors to cisplatin treatment. 
 
STUDY III 
“Orthoxenografts of Testicular Germ Cell Tumors Enable Identification of 
Glucosylceramide Synthase as a Cisplatin Resensitizing Target” 
 
Preclinical inhibition of GCS resensitizes cisplatin refractory germ cell tumors to 
cisplatin 
The genomic high-throughput analyses of our xenograft model, representative from 
paired non-seminoma cisplatin sensitive and refractory human tumors, prompted us 
several genes (GCS, ATP6V1G, CTR1/2, PAPPA or POLE3) with a possible 
implication in cisplatin resistance acquisition. 
 
As a proof-of-concept we evaluated the therapeutic value of GCS. This protein 
transfers a glucose residue from UDP-glucose to ceramide synthesizing 
glucosylceramide, which allows cellular escape from ceramide-induced programmed 
cell death. In vitro over-expression conferred cellular resistance to doxorubicin and 
daunorubicin [246, 247]. Its up-regulation was found in multidrug resistance cancer cell 
lines, in chemoresistant leukemia, and in metastatic breast cancer [247, 248]. We 
choose this gene since its messenger RNA expression and enzymatic activity was 
increased in most part of the engrafted refractory tumors; its knockdown by RNA 
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interference in worms conferred cisplatin sensitivity; and because there are specific 
inhibitors available, some of which are currently in clinical use.  
 
To investigate if over-expression of GCS contributes to cisplatin resistance in non-
seminomas, we decreased its expression in a human non-seminomas cisplatin 
resistant cell line and over-expressed it in a sensitive one. As in study II, the human 
non-seminoma resistant cell line was derived from a sensitive parental one, due to 
cisplatin increasing drug concentrations. Upon GCS inhibition resistant cells became 
more sensitive to the antiproliferative activity of cisplatin, in contrast with sensitive cells 
that after GCS expression, became more resistant. The same effect was found when 
we treated resistant cells with DL-treo-PDMP, an inhibitor of GCS. A possibility 
explanation is the same that happens in breast, ovary, cervical and colon cancer cells, 
where GCS activity triggers MDR1 expression, leading that to drug efflux [249], in our 
case to cisplatin efflux, and like this to appearance of resistant phenotype. Targeting 
glycosphingolipid synthesis has emerged as a novel approach for treating metabolic 
diseases such as Gaucher, Niemam-Pick and diabetes. In this context, GCS inhibitors 
are in clinical use or under development, including Migustat, DL-treo-PDMP, EXEL-
0346, etc. Our preclinical results demonstrate that DL-treo-PDMP resensitize cisplatin 
refractory cells to treatment, providing a firm preclinical rationale for developing further 
Phase II clinical trials, in order to do drug reposition in the field.  
 
Futures strategies exploring cisplatin resistance are guaranteed in our preclinical 
models. For example the study of the influence of the subunit of the vacuolar proton-
translocating ATP6V1G1 which is responsible for acidifying intracellular compartments, 
was found overexpressed in cisplatin-resistant cell lines [250]. Yeast genomic 
screening; have revealed its effect on the sensitivity to DNA-damaging agents such as 
cisplatin [251]. CTR1 and CTR2, Cu2+ influx transporters are also the main cellular 
cisplatin transporters and its under-expression was associated with cisplatin resistance 
[252]. 
 
STUDY IV: 
“Loss of MGMT Promoter Methylation and Resistance to Cisplatin in Non-
Seminoma Testicular Germ Cell Tumors” 
 
MGMT methylation status influences non-seminoma tumors sensitivity to 
cisplatin 
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MGMT DNA promoter methylation was previously related with non-seminoma tumors 
resistance to cisplatin [253]. Nonetheless it was never study on in vitro or in vivo 
models of cisplatin acquired resistance. This prompted us to examine an in vitro model, 
composed by a human non-seminoma cell line sensitive to cisplatin and it derived 
resistant counterpart. Once again we found less MGMT DNA promoter methylation in 
the resistant cell line. Although this difference was not too high (20%) it had a biological 
significance, since it was correlated with protein expression. This is in agreement with 
data published before where it was described that a cisplatin resistant human non-
seminoma cell line presented higher MGMT levels, than the sensitive counterpart [254]. 
To observe if MGMT higher expression was directly related to cisplatin resistance, first 
in the human cell lines, we blocked it with O6-benzylguanine and we found an increase 
on sensitivity to cisplatin. O6-benzylguanie is a potent, specific and irreversible blocker 
of MGMT DNA repair protein and thereby enhances the cytotoxic action of agents that 
produce lesions at the O6 position of guanine [255]. Pera et al, described before that 
human non-seminoma cells with highest levels of MGMT, were also more resistant to 
temozolomide, data that we also found [254]. 
 
MGMT promoter hypermethylation is correlated with better overall survival in 
testicular germ cell cancer metastasic patients, treated with cisplatin-based 
chemoterapy  
We also investigated MGMT methylation profile in a clinical set of metastasic patients 
with testicular germ cell tumors (n=72), where a positive statistical correlation between 
MGMT hypermethylation was related with a higher overall survival (p=0.025). 
Previously MGMT gene was described to be frequently inactivated in testicular germ 
cell tumors by promoter hypermethylation, especially in the sensitive ones [256, 253]. 
The same happens in glioblastomas, as mentioned before. Patients that present 
MGMT promoter hypermethylation are more sensitive to temozolomide, this because 
their cells cannot repair the DNA damage cause by this chemotherapeutic drug, fading 
[54]. This result makes us think that MGMT DNA methylation status could have in the 
future a clinical impact, in the same way that it has for gliomas [54]. However further 
validation studies are required. 
 
Preclinical inhibition of MGMT re-sensitizes cisplatin refractory non-seminoma 
tumors to cisplatin 
Despite the high cure rate obtained with cisplatin-based chemotherapy in testicular 
germ cell tumors, the management of patients with an adverse prognosis at 
presentation, or of those who fail to respond to first-line chemotherapy, remains a 
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therapeutic challenge [257]. Focus on a the possibility of re-sensibilize cisplatin 
resistant tumors, using the xenograft model established before, we proved that MGMT 
inactivation by O6-benzylguanine in resistant tumors over-expressing it, plus additional 
treatment with cisplatin and temozolomide can rescue these tumors. In preclinical 
studies temozolomide has demonstrated antitumor activity against human 
lymphoblastoma, myeloid leukemia, Burkitt’s lymphoma, choriocarcinoma, 
astrocytoma, lung and colorectal human cell lines [258]. The exceptional sensitivity of 
human non-seminoma cell lines to temozolomide was one reason for testing this new 
drug in the clinics [254]. Three clinical phase II studies were made before without 
positive results [259-261]. We think that the major limitation to the successful treatment 
of these patients was the absence of information about MGMT promoter methylation. 
Therefore, a further rationale for testing this new agent again is first study of MGMT 
promoter methylation and then decides if the chemotherapy schedule should include 
an MGMT inhibitor, like O6-benzylguanine drug.  
 
Other reason for testing temozolomide and when needed a MGMT inhibitor, is that this 
chemical agent has clinical activity against brain tumors [258, 262]. Brain metastases 
occur in 8-15% of patients with testicular tumors, almost always associated with 
relapse at other sites or as a terminal event [259]. Temozolomide may provide in this 
way a more effective treatment for testis tumors which have metastasized to the brain. 
 
Testicular germ cell cancer as mentioned before is mainly divided in two histological 
categories: seminoma and non-seminoma. In both studies where we investigate this 
type of cancer we only were able to use in vitro and in vivo representative non-
seminoma models. Until nowadays only two pure human seminomas cell lines were 
established. What concerns to mice models, none was established. Our laboratory tried 
to establish orthoxenographs; nevertheless none of the twenty two implanted pure 
gonadal seminomas grew in nude mice and from the mixed tumors, comprising both 
seminoma and non-seminoma components, only the last grew in mice. 
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Based on the findings of this PhD thesis we can conclude: 
STUDY I 
 In metastasic colorectal cancer, MGMT inactivation by DNA promoter 
methylation is associated with susceptibility to dacarbazine. 
 
STUDY II 
 Oxaliplatin resistance acquisition in colorectal cancer is related with DNA 
hypermethylation-associated silencing of SRBC.  
 
 SRBC promoter hypermethylation is a good candidate as oxaliplatin predictive 
marker for metastasic colorectal cancer patients that did not underwent 
metastases surgery, yet further prospective studies are required.  
 
STUDY III 
 Over-expression of GCS is related with cisplatin acquired resistance, in human 
non-seminoma cancer cell lines. 
 
 GCS inhibition decreases non-seminoma cancer cells resistance to cisplatin. 
 
 Inhibition of GCS with DL-treo-PDMP is a possible line of attack to revert 
cisplatin resistance in refractory non-seminoma tumors. 
 
STUDY IV 
 Non-seminoma cell lines and orthoxenografts tumors made resistant to 
cisplatin, present a re-expression of MGMT. 
 
 Inhibition of MGMT is a possible way to revert non-seminoma tumors cisplatin 
resistance. 
 
 MGMT methylation status is related with better overall survival in metastasic 
testicular germ cell tumors patients. 
 
 A better phase II study design, based on MGMT DNA promoter methylation, 
may offer the possibility to resensitize refractory patients to cisplatin. Thus we 
will detect the right patient for the right drug, on the right time. 
 
 
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Predictive Biomarkers and Personalized Medicine
Promoter CpG Island Hypermethylation of the DNA Repair
EnzymeMGMT Predicts Clinical Response to Dacarbazine in
a Phase II Study for Metastatic Colorectal Cancer
Alessio Amatu1, Andrea Sartore-Bianchi1, Catia Moutinho5, Alessandro Belotti1, Katia Bencardino1,
Giuseppe Chirico2, Andrea Cassingena1, Francesca Rusconi1, Anna Esposito3, Michele Nichelatti4,
Manel Esteller5,6,7, and Salvatore Siena1
Abstract
Purpose:O6-methylguanine-DNA-methyltransferase (MGMT) is a DNA repair protein removing muta-
genic and cytotoxic adducts from O6-guanine in DNA. Approximately 40% of colorectal cancers (CRC)
displayMGMTdeﬁciency due to the promoter hypermethylation leading to silencing of the gene. Alkylating
agents, such as dacarbazine, exert their antitumor activity by DNA methylation at the O6-guanine site,
inducing base pair mismatch; therefore, activity of dacarbazine could be enhanced in CRCs lackingMGMT.
We conducted a phase II study with dacarbazine in CRCs who had failed standard therapies (oxaliplatin,
irinotecan, ﬂuoropyrimidines, and cetuximab or panitumumab if KRAS wild-type).
Experimental Design: All patients had tumor tissue assessed forMGMT as promoter hypermethylation
in double-blind for treatment outcome. Patients received dacarbazine 250 mg/m2 intravenously every day
for four consecutive days, every 21 days, until progressive disease or intolerable toxicity. We used a Simon
two-stage design to determine whether the overall response rate would be 10% or more. Secondary
endpoints included association of response, progression-free survival, and disease control rate withMGMT
status.
Results: Sixty-eight patients were enrolled fromMay 2011 to March 2012. Patients received a median of
three cycles of dacarbazine (range1–12).Grades 3 and4 toxicities included: fatigue (41%), nausea/vomiting
(29%), constipation (25%), platelet count decrease (19%), and anemia (18%). Overall, two patients (3%)
achieved partial response and eight patients (12%) had stable disease. Disease control rate (partial response
þ stable disease) was signiﬁcantly associatedwithMGMT promoter hypermethylation in the corresponding
tumors.
Conclusion:Objective clinical responses to dacarbazine in patients with metastatic CRC are conﬁned to
those tumors harboring epigenetic inactivation of the DNA repair enzyme MGMT. Clin Cancer Res; 19(8);
2265–72. 2013 AACR.
Introduction
Globally, nearly 1.25 million patients are diagnosed and
more than 600,000 patients die from colorectal cancer
(CRC) each year (2008 estimates; ref. 1). At least 50% of
patients develop metastases (2), and most of these patients
have unresectable tumors (2, 3).
In the last 10 years, thanks to a wider clinical use of a
multidisciplinary approach, along with the introduction of
new cytotoxic drugs and the addition of targeted therapies
against the angiogenesis (bevacizumab and aﬂibercept), the
EGF receptor (EGFR) pathway (cetuximab and panitumu-
mab), or multiple receptor tyrosine kinases (regorafenib),
the survival of patients with metastatic CRC (mCRC) has
considerably been ameliorated (4–6). Nevertheless, prog-
nosis remains poor and patients carrying KRAS mutations
(35%–40% of CRCs), which preclude responsiveness to
cetuximab or panitumumab (6), have limited therapeutic
options after failure of 2 lines of standard treatments,
although a signiﬁcant percentage of these patients retain
a good performance status potentially allowing further
therapies. There is therefore an unmet need of therapeutic
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options, based on speciﬁc molecular alterations that could
prove their effectiveness also in the wide KRAS-mutated
subgroup of CRCs.
O6-methylguanine-DNA-methyltransferase (MGMT) is
a DNA repair protein that removes mutagenic and cyto-
toxic adducts from O6-guanine in DNA. MGMT protects
cells against these lesions, transferring the alkyl group
from the O6-guanine in DNA to an active cysteine within
its own sequence. Such reaction inactivates one MGMT
molecule for each lesion repaired (7). The inactivation of
tumor suppressor genes by the presence of cytosine
methylation encompassing the corresponding transcrip-
tion start site located in a CpG island is gaining "momen-
tum" in the management of oncology patients (8) and, in
this regard, promoter CpG island hypermethylation leads
to the transcriptional silencing of MGMT (9). The sub-
sequent lack of repair of O6-methylguanine adducts can
result in a higher frequency of G:C > A:T transitions (10,
11). It is known that approximately 40% of CRCs have
silencing of MGMT. Interestingly, in a retrospective
analysis on 244 CRCs samples, it has been found that
71% of tumors with G to A mutation in KRAS showed
MGMT epigenetic inactivation, showing a strong associ-
ation between the MGMT inactivation by promoter
hypermethylation and the appearance of G to A muta-
tions at KRAS (10). Furthermore, MGMT hypermethyla-
tion was also found in 35% of wild-type KRASmCRCs. de
Vogel and colleagues (12) found that MGMT hyper-
methylation is associated with G:C > A:T mutations in
KRAS, but not in adenomatous polyposis coli (APC),
suggesting that MGMT hypermethylation may succeed
APC mutations but it precedes KRAS mutations in colo-
rectal carcinogenesis.
In cells, loss of MGMT expression leads to compro-
mised DNA repair and may play a signiﬁcant role in
cancer progression and response to chemotherapy as it
occurs in glioma (13–16). The mechanism of action of
dacarbazine and temozolomide is DNA methylation at
the O6-guanine site, inducing base pair mismatch. The
methyl group at O6-site is removed by MGMT in a one-
step methyl transfer reaction. Therefore, we hypothesized
thatMGMT inactivation by hypermethylation may confer
sensitivity to these agents (17). However, discrepant data
about the clinical activity of these drugs in mCRC are
reported in the literature (18–21). A response rate of 19%,
including one complete response, was reported in 26
ﬂuoropyrimidine-resistant patients receiving cisplatin
and dacarbazine (19). In another study, 48 patients
refractory to ﬂuoropyrimidine were treated with dacarba-
zine, irinotecan, and cisplatin obtaining a 33% of
response rate (18). Temozolomide is an imidazotetrazine
derivative of dacarbazine. The combination of lomegua-
trib and temozolomide did not show activity in unselect-
ed mCRC (20). In a pilot study including patients selected
by tumor molecular proﬁling, temozolomide was effec-
tive in 2 patients with mCRC exhibiting loss of MGMT
expression (22). The latter ﬁnding was conﬁrmed by a
recent report by Shacham-Shmueli and colleagues (23)
documenting objective responses to temozolomide in 2
patients with MGMT-deﬁcient mCRC.
On the basis of these ﬁndings, we designed a phase II trial
aimed to assessing the antitumor activity of dacarbazine in
patients with mCRC with determined MGMT promoter
methylation status and refractory to the standard therapies.
Materials and Methods
Trial design
The study was designed as a phase II trial (DETECT-01
trial, EUDRACT number 2011-002080-21). Patients were
treated with dacarbazine monotherapy until progression
or unacceptable toxicity for 18 weeks (6 cycles). In case of
partial response with clinical beneﬁt, treatment was
allowed until dose-limiting toxicity. Primary endpoint
was to assess response rate to dacarbazine according to
Response Evaluation Criteria in Solid Tumors (RECIST
1.1) criteria. Secondary endpoints were to assess: disease
control rate (DCR), progression-free survival (PFS), iden-
tiﬁcation of KRAS, and O6-methylguanine-DNA-methyl-
transferase (MGMT) status in individual tumor samples
as potential molecular biomarkers of response to dacar-
bazine. Written informed consent was obtained from
each patient. The study followed the Declaration of Hel-
sinki and good clinical practice, being approved by Ethic
Committee of Ospedale Niguarda Ca’ Granda (Milan,
Italy).
Patients
All patients met the following inclusion criteria: age 18
years or more, Eastern Cooperative Oncology Group
performance status of  1, histologically conﬁrmed met-
astatic colorectal adenocarcinoma. A parafﬁn-embedded
Translational Relevance
O6-methylguanine-DNA-methyltransferase (MGMT)
is a DNA repair protein removing mutagenic and cyto-
toxic adducts from O6-guanine in DNA. Approximately
40% of colorectal cancers (CRC) display MGMT deﬁ-
ciency due to promoter hypermethylation leading to
silencing of the gene. Alkylating agents, such as dacar-
bazine, exert their antitumor activity by DNA methyla-
tion at theO6-guanine site, inducing base pairmismatch;
therefore, activity of dacarbazine could be enhanced in
CRCs lacking MGMT. Although several reports have
shown anecdotal efﬁcacy of dacarbazine in metastatic
CRC, there is a lack of translational evidence of CRC
sensitivity to this drug based onMGMT status. We report
here a phase II clinical study showing for the ﬁrst time
that dacarbazine activity is conﬁned to CRC harboring
promoter CpG hypermethylation ofMGMT. These data
therefore highlight a previously unidentiﬁed subgroup
of the patients with CRC who beneﬁt from treatment
with alkylating agents based on a speciﬁc epigenetic
alteration in individual tumors.
Amatu et al.
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block from archival tumor tissue of primary and/or
metastases for MGMT status analysis was requested. All
patients had measurable disease (by RECIST criteria
v1.1), and progressed on standard treatment with ﬂuor-
opyrimidine, oxaliplatin, irinotecan, and cetuximab or
panitumumab (the latter 2 drugs if KRAS wild-type). An
adequate bone marrow, liver, and renal function was
required.
Treatment schedules
Dacarbazine 250 mg/m2 intravenously everyday for 4
consecutive days, every 21 days, was administered until
progression, death, unacceptable toxicity, or patient with-
drawal of consent. Antiemetic agents and supportive care
were provided by treating physician as per standard clinical
practice. In case of G3 hematologic toxicity (absolute neu-
trophil count<1.5109/Landplatelet count<100109/L)
dacarbazine was delayed by 1-week interval until recovery.
Prophylactic use of colony-stimulating factors was allowed
as per standard clinical practice.
Evaluation criteria
Patients were evaluated for primary overall response rate
(ORR) and secondary endpoint (DCR and PFS) according
to RECIST criteria v1.1. Tumors were measured every 8  1
weeks throughweek 18 and then every 8 1weeks until the
tumor progressed. Complete response was deﬁned as dis-
appearance of all target lesions. Any pathologic lymph
nodes (whether target or nontarget) must have reduction
in short axis to 10mmor less. An objective response (partial
response)was deﬁned as a reduction of at least 30 percent in
the sum of all target lesions on computed tomography or
magnetic resonance imaging scanning. Conﬁrmed objec-
tive responses were those for which a follow-up scan
obtained at least 4 weeks later showed the persistence of
the response. Progressive disease was deﬁned as at least a
20% increase in the sum of diameters of target lesions,
taking as reference the smallest sum on study (this includes
the baseline sum if that is the smallest on study). In addition
to the relative increase of 20%, the sum must also show an
absolute increase of at least 5 mm. Stable disease was
deﬁned as shrinkage neither sufﬁcient to qualify for partial
response nor sufﬁcient increase to qualify for progressive
disease, taking as reference the smallest sum diameters
while on study. Clinical investigators and radiologists were
blinded as for MGMT status of the tumors.
Safety assessment
Safety assessments and blood biochemistry including
complete blood counts were carried out at baseline and
at the beginning of each treatment cycle. Any toxicity
was assessed using the National Cancer Institute (NCI)-
CTCAE version 4.0 and recorded at every visit until resolved.
Analysis of MGMT promoter methylation status
Loss of expression of MGMT was deﬁned as promoter
hypermethylation 25% or more as previously described
(9). Tumor samples from patients’ primary tumor were
obtained from Pathology Department of the Ospedale
Niguarda Ca’ Granda or others Pathology Departments as
referral. Formalin-ﬁxed parafﬁn-embedded tumor blocks
were reviewed for quality and tumor content. A single
representative block, from either the primary tumor or
metastasis, depending on availability, was selected for
each case. White slides (2 cut of 10 mm, if from a tumor
tissue parafﬁn block, or 3 cuts of 10 mm if from a biopsy)
were sent to Bellvitge Biomedical Research Institute (IDI-
BELL; Barcelona, Spain) for DNA extraction and evalua-
tion ofMGMT promoter methylation status in blind as for
clinical outcome. Genomic DNA was extracted from
parafﬁn tissue samples following manufacturer’s instruc-
tions (QIAamp DNA FFPE Tissue Kit). DNA was then
subjected to bisulfate treatment using EZ DNA methyla-
tion kit (Zymo Research). Brieﬂy, 1 mg of genomic DNA
was denaturated by incubating with 0.2 mol/L NaOH.
Aliquots of 10 mmol/L hydroquinone and 3 mol/L sodi-
um bisulfate (pH 5.0) were added, and the solution
was incubated at 50C for 16 hours. Treated DNA was
puriﬁed, desulfonated with 0.3 mol/L NaOH, repuriﬁed
on Zymo-Spin columns, and eluted with 25 mL water.
MGMT promoter methylation status was analyzed by
methyl-speciﬁc polymerase chain reaction (MSP). It was
carried out in a 15 mL volume containing 1 mL of the
sodium bisulﬁte-modiﬁed DNA. The characteristics of the
MSP reactions and the primer sequence have been pre-
viously described (14). SW620 cell line was used as a
positive control for hypermethylated alleles of MGMT
and DNA from RKO cell line used as a negative control
(Fig. 1).
M U M U M U M U M U M U M U M U M U 
H2OT8T7T4T3T2T1SW620RKO
D
N
A 
la
dd
er
Figure 1. Methyl-speciﬁc PCR for MGMT promoter. Example of results obtained for 6 metastatic colorectal cancer primary tumors from the study cohort.
Tumors T2 and T7 were methylated and all the others unmethylated. U indicates unmethylated tumors and M methylated tumors. RKO was the human
colorectal cancer cell line used as negative control for methylation and SW620 the human colorectal cancer cell line used as positive one. H2O is the
experiment negative control.
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Statistical analysis
According to clinical considerations and on the basis of
the available literature, the efﬁcacy of a treatment in this
setting of mCRC chemorefractory patients would be con-
sidered poor if the ORR is 3% or less, whereas it could be
considered of clinical usefulness if the ORR is 10% or
more. Assuming a¼ 0.05 and b ¼ 0.20, a Simon Optimal
2-stage design has been then chosen to test the null
hypothesis that P  0.03 versus the alternative that P 
0.10. According to this design, if at least 2 of the ﬁrst 40
patients would have achieved an objective response,
enrollment would have been extended by 28 patients.
Overall, objective response rate of dacarbazine mono-
therapy would have been deemed unacceptable if objec-
tive response was 4 or less. The association between
MGMT promoter methylation status and ORR and DCR
was determined by 2-sided Student t-tests or Fisher exact
test. PFS was estimated by Kaplan–Meier product-limit
method followed by log-rank test.
Results
Patients’ characteristics
Sixty-eight patients were enrolled in our institution
from May 2011 until March 2012. All patients had pro-
gressed on ﬂuoropyrimidines, oxaliplatin, irinotecan, and
cetuximab or panitumumab (the latter 2 drugs if KRAS
wild-type). 87% of patients had received prior bevacizu-
mab and 19% patient had received more than 4 lines of
treatment. Twenty percent of patients received mitomycin
C, 4% raltitrexed, and 12% previous experimental agents
within clinical trials. Clinical characteristics of patients
in this trial are reported in Table 1. Reasons for discon-
tinuation of dacarbazine treatment included hematologic
toxicity (1 patient), progression (61 patients), death
(4 patients), and withdrawal of consent (2 patients).
Cause of death was recorded as mCRC in all deceased
patients.
Toxicity
Adverse events are listed in Supplementary Table S1.
Hematologic toxicity was the most frequent adverse event
reported and general toxicity was consistent with the
known toxicity proﬁle of dacarbazine. We observed 3
hematologic G4 adverse events (2 platelet count decreased
and one neutrophil count decreased). Hepatic failure with
increased bilirubin due to progression of disease was
observed in 3 patients with extensive metastatic liver
involvement.
Analysis of MGMT promoter hypermethylation
Sixty-ﬁve of 68 patients were tested forMGMT promoter
CpG island methylation, as showed in Table 1. Overall,
MGMT hypermethylation was found in 40% (26/65) of the
colorectal neoplasmsDNAs analyzed, a similar frequency to
the previously reported for this tumor type (9). According to
the location of the tumor, MGMT promoter status was
assessed in 69% (45/65) in primary tumor, in 14% (9/
65) in metastatic site, and in 17% (11/65) in both primary
Table 1. Patients characteristics
Demographics Value (%)
Age
Median 63.5
Range 29–81
Sex
Male 47 (69)
Female 21 (31)
Clinical characteristics No. of patients (%)
Performance status
0 37 (54)
1 31 (46)
Tumor grade at diagnosis
G1 2 (3)
G2 43 (63)
G3 9 (13)
Not available 14 (21)
No. of prior treatments
2 14 (21)
3 18 (26)
4 23 (35)
5 5 (7)
6 6 (9)
7 2 (3)
Tumor KRAS status
Wild-type 35 (51)
Mutated 33 (49)
G12V 7
G12C 5
G12S 1
G12D 7
G12A 1
G13D 5
Codon not available 7
Tumor MGMT methylation status
Hypermethylated 26 (38)
Unmethylated 39 (58)
Not assessable 3 (4)
No. of metastatic sites
1 2 (3)
2 25 (37)
3 29 (43)
4 11 (16)
5 1 (1)
Patients previously treated with:
Bevacizumab 59 (87)
Mitomycin 17 (25)
Experimental drugs (clinical trial) 8 (12)
Amatu et al.
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and metastatic site from the same patient. In the latter case,
we observed concordance in 10 of 11 pairs, with only one
case showing a hypermethylated primary with unmethy-
lated liver metastasis, and the result from liver metastasis
was considered for the purpose of analysis. Sites of metas-
tases were: liver 75% (15/20), 5% (1/20) ovary, 10% (2/20)
lung, 5% (1/20) spleen, and 5% (1/20) cutaneous. MGMT
hypermethylation was more frequent (61% and 31%,
respectively) in tumors carrying KRAS mutation with G >
A transition (G12D, G12V, or G13D), as previously
described (10, 11), although the difference was not statis-
tically signiﬁcant due to the small size (only 26 patients
were evaluable for both analysis; P ¼ 0.238).
Antitumor activity of dacarbazine
ORRwas 3%, with 2 partial responses. Stable disease was
achieved in 8 of 68 patients (12%), accounting for a DCR
(partial responseþ stable disease) of 15%.Median PFS was
57 days. Preplanned analysis of secondary endpoints based
on assessments of MGMTmethylation and KRAS mutation
status in individual tumors showed that objective responses
occurred only in patients displaying MGMT-methylated
tumors (Fig. 2A and Fig. 3). In addition, we observed a
signiﬁcantly higher DCR (44.0% vs. 6%, P ¼ 0.012) in the
MGMT-hypermethylated group (Fig. 2). A trend toward
better PFS [HR ¼ 0.66; 95% conﬁdence interval (CI)
0.40–1.10; P ¼ 0.0982)] was also found in the MGMT-
hypermethylated cases (Fig. 4A). A similar tendency was
foundbetween reduction of tumor volume following dacar-
bazine treatment and MGMT methylation status: tumor
shrinkage of any size occurred more frequently in patients
displaying MGMT hypermethylation (Fisher exact test, P ¼
0.093). In contrast, KRAS status was not associated with
PFS, DCR, and ORR (KRAS mutant vs. KRAS wild-type, P¼
0.735, 0.999, and 0.492, respectively; Fig. 4B).
Discussion
In this study, we document that dacarbazine is active after
failure of standard therapies only in those patients with
mCRC whose tumor is harboring epigenetic inactivation of
the DNA repair enzyme MGMT. Overall, we observed 2
objective responses, accounting for 3%ofORR, and 8 stable
diseases, accounting for 12% of the cases. The observation
of a signiﬁcant associationbetweenMGMTpromoter hyper-
methylation and these clinical endpoints supports the
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Figure 2. A, waterfall plot showing best change in tumor size (%) along withMGMT promoter methylation status (hypermethylated/unmethylated) and KRAS
mutation status, if available. WT, KRAS wild-type; mutated, type of KRASmutation not available. B, pie-charts showing disease control rate [DCR ¼ partial
response (PR) þ stable disease (SD)] according to MGMT promoter methylation in individual CRC tumors.
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hypothesis that DNA repair-defective mCRC tumors are
more susceptible to this chemotherapeutic agent. However,
even in the case of MGMT hypermethylation, we observed
that a fractionof 44%of patients achieved control of disease
(stable disease þ partial response), thus suggesting that a
multiparametric signature including the DNAmethylation-
associated silencing of MGMT together with other molec-
ular traits would improve the identiﬁcation of CRC tumors
with defects in DNA repair, susceptible to the action of
dacarbazine.
The low response rate observed in the present cohort
could be linked to the inclusion of heavily pretreated
patients (median 4 lines of previous treatments). To inter-
pret this clinical result in the context of therapy-resistant
mCRC, one should consider that second-line treatment
with FOLFIRI or FOLFOX combination regimens induces
ORR of 10% to 12% (24–26) and dramatically decreases in
subsequent lines (6). It is also known that dacarbazine is
activated in liver by CYP450 microsomial N-demethylation
with formation of 5-[3-hydroxymethyl-3-methyl-triazen-l-
yl]-imidazole-4-carboxamide and 5-[3-methyl-triazen-1-
yl]-imidazole-4-carboxamide (MTIC). Rapid decomposi-
tion of MTIC produces the major plasma and urine
metabolite 5-amino-imidazole-4-carboxamide and the
reactive species methane diazohydroxide, which produces
molecular nitrogen and a methyl cation supposed to be
the methylating species (27). It is therefore conceivable that
the multiple (median 4) previous lines of cancer treatment
as well as the high (79%) rate of liver involvement in the
present study population may have exhausted the liver
function capacity to activate dacarbazine.
It was our hypothesis that anticancer activity of dacar-
bazine could be enhanced by a speciﬁc defect in DNA
A
B
Figure 3. Computed tomography
scan showing tumor shrinkage
(white arrows) after treatment
with dacarbazine in 2 patients,
one with lung (A) and another
with liver (B) metastases, both
displaying MGMT promoter
hypermethylation in primary
tumor.
0.00
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0.50
0.75
1.00
PF
S
0 15 30 45 60 75 90 105 120 135 150 165 180
Days
MGMT unmethylated
MGMT hypermethylated
Log-rank test: P = 0.0982
A
0.00
0.25
0.50
0.75
1.00
PF
S
0 15 30 45 60 75 90 105 120 135 150 165 180
Days
KRAS wild-type
KRAS mutated
Log-rank test: P = 0.7349
B
Figure 4. A, Kaplan–Meier PFS survival analysis according to MGMT
status in individual tumors. B, Kaplan–Meier PFS survival analysis
according to KRAS status in individual tumors.
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repair system as evaluated by MGMT promoter hyper-
methylation in individual tumors. This epigenetic defect
occurs in about 35% to 40% of mCRCs (9) and it is
detected in more than 70% of KRAS-mutated tumors
carrying the G > A transitions subtypes of mutation
(10, 11), a subgroup of mCRCs with limited therapeutic
options. Although the present trial was not designed, and
thus, powered to assess a signiﬁcant difference in PFS
between MGMT-hypermethylated/unmethylated groups,
we observed a trend toward better PFS in the MGMT-
hypermethylated group, together with a better DCR. The
2 patients displaying objective response were indeed
carrying MGMT-hypermethylated tumors (Fig. 2A) and
one of them showed a long-lasting maintenance of
response of 6 months, which is uncommon in the
advanced setting of mCRC.
In conclusion, present data document that speciﬁc DNA
repair defects can be associated with susceptibility to dacar-
bazine. The use of an alkylating agent that does not require
hepatic activation may be preferable in heavily pretreated
patients with metastatic liver disease. In this regard, temo-
zolomide is an alkylating agent whose activity is also
enhanced in tumors with MGMT loss (17) that is hydro-
lyzed in cells producing the active compoundMTICwithout
requiring liver passage. A phase II trial with temozolomide
has been designed and it is ongoing at our institution to
assess the efﬁcacy in patients withMGMT hypermethylated
mCRCs after failure of standard therapies.
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ARTICLE
Epigenetic Inactivation of the BRCA1 Interactor SRBC and 
Resistance to Oxaliplatin in Colorectal Cancer
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 Background A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of second-
ary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause.
 Methods A DNA methylation microarray was used to identify epigenetic differences in oxaliplatin-sensitive and -resistant 
colorectal cancer cells. The candidate gene SRBC was validated by single-locus DNA methylation and expression 
techniques. Transfection and short hairpin experiments were used to assess oxaliplatin sensitivity. Progression-
free survival (PFS) and overall survival (OS) in metastasic colorectal cancer patients were explored with Kaplan–
Meier and Cox regression analyses. All statistical tests were two-sided.
 Results We found that oxaliplatin resistance in colorectal cancer cells depends on the DNA methylation–associated inac-
tivation of the BRCA1 interactor SRBC gene. SRBC overexpression or depletion gives rise to sensitivity or resist-
ance to oxaliplatin, respectively. SRBC epigenetic inactivation occurred in primary tumors from a discovery cohort 
of colorectal cancer patients (29.8%; n = 39 of 131), where it predicted shorter PFS (hazard ratio [HR] = 1.83; 95% 
confidence interval [CI] = 1.15 to 2.92; log-rank P = .01), particularly in oxaliplatin-treated case subjects for which 
metastasis surgery was not indicated (HR = 1.96; 95% CI = 1.13 to 3.40; log-rank P = .01). In a validation cohort of 
unresectable colorectal tumors treated with oxaliplatin (n = 58), SRBC hypermethylation was also associated with 
shorter PFS (HR = 1.90; 95% CI = 1.01 to 3.60; log-rank P = .045).
 Conclusions These results provide a basis for future clinical studies to validate SRBC hypermethylation as a predictive marker 
for oxaliplatin resistance in colorectal cancer.
  JNCI J Natl Cancer Inst (2014) 106(1): djt322 
Colorectal cancer (CRC) is the second most common cause of 
cancer death in the western world (1). In metastatic CRC, poly-
chemotherapy based on fluoropyrimidines plus oxaliplatin or 
irinotecan, combined with biological agents such as cetuximab 
and panitumumab, is the gold-standard treatment (2). Oxaliplatin 
forms intrastrand adducts that disrupt DNA replication and tran-
scription (3,4). DNA damage induced by oxaliplatin is repaired in 
part by the nucleotide excision repair pathway (5), but the DNA 
double-strand breaks induced by the drug are also repaired by the 
BRCA1 complex (6–8). In this regard, epigenetic inactivation of the 
BRCA1 gene by promoter CpG island methylation has been associ-
ated with increased sensitivity to cisplatin and carboplatin in breast 
and ovarian cancer (9,10).
Genes critical to colorectal tumor biology are frequently inacti-
vated by hypermethylation of the CpG dinucleotides located in their 
5’-CpG island regulatory regions (11–13). We wondered whether 
this epigenetic alteration was involved in the resistance to oxalipl-
atin in CRC, where treatment failure due to primary or acquired 
resistance remains a major obstacle to the management of the dis-
ease. Herein, we demonstrate that the epigenetic inactivation of the 
BRCA1 interactor SRBC gene by promoter CpG island hypermeth-
ylation is associated with poor outcome upon oxaliplatin treatment.
Methods
Cell Lines
LoVo parental cell line (LoVo-S) and its derived 10-fold oxali-
platin-resistant cells (LoVo-R)(14) were cultured at 37ºC in an 
atmosphere of 5% (v/v) carbon dioxide in Dulbecco’s Modified 
Eagle’s Medium/Ham’s Nutrient Mixture F12 (DMEM-HAM’s 
F12) medium supplemented with 20% (w/v) fetal bovine serum, 
100 U penicillin, and 100 µg/L streptomycin (Invitrogen, Carlsbad, 
CA).The HCT-116, SW48, SW480, SW620, RKO, Co115, and 
HCT-15 CRC cell lines were obtained from the American Type 
Culture Collection (Manassas, VA). Cell lines were authenticated 
by short tandem repeat profiling.
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Determination of Drug Resistance
Oxaliplatin (5 mg/mL) and 5-fluorouracil (50 mg/mL) were 
obtained from TEVA (North Wales, PA) and Accord Healthcare 
SLU (Barcelona, Spain), respectively. Cell viability was deter-
mined by the 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-
2H-tetrazolium bromide (MTT) assay. Briefly, 1 × 103 cells were 
plated onto 96-well plates. Cells were treated for 120 hours with 
different drug concentrations (oxaliplatin: 0–250 µM; 5-fluoro-
uracil: 0–35  µM). MTT was added at a final concentration of 
0.1%. After 2.5 hours of incubation (37 ºC; 5% carbon dioxide), 
the MTT metabolic product formazan was dissolved in dime-
thyl sulfoxide (DMSO), and absorbance was measured at 570 nm. 
Prism Software (La Jolla, CA) was used to calculate the drugs’ 
half-maximal inhibitory concentration (IC50).
DNA Methylation Analyses
DNA was subjected to bisulfite using EZ DNA methylation kit 
(Zymo Research, Orange, CA) as previously described (15). To per-
form the genome-wide DNA methylation profiling we used the 
Illumina Infinium HumanMethylation27 BeadChip (Illumina, San 
Diego, CA) microarray following the manufacturer’s instructions 
(15).The Infinium assay quantifies DNA methylation levels at spe-
cific cytosine residues adjacent to guanine residues (CpG loci), by 
calculating the ratio (β value) of intensities between locus-specific 
methylated and unmethylated bead-bound probes. The β value is 
a continuous variable, ranging from 0 (unmethylated) to 1 (fully 
methylated). This microarray assesses the DNA methylation level 
of 27 578 CpG sites located at the promoter regions of 14  495 
protein-coding genes. DNAs were processed on the same microar-
ray to avoid batch effects. The array was scanned by a Bead Array 
Reader (Illumina), and intensity data were analyzed using Genome 
Studio software (version 2011.1; Illumina). Further details are 
described in the Supplementary Methods (available online). The 
data is freely avalilable at GeneExpressionOmnibus (http://www.
ncbi.nlm.nih.gov/geo/) under GEO accession code GSE44446.
We established SRBC CpG island methylation status using 
three different polymerase chain reaction (PCR)–based techniques: 
bisulfite genomic sequencing of multiple clones, methylation-specific 
PCR, and pyrosequencing. Further technical details are described 
in the Supplementary Methods (available online).The used primer 
sequences are shown in Supplementary Table 1 (available online).
mRNA and Protein Expression Analyses
mRNA extraction, cDNA synthesis, conventional and quantitative 
real-time PCR (RT-PCR) using Hs00376942_m1Taqman Gene 
Expression assay (Applied Biosystems. Madrid, Spain) were per-
formed as previously described (16). Primer sequences are shown 
in Supplementary Table  1 (available online). Anti-SRBC (1/1000) 
from Cell Signaling and anti-β-actin-HRP antibody (1/20 000) from 
Sigma (St. Louis, MO) were used to develop the western blot analysis.
SRBC Transfection and Depletion Experiments
Human short hairpin RNAs and cDNA plasmids for SRBC were 
obtained from Origene (Rockville, MD). After Escherichia coli trans-
formation, we proceeded to plasmid DNA purification. Forty-eight 
hours after electroporation, cells transfected with short hairpin 
RNAs (TR317747; Origene) were grown in medium containing 
0.8 or 0.6  µg/mL of puromycin (LoVo-S and HCT-116). Cells 
transfected with SRBC cDNA (SC320781; Origene) were grown 
with DMEM containing 0.8 or 0.6 mg/mL of geneticin (G418, 
LoVo-R, and HCT-15) to perform clonal selection. Once selected, 
clones were picked, grown, and tested by Western blot.
Patients
In our study, we analyzed two independent cohorts of white, stage IV 
CRC patients (17). In the discovery set, 131 metastatic CRC primary 
tumors that received oxaliplatin plus fluoropirimidines–based therapy 
were retrospectively included. Formalin-fixed paraffin-embedded 
tumors obtained by surgical resection came from three different hos-
pitals (ICO-Hospitalet, ICO-Badalona, and Niguarda Ca’ Granda). 
Clinical features of the patients are showed in Table  1. From this 
cohort, 65 patients could undergo surgery to remove metastases. 
After neoadjuvant regimen, 34 could be operated, and 31 received 
palliative regimen. The rest of the patients (n = 66) showed unresect-
able metastases and directly underwent palliative regimen. The great-
est time of follow-up of this group was near 10 years. The validation 
cohort consisted of 58 stage IV CRC patients from the Hospital Vall 
d’Hebron with a follow-up of nearly 3 years (Table 1). According to 
discovery set results, we selected patients with unresectable metas-
tases who received oxaliplatin plus fluoropirimidines–based therapy 
in a neoadjuvant (n = 20) or palliative regimen (n = 38). The distri-
bution of patients according to the different clinical features was 
similar in both cohorts. Signed informed consent was obtained from 
each patient, and the Clinical Research Ethical Committee from 
ICO-Hospitalet provided approval for the study. DNA from all case 
patients was obtained from formalin-fixed paraffin-embedded tissue 
sections (10 µm) by xilol deparafination and digestion by proteinase 
K (Qiagen, Manchester, UK). Tumor specimens were composed of 
at least 70% carcinoma cells. DNA extraction was performed using 
a commercial kit (Qiagen) following the manufacturer’s instructions.
Statistical Analysis
In both independent cohorts we analyzed SRBC promoter methyla-
tion status and its association with response rate, progression-free 
survival (PFS), and overall survival (OS). The associations between 
categorical variables were assessed by χ2 tests or Fisher exact test 
whenever required. Kaplan–Meier plots and log-rank test were used 
to estimate PFS and OS. The association between epigenetic vari-
ant and clinical parameters with PFS and OS was assessed through 
univariate and multivariable Cox proportional hazards regression 
models. The proportional hazards assumption for a Cox regression 
model was tested under R statistical software (Boston, MA) (cox.
zph function). Statistical analysis was performed by using SPSS for 
Windows, (Armonk, NY) and P values less than .05 were considered 
statistically significant. All statistical tests were two-sided.
Results
Identification of Epigenetics Changes Associated 
With Oxaliplatin Resistance Using a DNA Methylation 
Microarray
To address in an unbiased manner whether epigenetic changes 
can be associated with oxaliplatin resistance, we adopted a whole 
genomic approach by comparing the DNA methylation status of 
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27 000 CpG sites (15) in an oxaliplatin-sensitive CRC cell line 
(LoVo-S) and an oxaliplatin-resistant clone (LoVo-R) that we 
derived by exposure to increasing concentrations of the drug (14).
This approach yielded only three differentially methyl-
ated target genes: SRBC (protein kinase C delta binding pro-
tein), FAM111A (family with sequence similarity 111, member 
A) and FAM84A (family with sequence similarity 84, member A) 
(Supplementary Figure 1A, available online). The most noteworthy 
gene with the highest difference in DNA methylation was SRBC; 
thus, it was the logical option to pursue. However, we also stud-
ied initially the other two genes. For FAM111A, bisulfite genomic 
sequencing of multiple clones showed that indeed the CpG site 
included in the DNA methylation microarray was distinctly meth-
ylated in LoVo-S and LoVo-R cells; however, the remaining sites of 
the CpG island were unchanged (Supplementary Figure 1B, availa-
ble online). Thus, we excluded this gene from further experiments. 
For FAM84A, bisulfite genomic sequencing confirmed the differ-
ential methylation of the CpG island, but both conventional and 
quantitative RT-PCR did not show any difference in gene expres-
sion (Supplementary Figure 1, D and E, available online). Thus, we 
also excluded this second gene from further analyses. For the main 
target gene, SRBC, the DNA methylation microarray data showed 
that it had a CpG site located in its 5’-CpG island (−155 base-pair 
position) that was hypermethylated in LoVo-R but unmethylated in 
LoVo-S (Supplementary Figure 1A, available online). Interestingly, 
SRBC CpG island methylation-associated silencing has already 
been found in cancer (18,19), including colorectal tumors (20). 
From a functional standpoint, it is biologically plausible that SRBC 
is responsible for the different sensitivity to oxaliplatin because its 
protein interacts with the product of the BRCA1 gene (18), which 
is widely accepted as being a mediator of response to DNA damage 
induced by platinum compounds (21).
To further demonstrate the presence of SRBC 5’-CpG island 
methylation in resistant cells, we undertook bisulfite genomic 
sequencing analyses. We found CpG island hypermethylation 
in LoVo-R but mostly an unmethylated CpG island in LoVo-S 
(Figure  1A). Importantly, SRBC expression was diminished 
in LoVo-R, showing CpG island methylation, whereas it was 
expressed in the unmethylated LoVo-S at the mRNA and protein 
levels (Figure 1B). SRBC re-expression was observed upon treat-
ment with the DNA demethylating agent 5-aza-2’-deoxycytidine 
in LoVo-R cells (Figure 1B).
SRBC Epigenetic Inactivation and Oxaliplatin Resistance
We next sought to demonstrate that the epigenetic inactivation 
of this gene functionally contributed to oxaliplatin resistance. We 
restored the expression of SRBC in LoVo-R by stably transfecting 
an exogenous expression vector (Figure 1C). Upon SRBC transfec-
tion, the cells proved to be statistically significantly more sensitive 
to the antiproliferative activity of oxaliplatin measured by the MTT 
Figure  1. Epigenetic inactivation of SRBC is associated with resist-
ance to oxaliplatin in colon cancer cells. A) Bisulfite genomic sequenc-
ing of eight individual clones in the SRBC promoter CpG island was 
used to determine DNA methylation status. Presence of a methylated 
or unmethylated cytosine is indicated by a black or white square, 
respectively. Black arrows indicate the position of the bisulfite genomic 
sequencing primers. B) SRBC expression determined by semiquanti-
tative real-time polymerase chain reaction analyses (left) and Western 
blot (right). GAPDH and β-actin were used as controls, respectively. 
The oxaliplatin-resistant cell line (LoVo-R) features a hypermethylated 
CpG island that is associated with the downregulation of the SRBC 
transcript and protein, in comparison with the SRBC-unmethylated 
and expressing oxaliplatin-sensitive cells (LoVO-S). Pharmacological 
treatment with the DNA demethylating agent 5-aza-2’-deoxycytidine 
(5-AZA) restores SRBC expression. C) Western blot showing the in vitro 
enhancement (transfection in LoVo-R, left) or depletion (short hairpin 
[sh] RNA approach in LoVo-S, right) of the SRBC protein. D) Cell viability 
determined by the 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazo-
lium bromide assay upon use of oxaliplatin. External intervention by 
inducing SRBC overexpression (in LoVo-R cells) or depletion (in LoVo-S 
cells) gives rise to sensitivity or resistance to oxaliplatin, respectively 
(left panels). 5-Fluorouracil sensitivity is not dependent on SRBC activ-
ity (right panels). The corresponding half-maximal inhibitory concentra-
tion (IC50) values are also shown. SD = standard deviation.
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assay (Figure  1D) than were the empty vector-transfected cells 
(LoVo-R + SRBC 1 and 2: P =  .02 and P < .001, respectively). In 
sharp contrast, we observed that SRBC stable downregulation by 
the short hairpin RNA approach in SRBC-expressing and unmeth-
ylated sensitive cells (LoVo-S) (Figure 1C) had the opposite effect: a 
considerable enhancement of the resistance to the antiproliferative 
effect mediated by oxaliplatin (Figure 1D) (LoVo-S short hairpin 
SRBC A and B: P = .04 and P < .001, respectively). The observed 
effects were specific for oxaliplatin because the in vitro depletion 
or enhancement of SRBC activity did not change the sensitivity to 
5-fluorouracil (Figure 1D), other drug commonly used in CRC.
We extended our study to seven additional CRC cell lines 
(Co115, HCT-15, HCT-116, SW48, SW480, SW620, and RKO), 
in which we found SRBC promoter CpG island hypermeth-
ylation (Figure 2A) and the associated loss of expression only in 
HCT-15 cells (Figure 2B). Interestingly, these cells were the only 
ones showing resistance to oxaliplatin (IC50 ± standard devia-
tion  =  3.81 ± 0.18 µM); the remaining cells were sensitive to the 
drug (Figure 2C) (IC50 values ranging from 0.30 to 0.83 µM). As 
we did with LoVo-S and LoVo-R, we also sought to demonstrate 
that SRBC epigenetic inactivation functionally contributed to 
oxaliplatin resistance in these cells. We restored the expression of 
SRBC in the resistant cell line HCT-15 by stably transfecting an 
exogenous expression vector (Supplementary Figure 2A, available 
online). Upon SRBC transfection, the cells proved to be statisti-
cally significantly more sensitive to the antiproliferative activity of 
oxaliplatin (HCT15 + SRBC: P = .02) (Supplementary Figure 2B, 
available online). The opposite effect was observed with SRBC 
stable downregulation using the short hairpin RNA approach in 
SRBC-expressing and unmethylated sensitive cells (HCT-116): a 
noteworthy increase in the resistance to the antiproliferative effect 
mediated by oxaliplatin was found (Supplementary Figure  2B, 
available online) (HCT-116 short hairpin SRBC A and B: P < .001). 
The described effects were specific for oxaliplatin because the in 
vitro depletion or enhancement of SRBC activity did not change 
the sensitivity to 5-fluorouracil (Supplementary Figure 2B, avail-
able online). Western blot analyses showed that the level of expres-
sion of the SRBC protein in the transfected clones was similar to 
Figure  2. Epigenetic inactivation of SRBC is associated with oxaliplatin 
resistance in colorectal cancer cell lines. A) Bisulfite genomic sequencing 
of eight individual clones in the SRBC promoter CpG island was used to 
determine DNA methylation status. Presence of a methylated or unmethyl-
ated cytosine is indicated by a black or white square, respectively. Black 
arrows indicate the position of the bisulfite genomic sequencing primers. 
HCT-15 cells are the only cells that present SRBC promoter CpG island 
hypermethylation. Normal colon mucosa samples (NC1 and NC2) are 
unmethylated. B) Western blot analyses for SRBC expression show that the 
hypermethylated CpG island in HCT-15 cells is associated with loss of pro-
tein in comparison with the remaining SRBC-unmethylated and -express-
ing colon cancer cell lines. C) Half-maximal inhibitory concentration (IC50) 
values, determined by the 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-
2H-tetrazolium bromide assay assay, upon use of oxaliplatin in the panel 
of colon cancer cell lines. All the studied cells are sensitive to oxaliplatin 
except the SRBC-hypermethylated and -silenced HCT-15 cell line.
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that observed in unmethylated CRC cell lines (Supplementary 
Figure 2A, available online).
SRBC Hypermethylation and PFS in Oxaliplatin-Treated 
Cases of Unresectable Colorectal Cancer
Given these in vitro findings that colon cancer cells with SRBC 
methylation-associated silencing were resistant to oxaliplatin, we 
wondered whether the same effect could be observed in clinical 
samples. The study of a first clinical cohort of 131 stage IV colorec-
tal adenocarcinoma patients (termed “discovery cohort”) (Table 1), 
all of whom were treated with oxaliplatin in combination with a 
fluoropyrimidine, showed SRBC methylation in 29.8% (n  =  39 
of 131) of the case patients analyzed by both methylation-specific 
PCR and pyrosequencing analyses (Figure  3A; Supplementary 
Figure  3, available online). The described occurrence of SRBC 
hypermethylation in colorectal tumors was identical to the one 
available in the The Cancer Genome Atlas datasets (30.2%; n = 70 
of 232). Considering the whole population of studied advanced 
CRC case patients (n = 131), we observed that SRBC hypermethyl-
ation was associated with PFS (HR = 1.83; 95% confidence interval 
[CI] = 1.15 to 2.92; log-rank P = .01) (Figure 3B). For the 105 case 
patients for whom OS information was available, SRBC hyper-
methylation was not associated with this variable (Figure 3C).
According to Cox regression multivariable test, surgery of metas-
tases showed to be an independent PFS (HR = 0.43; 95% CI = 0.24 
to 0.76; log-rank P  =  .004) and OS (HR = 0.16; 95% CI = 0.04 
to 0.52; log-rank P  =  .003) prognostic factor (Supplementary 
Figure 4, available online). Taking this into account, our cohort was 
stratified in relation to this clinical feature and was divided into 
two groups: patients that underwent metastases resection (n = 34) 
and patients with unresectable metastases (n  =  97). Subdividing 
the discovery cohort into these resectable or unresectable groups, 
SRBC hypermethylation did not have any predictive effect in PFS 
and OS for those case patients that received oxaliplatin as neoadju-
vant therapy followed by the successful resection of the metastases 
(Supplementary Figure 5, available online).
However, the scenario was completely different in the context 
of patients with colorectal adenocarcinomas with unresectable 
metastases who received oxaliplatin as neoadjuvant therapy and 
were subsequently not eligible for surgery (n = 31) or patients with 
tumors that were originally classified as unresectable and were 
given oxaliplatin as palliative chemotherapy (n  =  66). For these 
97 oxaliplatin-treated advanced CRC case patients with unresect-
able metastases, SRBC CpG island hypermethylation was statisti-
cally significantly associated with shorter PFS (HR  =  1.96; 95% 
CI  =  1.13 to 3.40; log-rank P  =  .01) (Figure  3D). In this set of 
case patients, for whom OS data were available for 79 patients, we 
also observed that SRBC hypermethylation was statistically signifi-
cantly associated with shorter OS (HR = 2.01; 95% CI = 1.13 to 
3.40; log-rank P =  .04). These interesting results prompted us to 
study the SRBC methylation status in a second independent set of 
CRC patients with unresectable metastasis who also received oxali-
platin-based therapy (n = 58) (Table 1). In this validation cohort, 
we confirmed that the presence of SRBC hypermethylation was 
associated with shorter PFS (HR = 1.90; 95% CI = 1.01 to 3.60; 
log-rank P  =  .045) (Figure  4). Thus, the clinical data are similar 
to the results from the aforementioned cell cultures that suggest 
increased chemoresistance of SRBC hypermethylated colorectal 
tumors to oxaliplatin treatment.
Discussion
The preexistence (primary resistance) or the de novo development 
(secondary resistance) of cellular mechanisms to escape the anti-
tumoral effects mediated by the anticancer compounds probably 
involve a wide repertoire of genetic and epigenetic (22) events. 
From a genetics perspective in CRC, it has been described that 
the presence of KRAS mutations and gene amplification of the 
EGFR or MET genesis is associated with resistance to overall 
anti-EGFR therapies (23,24,25). However, from an epigenetics 
perspective, very little is known. In spite of promising pharmacoe-
pigenetics biomarkers, such as the example of MGMT hypermeth-
ylation and good response to temozolamide in gliomas (26), have 
been described for other tumor types, the examples in colorectal 
neoplasms are scarce, even more so if we just focus on resistance 
biomarkers. Herein, we provide an example to help fill this niche 
by showing that SRBC hypermethylation predicts resistance to 
the commonly used agent oxaliplatin in metastatic CRC, a disease 
stage that represents the second most common cause of death from 
cancer (1).
A role of SRBC in mediating different sensitivity to oxaliplatin 
can be clearly justified by its protein interaction with the product of 
the BRCA1 gene (18). The BRCA1 protein exerts an important role 
in DNA double-strand break repair through homologous recom-
bination 2, so its deficiencies can impair the capacity of cancer cells 
to repair DNA cross-links caused by chemotherapy drugs such 
as platinum derivatives (3–7).Two independent studies reported 
greater primary chemotherapy sensitivity to platinum-based chem-
otherapy agents in patients with ovarian cancer who were carriers 
of BRCA1 germline mutations (5,6). These observations have also 
been extended to BRCA1 epigenetic silencing in sporadic breast 
and ovarian tumors, where it also predicts a good response to cispl-
atin and carboplatin (9,10,27). However, the biology of mammary 
tumors is very different from colorectal malignancies, and in all 
cases of colon cancer, the BRCA1 promoter has always been found 
in an unmethylated status (28–30). Interestingly, in addition to its 
BRCA1-related roles, SRBC might have other functions related to 
the observed chemoresistance phenotype, such as its interaction 
with caveolin 1, which may putatively affect intracellular vesicle 
traffic of the drug (31).
It is worth mentioning two possible avenues of further research. 
First, there is the possibility to detect SRBC hypermethylation by 
sensitive user-friendly techniques, such as methylation-specific 
PCR and pyrosequencing, which could be useful in the clinical 
setting. Instead of always requiring the use of the surgical tumor 
sample, stool or serum/plasma DNA could be useful alterna-
tive biological materials to predict oxaliplatin resistance in CRC 
patients. In this regard, DNA methylation changes are also ame-
nable for the development of new powerful molecular techniques, 
such as those recently referred to as “liquid biopsies” (32). Second, 
our observation that sensitivity to oxaliplatin can be restored by 
the re-expression of the SRBC gene could represent a revival of 
the DNA demethylating agents in the therapy of solid tumors. 
With little therapeutic options against metastatic CRC once it has 
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Figure 3. SRBC promoter hypermethylation occurs in primary tumors 
from colorectal cancer patients, where it predicts shorter progression-
free survival (PFS) in oxaliplatin-treated case patients. A) Analysis by 
methylation-specific polymerase chain reaction (MSP) of the promoter 
region of SRBC in primary colorectal tumors. The presence of a vis-
ible polymerase chain reaction product in lanes marked U indicates 
unmethylated SRBC sequences; the presence of a product in lanes 
marked M indicates methylated sequences. In vitro methylated DNA 
(IVD) was used as a positive control for methylated SRBC sequences. 
DNA from normal lymphocytes (NL) was used as a negative control 
for methylated SRBC sequences. MSP of SRBC in five colon cancer 
patients demonstrates SRBC promoter hypermethylation in tumors 1, 
3, and 5. B) Kaplan–Meier analysis of PFS among the whole popula-
tion of advanced colorectal cancer cases by SRBC methylation status. 
Numbers of events (progression) are shown from 24 to 240 months in 
unmethylated (U) and methylated (M) groups. C) Kaplan–Meier analy-
sis of overall survival (OS) among the whole population of advanced 
colorectal cancer cases by SRBC methylation status. Numbers of 
events (exitus) are shown from 6 to 36 months in unmethylated (U) 
and methylated (M) groups. D) Kaplan–Meier analysis of PFS among 
the oxaliplatin-treated advanced colorectal cancer case patients with 
unresectable metastases by SRBC methylation status. Numbers of 
events are shown from 24 to 240  months in unmethylated (U) and 
methylated (M) groups. E) Kaplan–Meier analysis of OS among the 
oxaliplatin-treated advanced colorectal cancer case patients with unre-
sectable metastases by SRBC methylation status. Numbers of events 
are shown from 6 to 36 months in unmethylated (U) and methylated 
(M) groups.
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become insensitive to oxaliplatin, DNA methylation inhibitors, 
such as 5-azacytidine and 5-aza-2′-deoxycytidine, could be used to 
resensitize these tumors to the oxaliplatin therapy. This idea has 
been recently explored in non–small cell lung carcinoma patients 
who had reached the last line of chemotherapy. The subsequent 
administration of 5-azacytidine was able to rescue previous chemo-
sensitivity (33).
Limitations of our study to be addressed in further research 
include the lack of knowledge about the molecular mechanisms 
linking SRBC activity and DNA damage repair triggered by oxali-
platin, the use of nonquantitative DNA methylation assays that will 
require transformation to quantitative DNA methylation tests to 
get specific cut offs for a future clinical application, and the exten-
sion of our CRC patient data source to stage II and III tumors and 
samples from other geographical origins.
In conclusion, we have demonstrated that DNA methyla-
tion–associated silencing of the BRCA1 interactor gene SRBC 
is associated with the acquisition of chemoresistance to the 
DNA damaging agent oxaliplatin in CRC both in vitro and in 
vivo. The validation of SRBC hypermethylation as a predictive 
marker will require further prospective studies. If successful, 
clinical trials would also be necessary to develop strategies to 
overcome or prevent the development of SRBC-mediated epi-
genetic resistance.
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